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ABSTRACT 
 
Manipulation of complex genomes has many beneficial downstream applications in agriculture 
and human gene therapy. Precise genome-editing requires the introduction of a specific DNA 
double-stand break at a locus of interest, in turn inducing host DNA repair pathways to cause gene 
knockout through non-homologous end-joining or gene repair using homologous recombination 
and donor template. No matter the application, the field has depended on a few reagents to 
introduce precise double-strand breaks in host genomes. LAGLIDADG homing endonucleases or 
meganucleases harness the natural properties of these rare-cutting enzymes to target precise 
sequences in a complex genome. Other successful reagents are derived from a type IIS restriction 
endonuclease, FokI, fused to various DNA-binding architectures such as zinc finger domains and 
transcription activator-like effector domains. However, the discovery of clustered regularly 
interspaced short palindromic repeat-associated protein, CRISPR-Cas9, has dominated the field 
with its ease of design requiring a single RNA molecule to target the sequence of interest. Even 
with a handful of reagents to choose from, no one reagent is suitable for every application as every 
reagent has its own set of limitations and advantages. 
Here we present another potential genome-editing reagent derived from a GIY-YIG homing 
endonuclease, I-TevI, fused to all four DNA-targeting proteins described above. First, we 
demonstrate that I-TevI is a portable nuclease domain that can be targeted using Zinc-Fingers and 
LAGLIDADG proteins. Using these new reagents, we were able to further characterize I-TevI 
specificity using high throughput in vitro and in vivo screens to highlight important sequence 
requirements for targeting. Using this knowledge, we systematically engineered new I-TevI 
variants with altered specificity to broaden the number of targets available for I-TevI-derived 
reagents. We incorporated these new I-TevI variants into a more versatile dual-active nuclease, 
TevCas9, capable of introducing two double-strand breaks at a single target site. This dual 
cleavage event is capable of excising a short DNA fragment from the target site and is unique to 
I-TevI derived fusions. We envisioned that the monomeric, sequence-specific I-TevI catalytic 
domain would improve current tools by providing additional specificity and the ability to introduce 
dual-cleavage event would present unique applications for genome engineering. 
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Chapter 1 
1     Introduction 
Macromolecules have evolved to recognize DNA and perform a multitude of functions from DNA 
organization, DNA repair, gene expression and DNA hydrolysis (1–7). These processes require 
macromolecules, such as RNA and proteins, to recognize structural and biochemical features of 
DNA and bind either non-specifically through phosphate-backbone contacts or specifically 
through hydrogen bonding interactions (8–12). The requirement for non-specific or sequence-
specific contacts is highly role dependent. Histones, a conserved chromosomal packing protein in 
eukaryotic cells, are examples of proteins that have evolved to bind DNA non-specifically, 
recognizing primarily the phosphate backbone to help package the large DNA molecule into the 
nucleus via nucleosomes (9). Other proteins, such as a majority of transcription factors and 
endonucleases, have evolved to locate specific sequences for gene regulation and DNA hydrolysis, 
respectively. Whatever the function, there has always been the intriguing question how these 
proteins locate their specific site in complex genomes (13). Some groups have tried to decipher 
the amino acid/nucleic acid binding code is but with a large variety of interacting domain 
structures, determining a simplistic code appears to be a difficult task (5, 8). Better understanding 
of protein specificity could benefit the genome engineering field greatly, by aiding in engineering 
novel reagents targeted to new sequences (14–16). Understanding specificity of the LAGLIDADG 
homing endonuclease (LHE) family (alternatively known as Meganucleases) has been pivotal in 
engineering new endonucleases with alternative target sites (17–19). The focus of this thesis is to 
characterize and decipher the DNA recognition of a GIY-YIG homing endonuclease (GIY-HE), I-
TevI, and adapt it to novel DNA targets for genome engineering applications. 
Using a well-studied GIY-HE, I-TevI, I sought to fuse the nuclease and linker domain to various 
DNA-binding platforms and demonstrate their genome-editing potential. To first demonstrate that 
I-TevI nuclease and linker domain were portable to various DNA-binding platforms, we created I-
TevI fusion proteins to zinc-finger (ZF) DNA-binding domains and LHEs to create GIY-YIG zinc-
finger endonucleases (GIY-ZFE) and GIY-YIG/LAGLIDADG homing endonucleases (GIY-LHE, 
or alternatively, MegaTev). As described in Chapter 2, we investigate I-TevI as a portable nuclease 
domain and optimize I-TevI fusions using in vitro biochemical assays and in vivo bacterial and 
yeast selection assays. In Chapter 3, we examine a potential unique application for MegaTev, a 
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fusion of two nuclease domains capable of creating two double-strand breaks (DSBs) at a single 
target site. Using biochemical and mammalian cell assays, we investigate if MegaTev could help 
escape a persistent cleavage and re-ligation cycling event resulting from unproductive 
modifications at the target site. This cyclic cleavage event has been described previously for single 
cutting genome-editing reagents (20). In addition, we probed the cleavage site specificity of the I-
TevI nuclease domain in an attempt to define the activity for all 64-nucleotide combinations in its 
5 base pair (bp) 5’-CNNNG-3’ cleavage motif. Our next goal was to develop a more versatile I-
TevI genome-editing reagent, as described in Chapter 4 and 5. We deciphered targeting guidelines 
for I-TevI nuclease and linker domains and appied these rules to identify novel I-TevI target sites. 
To aid in increasing applicability of I-TevI derived reagents, we created fusions to a fourth DNA-
binding platform, the clustered regularly interspaced short palindromic repeat-associated protein 
CRISPR-Cas9 protein. By understanding the targeting requirements of the GIY-HE, I-TevI, we 
hope to transform this HE into a malleable genome-editing reagent that can be targeted to various 
human gene targets. 
1.1     Homing endonucleases 
HEs are considered selfish genetic elements that have evolved for the sole purpose of propagating 
their own DNA. HEs are found in all three domains of life. Although viewed as selfish elements, 
there is some evidence of providing beneficial properties to the host (21, 22). One LHE in 
particular, HO, is an example of a beneficial HE as it is responsible for mating-type switch in 
Saccharomyces cerevisiae (23, 24). Another HE first described in the 1980s was originally known 
as the genetic element ‘ω’. It was present in some Saccharomyces cerevisiae strains and was 
observed to transfer when a ω- strain was crossed with a ω+ strain (25, 26). Not too long after, it 
was discovered that a LHE known as I-SceI was responsible for this observation. The transfer of 
the genetic information by a HE was termed “homing” process (27, 28). The homing process 
begins with the introduction of a double-strand break (DSB) by an HE, subsequently inducing 
homologous recombination (HR) to repair the break utilizing the HE open reading frame (ORF) 
(Figure. 1.1) (27–29). Therefore, homing endonuclease specificity is an important aspect to ensure 
successful gene transfer and to prevent toxicity to the host organism. To ensure the correct 
sequence is cleaved, homing endonucleases have evolved to recognize long  
2 
 
 
 
 
Figure 1.1: Mobility of homing endonucleases 
Homing endonuclease expression from an intron or intein results in double-strand break 
formation at an intronless sequence resulting in lateral gene transfer through homologous 
recombination. The HE ORF DNA is used as the repair template to propagate the HE coding 
sequence. 
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sequences of DNA, from 12-40 bp (30–34). There are five distinct families of homing 
endonucleases characterized by their conserved nuclease active-site core motifs known as 
LAGLIDADG, GIY-YIG, HNH, HIS-Cys box and PD-(D/E)XK. For the purpose of this thesis, 
our focus is on the largest family, the LAGLIDADG or Meganuclease homing endonucleases, and 
the GIY-HEs. 
1.1.1 Mobility and evolution 
HEs ORFs occur in many different forms including introns, inteins and freestanding. Once 
translated HEs scan for their homing site to introduce a DSB and promote their own proliferation. 
As with group I introns and inteins, the transfer of biological information is initiated solely by the 
endonuclease, whether as a free or fusion protein from an intron- or intein-encoded sequence, 
respectively (Figure 1.1) (7, 27, 29, 35). The cleavage of the intron-less homing site is then 
converted through host repair pathways to an intron or intein containing allele with the HE ORF 
(Figure 1.1). HEs and their hosts possess a very dynamic relationship assures that they rapidly 
spread through a population. However, once this occurs there is no selective pressure to keep a 
functional HE, so the intron/ORF is lost. This results in an increase of intron-less sites available 
for cleavage and reactivates the HE for site re-invasion (36). 
Although HEs target long sequences of DNA in their host genome, they must maintain a certain 
level of sequence tolerance or malleability to adapt to mutations at their homing sites. The extra 
flexibility in sequence recognition may also aid in targeting new sites in a gene duplication event. 
As proposed for the LHE family, single-motif enzymes form dimers bringing two “LAGLIDADG 
motifs” together to form an active protein against pseudopalindromic targets (37). Interestingly, it 
is proposed that double-motif monomers evolved from a duplication event, allowing further 
relaxation of sequence requirements for symmetry, expanding the substrate repertoire (19, 38, 39). 
Evolution of GIY- HEs is thought to be distinct from LHEs, because the GIY-HE DNA-binding 
domain is distant from the catalytic domain, therefore the catalytic domain is more promiscuous 
and can utilize a large variety of DNA-binding proteins (40, 41). As part of this thesis, we expand 
on this hypothesis for the GIY-HE I-TevI, by demonstrating its ability to use various DNA-binding 
platforms to target novel DNA sequences. 
1.1.2 GIY-YIG homing endonuclease 
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The GIY- HE family is a well characterized HE family defined by their conserved GIY-X(10-11)-
YIG motif. The conserved GIY-YIG motif is involved in folding and catalytic activity of the N-
terminal catalytic domain. One of the best-studied GIY-YIG HEs, I-TevI, was found in the 
thymidylate synthase (td) gene of bacteriophage T4 and has been used to studies GIY-YIG HE 
structure and function. Limited proteolysis and footprinting analysis first demonstrated I-TevI was 
a bipartite enzyme, where the N-terminal catalytic domain is connected by a flexible linker region 
to the C-terminal DNA-binding domain (Figure 1.2) (40). NMR and X-ray crystallography studies 
were used to solve the structure of 1-96 amino acids (aa) of the catalytic domain and 148-245 aa 
of the C-terminal DNA-binding domain in complex with DNA provided a closer look at I-TevI 
structure (42–45). The catalytic domain consisted of a globular structure with the conserved GIY-
YIG motif located in the first two β-strands of the core ββααβα fold (46, 47). The catalytic domain 
was crystalized in the absence of DNA substrate, presumably due to the weak binding affinity of 
the catalytic domain for DNA (46). Surprisingly, the C-terminal DNA-binding domain contained 
a non-canonical zinc finger domain from residues 148-169 (42). Previous studies have 
demonstrated that the zinc finger region acts as a molecular ruler in determining the distance for 
I-TevI cleavage and does not make any specific DNA contacts (42, 46). Interestingly, the zinc 
finger region was required for our shortest, most active I-TevI fusions containing aa 1-169 
suggesting it must be important for DSB formation (48). 
I-TevI recognizes a relatively long target site of about ~40 bp, making mostly minor groove and 
phosphate backbone contacts along the full length of its homing site (49, 50). Mutagenesis and 
chemical interference studies have demonstrated that I-TevI can tolerate high abundance of 
nucleotide substitutions at its homing site (49, 50). Mapping the cleavage site for I-TevI identified 
a dinucleotide requirement, 5’-CNNNG-3’, within the 5 bp cleavage motif (51). Not surprisingly, 
I-TevI has evolved to recognize conserved codons found within the thymidylate synthase gene 
active site such as the C and G nucleotide in the cleavage motif of the conserved glutamine (CAR) 
and arginine (CGN or AGR) codons (51). Probing the specificity of the I-TevI linker region 
resulted in similar findings, as described in Chapter 4. Previous studies have shown that I-TevI 
induces a ~40o bend toward the major groove and a similar homing site distortion has been reported 
for the LHEs and restriction  
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Figure 1.2: Structures for GIY-YIG and LAGLIDADG homing endonucleases 
Crystal structures and schematics for the GIY-YIG homing endonuclease I-TevI and 
LAGLIDADG homing endonuclease I-OnuI. LAGLIDADG alpha-helices critical for the two 
domain interactions and forming the active sites are highlighted in orange. Schematic 
representations with red triangles indicating cleavage sites. 
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endonucleases (REs) (30, 38, 49). The DNA distortion by homing endonucleases is thought to help 
expose the phosphate backbone to catalytic residues, helping I-TevI sequentially nick the bottom 
and top strands (30). Biochemical assays have demonstrated that I-TevI binds DNA as a monomer 
with a single active site to create a DSB (30). To better study the mechanism of GIY-YIG HEs, an 
alternative protein, I-BmoI, with ~750-fold reduced specific activity than I-TevI was utilized (52). 
I-BmoI targets a homologous thymidylate synthase gene from Bacillus mojavensis containing a 
similar bipartite structure as I-TevI (53). Both enzymes sequentially nick their target sites leaving 
a 2 bp 3’ overhang, but the reduced specific activity of I-BmoI permitted study of the mechanism 
of GIY-HEs in more detail (52, 54). Using biochemical assays such as OP-Cu footprinting and gel 
filtration, I-BmoI was demonstrated to bind DNA as a monomer and sequentially nick DNA with 
only a single active site (55). In addition, a critical guanine (G) contacted by the I-BmoI linker 
region is responsible for anchoring the linker region on DNA allowing the catalytic domain to 
undergo a conformational change to cleave both strands of DNA (55).This critical G anchor 
position by the I-BmoI linker region parallels an important G requirement for I-TevI cleavage 
described in Chapter 4. 
1.1.3 LAGLIDADG homing endonuclease 
LHEs, often referred to as Meganucleases, are the best-studied group with the largest number of 
characterized proteins. The members are segregated into two main groups depending on whether 
they have a single or double copy of the conserved LAGLIDADG motif. I-CreI is a well-studied 
single copy LAGLIDADG protein that requires dimerization to form an active enzyme (56). Other 
members of the LHE family are monomeric enzymes containing two copies of the LAGLIDADG 
motif expressed as a single polypeptide (19, 57). Surprisingly, with a sequence similarity of only 
~30%, both homodimeric and monomeric LHEs form very similar 3D structures (34, 19, 58, 59). 
The two LAGLIDADG motifs are located in α-helices and have a critical role bringing the two 
halves of the enzyme together to form the catalytic core at the base of the enzyme. Many crystal 
structures have been solved showing an α/β topology, where the β-sheets form a saddle containing 
a large number of basic and polar residues for DNA contacts (Figure 1.2) (34, 37, 19, 58). The 
saddle sits on the ~20 bp homing site and projects amino acid residues into the major groove to 
locate the homing site. Similar to the GIY-HEs, LHEs place a great deal of strain on the DNA 
substrate to help facilitate DNA binding and scissile phosphate positioning in the active site 
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(Figure 1.3) (38). This strain helps LAGLIDADG cleave across the minor groove leaving a 4 bp 
3’ overhang. Their compact size containing both the DNA recognition and catalytic activity packed 
into ~300 amino acids is just one characteristic that has highlighted LHEs as potential genome-
editing reagents. 
1.2 DNA sequence specificity for site-specific proteins 
There has been a large effort to try and decipher a protein-DNA binding code as it would be helpful 
in many downstream applications to help determine transcription binding sites or potential off-
target binding sites. However, proteins contain diverse tertiary and quaternary structures that 
makes deciphering a simple code for sequence-specific contacts a very tough task (8). Surprisingly, 
about two-thirds of all protein-DNA interactions are from van der Waals contacts, while about 
one-sixth are from hydrogen and water-mediated bonds (8). Diverse protein-DNA interactions 
present a problem when mutating proteins with the goal of changing overall specificity. 
Unfortunately, altering the specificity of DNA-binding proteins is not as simple as mutating a 
couple aa-DNA contacts as this may disrupt protein intramolecular interactions. As described in 
previous studies, mutating HEs or zinc-finger (ZF) domains and changing only DNA-contacting 
residues often reduces binding affinity or cleavage activity (19, 60). Another consideration is the 
general flexibility of the DNA sequence. It is well known that HEs and REs distort their DNA 
target sites and a general protein flexibility must be maintained for effective binding and cleavage 
(11, 30). This presents an indirect readout mechanism that is very difficult to characterize and 
generalize across all sequence-specific DNA-binding proteins. A third problem was observed 
when creating de-novo DNA-contacting transcription activator-like effector (TALE) and ZF 
domains. In both cases, intramolecular interactions within the protein structure affected the 
intermolecular DNA-binding contacts (10, 61–63). Although large barriers exist when attempting 
to change specificity, high throughput protein engineering methods have aided in overcoming 
some problems with creating novel DNA-binding proteins. 
1.2.1 Restriction endonuclease sequence specificity 
Restriction endonucleases (REs) are some of the most specific DNA-binding endonucleases as 
single bp substitutions can abolish activity. Therefore, REs have transformed into a massive 
industry allowing scientists to readily manipulate DNA sequences and clone their gene of 
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Figure 1.3 Crystal structures of various DNA binding domains and nucleases 
Crystal structure of DNA bound proteins highlighting the diversity in DNA recognition. (A) 
Restriction endonuclease I-EcoRV and homing endonuclease I-OnuI bound to DNA with 
indirect readout portion of DNA highlighted in red. (B) Crystal structure of transcription 
activator-like effector (TALE), zinc-fingers and Cas9 bound to DNA with contacting residues or 
RNA molecule highlighted in purple. 
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interest. Although REs may be known mainly for cloning purposes, they were originally 
discovered in the mid 1950’s as a bacterial defense mechanism (64–66). Their natural purpose 
was to identify foreign DNA and cleave it to protect the host from invading DNA molecules (67, 
68). Therefore, REs have evolved to recognize more frequentshort short DNA sequences from 4-
8 bps. In addition, there was evolutionary pressure to become ultra-specific, as introducing a 
DSB in the host genome can be detrimental. Mutagenesis studies making single substitutions in 
the recognition sequence of EcoRI resulted in a reduction in kcat/km cleavage from 105 to 109 
(69, 70). It was observed that single nucleotide substitutions affected DNA cleavage rate larger 
than DNA binding of the enzyme. This stringent discrimination at the EcoRI recognition site is a 
result of both direct and indirect readout of the DNA target site (69). A recurring theme is the 
requirement for DNA distortion, observed in both HEs and REs, to properly bind and access the 
scissile phosphates for cleavage (Figure 1.3). In the case of EcoRI, the DNA distortion allows 
access for a bundle of four α-helices to contact the major groove (71). EcoRI saturates 16 out of 
the 18 possible hydrogen-bonding positions in its 6 bp recognition sequence and makes 
additional van der Waals’ contacts to all thymidine methyl groups (71). Almost complete 
saturation of target site contacts is the main reason why REs are so intolerant to substitutions. 
However, there are examples of REs that do not completely saturate their recognition site, such 
as EcoRV. EcoRV only contacts 4 positions in its target site, as there are no observable 
sequence-specific interactions with the central TA in the recognition site (11). The central two 
bps could be an indirect readout mechanism as severe DNA distortion is observed upon EcoRV 
binding (11, 72). Interestingly, LAGLIDADG homing endonucleases are thought to have an 
indirect readout mechanism for the central 4 bps in their target site, as no contacts have been 
observed in crystal structures (58, 73–75). 
1.2.2 Homing endonuclease sequence specificity 
Altering HE sequence specificity can be a very complex challenge even with a large number of 
crystal structures readily available. With at least 15 crystal structures for LHEs published to date, 
the base-specific residues and hydrogen binding contributions that identify the ~20 bp homing site 
are known. Unlike REs, HEs only contact 65-75% of the possible hydrogen donors and acceptors 
in the major groove and one third of phosphate backbone contacts (59). This makes sense 
evolutionarily, as HEs need to remain flexible to individual polymorphisms that occur at their 
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homing site to prevent loss of binding or cleavage. Therefore, LHEs may target long sequences 
~20 bp, but sacrifice some specificity by under-saturating DNA-protein contacts to maintain the 
ability to adapt to polymorphisms (58, 76, 77). In addition, LAGLIDADG contain a central 4-bp 
region that has no direct contacts but is restricted by an indirect readout mechanism. Substitutions 
at these positions have minimal effects on enzyme binding affinity but cause significant reduction 
in DNA cleavage, presumably because DNA flexibility disrupts metal coordination by catalytic 
residues (75). Some groups have utilized computer modeling to study LHE binding and help 
predict residue combinations to help alter specificity (78–80). One example was using the 
homodimer I-MsoI, the Thr83 residue was predicted to change specificity at +6 and -6 and an 
additional Lys28 mutation would reduce activity on the cognate homing site (Ashworth 2006). 
These two mutations enhanced activity on the mutant target site and reduced the activity on the 
cognate site by 4,000 fold (79). 
GIY-HEs, such as I-TevI and I-BmoI, make mostly minor groove contacts and can tolerate 
multiple nucleotide substitutions at their target site (30, 49). No full-length crystal structure in 
complex with DNA has been solved, leaving little information on direct or indirect contacts. 
Biochemical assays using I-BmoI identified a critical guanine base required to anchor the linker 
region and thought to promote rearrangement of the catalytic domain (55). In addition, the catalytic 
domains of both I-BmoI and I-TevI both have inherent sequence specificity for 5’-NNNNG-3’ and 
5’-CNNNG-3’, respectively (51, 52). However, little is known about how these catalytic domains 
discriminate the identified sequence-specific requirements.  
1.2.3 ZF and TALE DNA-binding sequence specificity 
Zinc fingers are a common DNA-binding platform found in more than a thousand characterized 
transcription factors (81). Each zinc finger is very small consisting of a simple ββα fold and 
recognizing a 3 bp target site (82). Therefore, ZF transcription factors often have multiple fingers 
that wrap around DNA in a spiral manner. Each finger recognizes the 3 bp by inserting the α-helix 
into the major groove to contact DNA bases (Figure 1.3) (10, 83). There are three main positions 
in the alpha helix that recognize each base, the -1 residue contacts 3’ base, position 3 contacts the 
central base and position 6 contacts the 5’ base. A simple rule-based system for zinc-finger 
specificity to govern targeting new DNA sequences was not accomplished as no single approach 
was successful at predicting all possible DNA sequences for new ZFs (84). Swapping the order of 
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the fingers resulted in significant context-dependent effects that were difficult to predict (84). 
Although disappointing, complex protein interactions were found in crystal structures revealing a 
cross-strand interactions through position 2 (10). In addition, the insertion of linker regions 
between adjacent zinc-fingers along with mutational analysis has demonstrated to destabilize 
neighboring zinc-finger protein-DNA complexes (85–87). Since no simple code has been 
described, robust screening is required to isolate highly specific ZF domains and these are typically 
biased to G/C rich target sites, limiting programmability (87). 
Transcription activator-like effector (TALE) was the most recent protein-DNA binding 
architecture introduced to the genome-editing field. Naturally, TALEs are transcription factors 
utilized by the bacterial plant pathogen, Xanthomonas, who injects the protein into the plants to 
hijack the plants resources. The first indication of a TALE DNA-binding code was found in the 
avrBs3 gene as it contained a repetitive region that encoded for 34 aa repeats (88). Comparing the 
AvrBs3 and AvrXa10 TALE repeats highlighted a hypervariable di-residue (RVD) region at the 
12th and 13th position in the repeats suggesting that the repeats must determine TALE specificity 
(Figure 1.3) (89, 90). The true breakthrough in deciphering the TALE code was from two 
independent studies, describing how the hypervariable residues 12 and 13 correlated with specific 
bases in the target sequence (62, 63). For example, NI (Asn-Ile) aa coded for adenine and HD (His-
Asp) aa coded for cytosine binding. However, assembling novel TALEs to target any sequence of 
interest was not quite as easy as initially thought, as the putative repeat at the beginning of the 
TALE required a thymine base. Also similar to ZF domains, TALEs had some unexplainable 
context dependent interactions. A simple strategy of increasing the number of repeats to increase 
specificity was not plausible either as the longer TALEs could tolerate more mismatches because 
moderate affinity was maintained through matching repeat-DNA combinations. Therefore, a set 
of rules were defined to help construct reliable TALEs including: (i) minimal number of repeats 
are required; (ii) non-matching repeat-DNA combinations contribute more strongly to overall 
interaction; (iii) different repeat types exhibit different DNA-interaction binding strength; (iv) and 
effect of individual non-matching repeat-DNA combinations are position and context-dependent 
(91). 
1.2.4 CRISPR-Cas9 sequence specificity 
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Clustered regularly interspaced short palindromic repeat-associated protein (CRISPR) evolved as 
a prokaryotic adaptive immunity to recognize and cleave invading DNA (92). CRISPR-associated 
(cas) genes are expressed and function in all steps of host immunity including processing RNA 
molecules used for recognizing invading DNA and endonucleases used to cleave exogenous DNA. 
The Type II CRISPR system is of particular interest as the targeting endonuclease, Cas9, uses a 
single polypeptide loaded with a targeting RNA molecule (crRNA) and a stabilizing RNA 
molecule known as the tracrRNA (Figure 1.3) (93). Since Cas9 uses a RNA molecule to target 
DNA, it depends on Watson-Crick rules for targeting which is different then all previously 
described DNA binding platforms used for genome-editing. One restriction for Cas9 targeting is 
the requirement for a protospacer associated motif (PAM) which evolved to limit off-target 
cleavage by Cas9 (94). The most extensively studied CRISPR-Cas9 is from Streptococcus 
pyogenes and requires a NGG PAM motif (95). The PAM motif varies depending on the organism, 
as different Cas9 orthologs contain different PAM motifs. Cas9 binds a crRNA to target a 20 bp 
DNA sequence and introduce a blunt DSB 3 bp upstream from the PAM motif. Although the 
crRNA is 20 bp in length, the specific recognition is limited to 7-12 nucleotides adjacent to the 
PAM motif as multiple mutations are tolerated in the crRNA (96–100). Early studies identified 
that Cas9 could tolerate many insertions or deletions (indels) in its Watson-Crick binding site. This 
was problematic, as a short recognition sequence in combination with flexible binding of the RNA-
DNA combination results in a large number of unwanted cleavage sites. Efforts to mitigate off-
target cleavage by Cas9 have been performed and are discussed in Chapter 1.3.4. 
1.3 Genome editing 
The ability to modify complex genomes has many downstream applications in agriculture, research 
and human disease treatment. The first therapeutic trial involving a human gene was approved by 
the FDA in the early 1990s to treat adenosine deaminase deficiency (ADA-SCID) (101). This 
monogenetic disease leads to severe immunodeficiency and was thought to be treatable using an 
ex vivo retroviral treatment, where the adenosine deaminase wild-type gene is integrated back into 
the patients (101). Initial treatments were not as effective as researchers hoped, and detrimental 
results were observed in some cases where patients either reacted poorly to the retrovirus or 
random insertions caused leukemia (101, 102). Even with unsettling first results, there have been 
over 1000 approved gene therapies to treat a wide range of human diseases (103). The  
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Figure 1.4: Schematic of two outcomes of genome-editing.  After the introduction of a double-
strand break, the DNA can be repaired through NHEJ or HR. If no repair template is present, Ku 
proteins will recognize the free ends and they will be ligated back together through NHEJ. If a 
template DNA is provided then the host can use homologous recombination for gene correction. 
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largest fear annotated with integrating vector gene therapy continues to be insertional mutagenesis 
into important host genes, as DNA integration is essentially random (104, 105). In the last 15 years, 
genome engineering has exploded into an exciting field composed using a number of site-specific 
reagents (Table 1.1). Genome-editing reagents have replaced retroviral integrases in non-specific 
‘gene augmentation’, as they are the most efficient method to achieve targeted integration through 
HR (106). Genome-editing reagents take advantage of host repair pathways, in order to correct or 
knockout genes of interest through the HR or non-homologous end joining pathway (NHEJ), 
respectively (Figure 1.4). First generation genome-editing reagents used the FokI Type IIs RE, 
fusing the nuclease domain to various DNA-binding platforms such as ZF and TALE domains to 
target various sequences. The FokI nuclease domain is a non-specific nuclease domain that 
requires dimerization for efficient DNA cleavage (107, 108). One of the first proof of concept 
experiments using FokI/zinc-finger fusions, known as ZFNs, successfully cleaved the ‘common 
gamma chain’ (IL2ry) gene in cultured human cells (109). Initial studies in human embryonic 
kidney (HEK293) cells demonstrated that ZFNs could induce an 1% gene correction efficiency at 
their target site (110–112). Around the same time, engineered LHEs were developed to recognize 
novel targets and were demonstrated to induce modifications at intended target sites (19, 41, 113, 
114). In 2010, the genome engineering field transitioned to TALE/FokI fusions, called TALENs, 
as the repeat:DNA 1:1 code was deciphered and offered a more programmable DNA-binding 
domain. However, TALENs had their own disadvantages and were short lived with the emergence 
of the CRISPR-Cas9 system in 2013. This RNA-guided genome-editing platform now dominates 
the field of genome engineering because of its ease of use. However, it was not long before 
specificity issues emerged in the new CRISPR-Cas9 system. 
1.3.1 Engineered LAGLIDADG homing endonucleases 
The first nuclease to successfully modify mammalian cells was the I-SceI LHE, presenting an 
exciting future for site-specific genome-editing. When I-SceI was co-transfected with a donor 
template in mammalians cells, a 100-fold increase in gene conversion (gene was repaired using 
tamplate DNA) was observed (115). The compact size containing both catalytic and DNA-binding 
capabilities made it an attractive genome-editing reagent. Successful gene modification in 
mammalian cells was only the beginning, since researchers next needed to demonstrate that LHEs  
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Figure 1.5: Schematic of various genome-editing reagents. 
Dimeric genome-editing reagents, zinc-finger nucleases (ZFN) and transcription activator-like 
effector (TALEN) reagents are derived from the non-specific Type IIs restriction enzyme FokI fusions. 
Monomeric genome-editing reagents depicted below with engineered LAGLIDADG homing 
endonuclease in green and Cas9 RNA-guided nuclease in blue. 
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could be reprogrammed to target different sequences. The compact structure of LHEs-two DNA-
binding saddles flanking the central catalytic core-has made engineering these enzymes a daunting 
task. The first two engineered LHE described were chimeras, H-DreI and DmoCre, created by 
fusing the N- and C- terminus of two different LHEs (77, 116). Fusing LHEs halves together to 
create novel engineered LHE was further explored by Baxter et al. 2012, they found roughly 50% 
of chimeras created were active enzymes. With a family of over 300 members characterized to 
date, being able to create chimeras could exponentially increase the number of available targets.  
Other studies have focused on engineering specific members in the LHE family, including the 
homodimeric enzyme I-CreI and monomeric I-OnuI. This approach used rational re-design 
creating libraries of locally altered specificity modules, designed to change specificity for 3 bp at 
a time. Directed evolution of LHE has been successful in creating novel LAGLIDADG targets in 
various human genes including MAO-B, RAG-1 and XPC (17, 15, 19, 117). Since catalytic 
activity is intrinsically related to DNA-binding, reprogramming LHEs often reduces or abolishes 
LHE activity. Other implications to consider when engineering LHE is that binding can involve 
partially folded protein requiring the two LAGLIDADG halves to communicate with each other 
to locate the correct target. Also, a conformational change in the DNA target site occurs upon LHE 
binding requiring intermolecular interactions between the two LAGLIDADG halves. Some pivotal 
high throughput techniques including in vitro compartmentalization and yeast surface display has 
made protein engineering of LAGLIDADG more feasible (118, 119). In addition, to enhance 
LAGLIDADG activity and specificity, recent groups have fused engineered LAGLIDADG 
enzymes to TALE domains to create “MegaTALs”. However, the technical skills involved in 
engineering LHE have limited it to a few specialized labs and in turn has limited their application 
as a genome-editing reagents.   
1.3.2 Zinc-finger and TALE nucleases 
Some of the most successful genome-editing reagents utilized the Type IIs restriction enzyme FokI 
fused to various DNA-binding platforms described in Chapter 1.2.3. Some important 
characteristics of the FokI nuclease include a bi-partite structure, requirement for dimerization for 
cleavage, and a non-specific nuclease domain. The FokI nuclease domain was fused to DNA-
binding platforms ZFs and TALEs to create zinc-finger nucleases (ZFNs) and transcription 
activator-like effector nucleases (TALENs), respectively. One caveat was FokI required 
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dimerization for efficient cleavage making the design more complex, as two ZFNs or TALENs 
were required to bind in a “head-to head” fashion for efficient cleavage. The first ZFNs presented 
many problems with specificity due to both the catalytic domain and DNA-binding domain. As 
described in Chapter 1.2.2, the ZF DNA specificity code was tough to predict and ZFNs required 
lots of optimization for efficient cleavage. Similar to engineered LAGLIDADG, the development 
of high-throughput assembly and screening brought some success to creating active ZFNs (120–
123).  Unfortunately, undesired cleavage was observed as the ZFNs dimerization occurred at 
weakly bound sites (122, 124). Although ZFNs were not very specific, this first generation reagent 
helped pioneer the genome-editing field, developing a lot of the current techniques that are still 
used today.  
The second generation FokI fusions were more customizable utilizing the TALE DNA-binding 
domain to create TALENs. As described in Chapter 1.2.3, TALEs advantage over ZF domains was 
their 1:1 protein-DNA code, where each repeat-variable diresidue (RVD) dictated a single bp 
contact. The discovery of the TALE protein-DNA code in 2010 changed the genome engineering 
field, as TALEs were quickly fused to the FokI nuclease domain and demonstrated to efficiently 
cleave desired targets in a wide range of model organisms (125–128). Although TALENs were 
more programmable, they presented new challenges including the large size ~130 kDa and repeat 
sequences made it difficult to assemble/clone and deliver using lentiviral systems (129, 130). Many 
protocols were developed to overcome the assembly problem including Golden Gate (GG) 
assembly and ligation independent cloning (126, 131). This allowed for easier assembly of a large 
number of TALENs at a single time. Packaging problems were also addressed using an alternative 
scaffold with arrays that are non-repetitive sequences the BurrH domain called BuDs (132). In 
addition, BuDs circumvented another restriction of classic TALENs requiring a 5’ thymine (T) 
due to a non-canonical repeat at the start of classic TALENs (133). TALEs have been used in an 
array of applications apart from nuclease reagents, playing a role in gene regulation by fusing 
TALEs to various transcription factors (125, 134–136). The TALEN platform did have some 
success in genome-editing as they were more specific then ZFNs but were quickly replaced by 
CRISPR-Cas9 technologies because of its ease of use and programmability. 
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Table 1.1: Properties of genome-editing reagents 
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1.3.4 CRISPR-Cas9 nucleases 
The introduction of the CRISPR-Cas9 system into the genome-editing field, it has made an 
astonishing impact on the scientific community. The main reason this platform has been so 
successful is its “ease-of-use”, governed by classic Watson-Crick base pairing to target DNA 
sequences. Therefore, changing the target sequence did not require complex protein engineering 
but a simple change in a RNA sequence. One pivotal study to transition Cas9 into an easy-to-use 
genome-editing reagent, was fusing the crRNA to the stabilizing tracrRNA to create one RNA 
molecule for gene targeting known as the guide RNA (gRNA) (96). Although Cas9 could be 
readily adapted to various sequences, it still had its own limitations that needed to be overcome. 
First, all Cas9 known to-date require a short PAM sequence adjacent to the intended target site. 
For Streptococcus pyrogenes, spCas9, the most widely used CRISPR system in genome-editing 
requires a NGG PAM motif at its target site (95). To expand the NGG requirement, a protein 
engineering approach was used to evolve new Cas9 with novel PAM sequences such as NAG (14). 
Another limitation was that the short 20 bp Watson-Crick target site presented off-target cleavage 
problems. The true specificity was limited to 7-12 nucleotides adjacent to the PAM motif as the 
more distal base-pairing was mismatch tolerant (96–100). Therefore, 12 bps plus the 3 bps for the 
PAM motif was not specific enough for the human genome (415 = 1.07 x 109). Many approaches 
were devised to overcome this problem, one approach used Cas9 nickase mutants as single-strand 
nicks are less detrimental to the genome but off-target cleavage was still observed (137). Another 
study created dimeric FokI-Cas9 fusions using inactive Cas9 proteins to reduce off-target cleavage 
but this also reduced the number of available targets (138). Utilizing truncated gRNAs with only 
17-bp or 18-bp of crRNA sequence aided in reducing the overall binding affinity allowing fewer 
mismatches but did not completely abolish off-target cleavage (139). Finally, through mutating 
the non-specific contacts, a high-fidelity Cas9 with significantly decreased off-target cleavage was 
developed (140, 141). Other applications of Cas9 included using a multiplex gRNA expression 
system to target and knock-out multiple genes simultaneously (99). This approach could be used 
to study protein pathways or redundant proteins. The success of CRISPR technology has scientific 
articles using CRISPR being published almost daily, with over 15 model organisms modified by 
CRISPR-Cas9 (142). 
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1.4 Scope of the thesis: dual-active nucleases utilizing the GIY-YIG I-
TevI nuclease domain for genome engineering 
This thesis focuses on the GIY-HE, I-TevI, with the goal to further characterize its catalytic and 
linker specificity and apply this knowledge to I-TevI derived genome-editing reagents. There have 
been a number of biochemical and structural studies characterizing the catalytic and linker domain 
specificity and function, but due to the inherent toxicity of native I-TevI, all previous studies were 
performed in vitro (30, 46, 49, 51). Biochemical studies highlighted regions in the native I-TevI 
homing site that were hypo- or hyper-sensitive to chemical modifications but sequence specificity 
was still not well characterized (49). Cleavage specificity of I-TevI was determined almost 20 
years ago, having a requirement for a 5’-CNNNG-3’ cleavage motif but the lack of sensitivity of 
the in vitro assay could not determine discrimination in the central 3 bp at the cleavage motif (51). 
By fusing the native I-TevI nuclease and linker domain to different DNA-binding platforms, we 
de-toxified the catalytic domain allowing us to study the specificity of I-TevI in vivo. We exploit 
one of the first I-TevI fusions to the LHE I-OnuI, referred to as MegaTev, to study the inherent 
specificity of the catalytic and linker domain of I-TevI in more depth. We hoped that knowledge 
gained from this platform could be used for other Tev-derived genome-editing reagents. 
Our first goal was to demonstrate that I-TevI could be fused to different DNA-binding platforms 
similar to FokI derived ZFNs and TALENs, to create a monomeric genome-editing reagent. The 
unique aspects of I-TevI fusions compared to FokI fusions included its inherent cleavage motif 
specificity 5’-CNNNG-3’, its ability to function as a monomer resulting in a more simplistic design 
and an opportunity of creating a dual-active endonuclease that can create two DSB at a single 
target site. A dual-active endonuclease could excise a short DNA fragment from the genome, 
resulting in the free DNA ends being ligated together in vivo. We envisioned this would increase 
the efficiency of gene knockouts as persistent cleavage and re-ligation from single cutting 
endonucleases would not occur. Previous studies utilized the DNA 5’-exonuclease Trex2 to 
increase gene modification for LAGLIDADG and ZFNs (20, 143).  All other genome-editing 
reagents, MegaTALs, ZFNs, TALENs, and Cas9 create only a single DSB at their target site. 
Although they all vary in efficiency ranging from 15-80% depending on the target site and reagent, 
the indels created are random and unpredictable (108, 144–146). We proposed that our dual-active 
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endonucleases are able to bias these events to further favour gene-knockout as the excised fragment 
creates a predictable repair event between the two free ends.  
Here, we develop I-TevI fusions to programmable DNA-binding platforms and investigate the 
specificity of the I-TevI nuclease and linker domain in vivo. With this fundamental knowledge we 
were able to engineer novel I-TevI mutants with enhanced activity and altered specificity. Using 
the dual-active nuclease platforms, MegaTev and TevCas9 fusions, could prove advantageous over 
traditional reagents because their ability to create more predictable modifications at their target 
sites. The genome-editing field is always in search of the most specific, easy-to use, and efficient 
reagents. It is difficult to engineer a reagent that checks all three boxes but our most recent TevCas9 
reagent is at least 2 out of 3, being relatively easy-to-use and more efficient then Cas9 alone. 
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Chapter 2 
2 Monomeric site-specific nuclease for genome editing 
The work presented in this chapter is reproduced (with permission, Appendix S1) from: 
Kleinstiver, B.P., Wolfs, J.M., Kolaczyk, T., Roberts, A.K., Hu, S.X., Edgell, D.R. 
(2012) Monomeric site-specific nucleases for genome editing. Proceedings of the 
National Academy of Sciences USA 109(21):8061-6 
2.1 Introduction 
Precise genome editing often requires the introduction of a double-strand break (DSB) at defined 
positions (1-3), and two distinct site-specific DNA endonuclease architectures have been 
developed towards this goal. One of these architectures relies on reprogramming the DNA-binding 
specificity of naturally occurring LAGLIDADG homing endonucleases (LHEs) to target desired 
sequences (4, 5). The other architecture utilizes the reprogrammable DNA-binding specificity of 
zinc-finger proteins or TAL-effector domains that are fused to the non-specific nuclease domain 
of the type IIS restriction enzyme FokI to create chimeric zinc-finger nucleases (ZFNs) or TAL 
effector nucleases (TALENs) (6-8). Regardless of the architecture, the underlying biology of the 
component proteins imposes design challenges and the relative merits of the LHE and the 
ZFN/TALEN architectures are the subject of much debate in the literature (6, 9). One notable 
constraint imposed by the FokI nuclease domain is the requirement to function as a dimer to 
efficiently cleave DNA (10, 11). For any given DNA target, this necessitates the design of two 
distinct ZFNs (or two TALENs), such that each pair of zinc finger or TAL effector domains is 
oriented for FokI dimerization and DNA cleavage (12).  
Expanding the repertoire of DNA nuclease domains with distinctive properties is necessary to 
facilitate the development of new genome editing reagents. Indeed, a number of recent studies 
have explored the potential of the PvuII restriction enzyme as an alternative site-specific nuclease 
domain for genome editing applications (13, 14). The PvuII chimeras, however, share similar 
design constraints as ZFNs and TALENs, requiring two nuclease fusions for precise targeting. In 
considering alternative nuclease domains for genome editing, we were intrigued by the properties 
of the GIY-YIG nuclease domain that is associated with a variety of proteins of diverse cellular 
functions (15). The small (~100 aa) globular GIY-YIG domain is characterized by a structurally 
conserved central three-stranded antiparallel β sheet, with catalytic residues positioned to utilize a 
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single metal ion to promote DNA hydrolysis (16-18). Intriguingly, the GIY-YIG homing 
endonucleases, typified by the isoschizomers I-TevI and I-BmoI (19), bind DNA as monomers 
(20), and generate a DSB with 2-nt, 3’ overhangs. It is unknown, however, if GIY-YIG homing 
endonucleases function as monomers in all steps of the reaction, as the oligomeric status during 
cleavage has yet to be studied. Notably, GIY-YIG homing endonucleases prefer a specific DNA 
sequence to generate a DSB (21, 22). For I-TevI, the bottom (↑) and top (↓) strand nicking sites lie 
within a 5‘-CN↑NN↓G-3’ motif (CNNNG), with the critical G optimally positioned ~28 bp from 
where the H-T-H module of the I-TevI DNA-binding domain interacts with substrate (21, 22). 
From an engineering perspective, the modularity and sequence specificity of the GIY-YIG 
nuclease domain makes it an appealing candidate to create new chimeric endonucleases. Indeed, 
swapping of the I-BmoI and I-TevI catalytic and DNA-binding domains suggested that the GIY-
YIG nuclease domain could be fused to unrelated DNA-targeting platforms (23). 
To highlight the genome engineering potential of the GIY-YIG nuclease domain, we fused the 
domain to 3-member zinc fingers to construct GIY-YIG zinc finger endonucleases (GIY-ZFEs). 
The GIY-ZFEs are active in bacterial and yeast cells, and in vitro data show that they function 
catalytically as monomers and retain the cleavage specificity associated with the parental GIY-
YIG nuclease domain. The GIY-YIG nuclease domain is also portable to the LHE platform, as we 
constructed monomeric GIY-LHEs that are active in vivo and possess ~18-bp binding specificity. 
We selected LHEs as a DNA targeting domain because of the greater sequence specificity 
compared to 3-member zinc fingers, the ability to reprogram LHE DNA-binding specificity (24-
26), and recent success in generating PuvII-LHE fusions (13). Collectively, our data highlight the 
unique biochemical properties of the GIY-YIG nuclease domain as an alternative to the FokI 
nuclease domain for genome editing applications. 
2.2 Material and methods 
See detailed Supplemental materials and methods. Briefly, Tev-ZFE and Tev-LHE fusions and 
hybrid target sites were modeled in PyMOL using the I-TevI 130C (PDB 1I3J), Zif268 (PDB 
1AAY), and I-OnuI (PDB 3QQY) cocrystal structures (25, 27, 28). The in vivo activity of fusions 
was determined using a two-plasmid bacterial selection (31) or yeast-based reporter assay (that 
was used to calibrate activity of Tev-ZFEs and Tev-TALs) against a characterized ZFN (35). 
TevN201-ryA was purified using nickel affinity chromatography to determine the in vitro 
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biochemical properties of Tev-ZFEs. Cleavage assays were performed as described (43). A custom 
Perl script was created to determine CNNNG occurrences relative to 8,829 predicted ZFN sites on 
zebrafish chromosome 1 (40). 
2.3 Results 
2.3.1 Construction and validation of GIY-zinc finger endonucleases 
To create novel chimeric enzymes, we modeled GIY-zinc finger endonucleases (GIY-ZFEs) using 
existing crystal structures of the I-TevI 130C DNA binding domain and the Zif268 zinc finger (27, 
28). One notable feature of our constructs is the polarity, as the I-TevI nuclease domain is fused to 
the N-terminal end of the ryA protein to mimic its native orientation, unlike FokI constructs that 
are fused to the C-terminal end of zinc-finger proteins. We modeled the Zif268 zinc finger in place 
of the H-T-H at the C-terminus of I-TevI, providing the rationale to subsequently fuse various 
lengths of the I-TevI N-terminal region to the ryA zinc finger that targets a sequence in the 
Drosophila rosy gene to create Tev-ryA zinc finger endonucleases (Tev-ZFEs, Fig. 2.1A) (29). 
The Tev-zinc finger DNA substrates (TZ) consisted of 30 to 38 bps of the I-TevI td homing site 
joined to the 9-bp ryA target site. The TZ substrates differ in the distance of the CNNNG cleavage 
motif relative to the ryA-binding site (Fig. 2.1B). Each TZ substrate possesses a single zinc finger 
targeting sequence, rather than two head-to-head zinc finger sites necessary for efficient ZFN 
cleavage. A similar set of I-BmoI-ryA fusions (Bmo-ZFEs) and substrates (BZ) were constructed 
(Fig. S1).  
We tested the activity of the GIY-ZFEs using a well-described two-plasmid bacterial selection 
system, where survival is dependent on the endonuclease cleaving a target plasmid (30, 31). Eight 
Tev-ZFEs were tested on seven TZ substrates cloned into the reporter plasmid (Fig. 2.1B and C, 
Table S2.1). In general, the survival of all Tev-ZFEs was highest against TZ substrates where the 
preferred CNNNG motif was positioned between 33 and 35-bp from the ryA binding site. Low 
survival (~4-6%) was observed for all Tev-ZFEs against the TZ1.32 substrate, while none survived 
on the TZ1.30 substrate. Likewise, there was no survival against the longer substrates, with the 
exception that the longest fusion (TevS206-ryA) exhibited ~22% survival against the TZ1.36 
substrate. No survival was observed when the Tev-ZFEs were tested against the target plasmid 
without a target site (p11lacYwtx1). Mutation of the catalytic arginine 27 of the I-TevI nuclease 
domain to alanine to create TevR27A-ryAs showed that survival is dependent on GIY-YIG  
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Figure 2.1: Design and functionality of Tev-ZFEs  
(A) Modeling of a Tev-zinc finger fusion with DNA substrate (light green) using structures of the 
I-TevI catalytic domain in green (PDB 1MK0), the I-TevI DNA-binding domain co-crystal in blue 
(PDB 1I3J), and the Zif268 co-crystal in red (PDB 1AAY) (B) The TZ-ryA substrate is colored 
according to the structural model. Shown is the top strand of the I-TevI td homing site substrate 
fused to the 5’ end of the ryA-binding site for all wild-type substrates tested. The substrate is 
numbered from the first base of the td homing site sequence (the numbering scheme is reverse of 
that used for the native td homing site). The substrates tested differ by insertion or deletion of td 
sequence at the junction of the td/ryA sites. (C) Percent survival of three representative Tev-ryA 
ZFEs in the bacterial two-plasmid selection. All Tev-ryA ZFEs were tested against plasmids 
containing various length substrates (TZ1.30-1.38), plasmids lacking a target site (p11lacY), and 
TZ1.33 plasmids with single or double mutations in the CNNNG motif (G5A and C1A/G5A) 
(Table S1). (D) Percent survival of TevN201-ryA and TevN201-ryB ZFEs on their cognate and 
reciprocal target sites. Data are plotted with standard deviation for n  3. 
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nuclease activity as none of the Tev-R27A constructs survived (Table S2.1). We also constructed 
and tested a fusion of the TevN201 domain to a different 3-member zinc finger, the ryB zinc finger, 
creating TevN201-ryB. The TevN201-ryB showed survival in the bacterial selection assay against 
a corresponding TZ-ryB target, indicating that the I-TevI nuclease domain can function in the 
context of two different 3-member zinc fingers, but did not survive when tested against the TZ-
ryA substrate (Fig. 2.1D). Likewise, the TevN201-ryA fusion did not survive against the TZ-ryB 
substrate, indicating that the zinc finger alone directs DNA-binding. We also tested the Bmo-ZFEs 
in the genetic selection, but did not observe significant survival for any of the fusions, consistent 
with the ~750-fold reduced activity of wild-type I-BmoI relative to I-TevI (32). However, as 
described below, enzymatic activity was detected in vitro using purified Bmo-ZFEs. Collectively, 
these data show that two different GIY-YIG nuclease domains could be fused to zinc finger DNA 
binding domains to create active site-specific chimeric nucleases. 
2.3.2 Tev-ZFEs function as monomers to cleave at a specific sequence 
To study the GIY-ZFE biochemical characteristics in more detail, we purified TevN201-ryA for 
cleavage assays and in vitro mapping. We first performed cleavage assays to determine the 
relationship between TevN201-ryA enzyme concentration and initial reaction velocity using a 
plasmid substrate with a single TZ-ryA target site. The reaction progress curves indicated an initial 
burst of cleavage followed by a slower rate of product accumulation (Fig. 2.2A), consistent with 
product release being the rate-limiting step.  The initial burst phase was used to estimate initial 
velocity, and plotting against protein concentration yielded a linear relationship (Fig. 2.2A), 
suggesting that DNA hydrolysis catalyzed by TevN201-ryA is first order with respect to protein 
concentration.  
The model TZ-ryA substrates were designed as a single ryA zinc finger site fused to the I-TevI 
target sequence. To determine if cleavage by TevN201-ryA was influenced by additional Tev-ryA 
target sites, we constructed two-site plasmids that differed in whether the target sites were in the 
same or opposite orientations relative to each other. The single- or two-site plasmids were used in 
time-course cleavage assays under single-turnover conditions (~10-fold molar excess of protein to 
substrate) to determine reaction rates. As shown in Fig. 2.2B, cleavage of the one-site plasmid 
yielded kobs(1-site) = 0.099 ± 0.001 s
-1, and cleavage of the two-site plasmids with target sites in the 
opposite or same (Fig. S2.2B) orientations generated very similar rate constants, kobs(2-site) = 0.088  
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Figure 2.2: TevN201-ZFE is a monomer with a preferred cleavage site.   
(A) Left panel: plot of initial reaction progress for seven TevN201-ZFE concentrations expressed 
as percent linear product. Protein concentrations from highest to lowest are 47 nM, 32.5 nM, 23 
nM, 11nM, 6nM, 3 nM, and 0.7 nM. Right panel: graph of initial reaction velocity (nM s-1) versus 
TevN201-ZFE concentration (nM). (B) Graphical representation of cleavage assays with 90 nM 
TevN201-ZFE and 10 nM one- or two-site TZ1.33 plasmids (left and right panels, respectively). 
The two-site plasmid had the TZ-ryA sites in the opposite (shown) or same (Fig. S2B) orientation. 
SC, supercoiled; OC, open-circle (nicked); FLL, full-length linear; L1+L2, linear products. (C) 
Mapping of TevN201-ZFE cleavage sites on the TZ1.33 substrate, with top and bottom cleavage 
sites indicated below on the TZ-ryA substrate by open and closed triangles, respectively. (D) 
Activity of TevN201-ZFE on the wild-type TZ1.33, or the TZ1.33 G5A and TZ1.33 C1A/G5A 
mutant substrates. A graph of EC0.5max determinations for each substrate is shown to the right, with 
EC0.5max values in nM. Data are plotted as averages of three independent replicates with standard 
deviations 
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± 0.001 s-1 and 0.089 ± 0.001 s-1, respectively, to the one-site plasmid. In contrast, similar 
experiments with FokI showed a significant rate enhancement for two-site plasmids relative to 
one-site plasmids, consistent with FokI functioning as a dimer (33). We conclude that cleavage by 
TevN201-ryA is non-cooperative and that efficient DNA hydrolysis does not require two sites, 
consistent with TevN201-ryA functioning catalytically as a monomer. 
The I-TevI nuclease domain preferentially cleaves DNA within a 5’-CN↑NN↓G-3’ motif, with ↑ 
and ↓ representing the bottom- and top-strand nicking sites, respectively (22). Wild-type I-TevI 
defaults to cleave at the correct distance on substrates in vitro when this motif is moved closer to, 
or distant from, the primary binding site, whereas mutants in the I-TevI specific zinc finger cleave 
at the correct sequence rather than the correct distance on mutant substrates (34). To determine the 
cleavage preference of the TevN201-ryA construct, we mapped the bottom- and top-strand nicking 
sites using strand-specific end-labeled substrates to the CNNNG motif (Fig. 2.2C). Combined with 
data from the genetic assays showing no survival on substrates that displace the CNNNG motif 
from an optimal position, our data suggests that in the context of a ryA fusion, the TevN201 
domain acts as a molecular ruler with a distance preference.  
To further demonstrate TevN201-ryA cleavage preference, we introduced mutations in the 
CNNNG motif that were previously shown to drastically reduce I-TevI cleavage efficiency (Fig. 
2.2D) (21, 22). Significantly, we observed no survival in the two-plasmid selection assay on 
plasmids carrying either the single G5A (CNNNA) or double C1A/G5A (ANNNA) substitutions 
(Fig. 2.1C), equivalent to positions C-27 and G-23 of the I-TevI td substrate, respectively. We also 
performed in vitro cleavage assays on wild type and mutant substrates with increasing 
concentrations of TevN201-ZFE to determine the amount of protein required for half-maximal 
cleavage (EC0.5max). As shown in Fig. 2.2D, ~60 fold and ~4.7 fold more protein were required to 
achieve half-maximal cleavage of the double- and single-mutant substrates relative to the wild-
type substrate. The greater substrate discrimination observed in the genetic assay likely reflects 
lower in vivo protein concentrations than those used for in vitro cleavage assays. These results 
show that the TevN201-ryA fusion retains the cleavage specificity of the parental I-TevI enzyme 
and that double nucleotide substitutions significantly reduce cleavage efficiency. To determine if 
Bmo-ZFEs also retained substrate specificity, the bottom- and top-strand nicking sites of the 
BmoN221-ryA fusion were mapped to a 5’-NN↑NN↓G-3’ motif, consistent with the cleavage site 
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preference of I-BmoI (Fig. S2.1D) (19).  
2.3.3 The Tev-ZFEs function in a yeast-based recombination assay 
To extend the in vivo relevance of the Tev-ZFE fusions, we utilized a well-described yeast-based 
recombination assay to test Tev-ZFE function in a eukaryotic system (35). This assay provides a 
quantitative -galactosidase readout if the nuclease cleaves its target site that is positioned between 
a partially duplicated lacZ gene. Furthermore, the assay allowed us to calibrate TevN201-ryA 
activity relative to a homodimeric FokI-Zif268 control with previously measured in vivo activity 
sufficient to induce recombination events for genome engineering applications (35). As shown in 
Fig. 2.3, the level of -galactosidase activity for the TevN201-ryA fusion on its cognate TZ-ryA 
substrate was ~1.4-fold higher than the Zif268 ZFN control. The TevN201-ryA or Zif268 ZFN 
constructs displayed no activity on each other’s substrates, and activity was dependent on a 
functional I-TevI nuclease domain, as the TevN201R27A catalytic mutant was unable to induce 
recombination. Furthermore, TevN201-ryA activity was not observed on mutant substrates where 
one or both of the critical residues of the CNNNG motif were mutated in the TZ1.33 substrate. 
Collectively, these assays show that the I-TevI nuclease domain functions in a eukaryotic system 
with activity on par to a characterized ZFN.  
2.3.4 The I-TevI nuclease domain is portable to the LAGLIDADG architecture 
To demonstrate that the I-TevI nuclease domain functions in the context of DNA-targeting 
platforms other than 3-member zinc fingers, we constructed fusions of the domain to a catalytically 
inactive monomeric single-chain LAGLIDADG homing endonuclease (Tev-LHE). As with the 
Tev-ZFE constructs, we modeled a Tev-LHE chimera using the co-crystal of I-OnuI with its DNA 
substrate such that the I-TevI nuclease and linker domains were fused to the N-terminus of I-OnuI, 
which is partially disordered in the structure (Fig. 2.4A) (25). Based on this model, we fused 
TevN201G4 and TevK203 fragments to a catalytically dead I-OnuI E1 E22Q mutant. A series of 
model DNA substrates were constructed by fusing the td target site to the I-OnuI E1 binding site 
in the human MAO-B gene, differing in the position of the CNNNG cleavage motif relative to the 
I-OnuI E1 site (TO1.12 to TO1.30) (Fig. 2.4B).  
In the bacterial two-plasmid selection, we found that the TevN201G4-Onu and TevK203-Onu 
fusions were active against a range of DNA substrates. Notably, the fusions displayed maximal  
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Figure 2.3: Tev-ZFEs can induce recombination in a eukaryotic system 
Shown are normalized -galactosidase units from a yeast-based recombination assay for the 
indicated nuclease/substrate combinations. Activity was normalized to a homodimeric FokI-
Zif268 ZFN positive control. Data are plotted with standard deviation for n = 4.  
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survival on longer targets (TO1.26, TO1.28, and TO1.30), and lower survival against shorter 
targets (TO1.18 and TO1.20 targets). The two groups of substrate differ by approximately one 
helical turn of DNA, meaning that the preferred CNNNG motif would be presented on the same 
face of substrate even though the motif is closer to the I-OnuI E1 binding site on the shorter targets. 
Similar periodic cleavage patterns have been observed in vitro with I-TevI on substrates with a 
displaced CNNNG motif (36). This result also implies that the N-terminus of I-OnuI possesses 
inherent flexibility to allow the I-TevI nuclease domain to search out the CNNNG motif, in contrast 
to the ruler-like behaviour of the Tev-ZFE constructs, likely because the zinc finger N-terminus is 
inflexible. Importantly, the Tev-Onu fusions were not active against the TZ-ryA zinc finger 
substrates (Table S2.2), showing that the LHE, and not the I-TevI linker, directs DNA targeting. 
Survival was also dependent on an active I-TevI nuclease domain, as TevR27A fusions in the 
context of the I-OnuI E22Q mutant did not survive (Fig. 2.4D). Conversely, the targeting and 
activity of wild-type I-OnuI E1 was not affected by fusion of the I-TevI domain, as the TevR27A-
OnuWT fusions survived against TO substrates (Fig. 2.4D).  
The apparent flexibility of the N-terminus and the greater specificity of I-OnuI prompted us to test 
fusions containing shorter fragments of the I-TevI nuclease domain (Fig. 2.4A). Based on structural 
and genetic data, we constructed TevS114-Onu, TevD127-Onu, TevN140-Onu, TevN169-Onu, 
and TevD184G2-Onu fusions, progressively removing amino acid residues of I-TevI that make 
specific base-pair contacts to the td substrate (28)(Fig. 2.4A). Notably, the TevS114, TevD127, 
TevN140 and TevN169 removed the -helix that binds in the minor groove, as well as residues 
shown by structural data to make base-specific contacts (28). The TevS114 fusion point lies at the 
boundary of the deletion tolerant region of the I-TevI linker, and represents a functionally minimal 
GIY-YIG nuclease domain (36, 37). We found that the shorter fusions were not active against the 
longer TO1.28 and TO1.30 substrates, yet displayed the same periodic activity on the shorter 
substrates (Fig. 2.4C and Table S2.2). A single exception was the TevD184G2 fusion that showed 
low survival against the TO1.22 substrates, against which no other fusion survived. No survival 
was observed on mutant substrates that contained single (CNNNA) or double (ANNNA) mutations 
in the CNNNG motif, recapitulating the necessity for an appropriately positioned CNNNG as seen 
with the Tev-ZFE fusions. 
2.3.5 A 5’-CNNNG-3’ cleavage motif is not limiting for targeting 
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Figure 2.4. Design and functionality of Tev-LHEs 
(A) Modeling of a Tev-Onu E1 fusion with DNA substrate (light green) using structures of the I-TevI 
catalytic domain in green (PDB 1MK0), the I-TevI DNA-binding domain co-crystal in blue (PDB 1I3J), 
and the I-OnuI co-crystal in red (PDB 3QQY). Shown are fusion points at which the I-TevI fragment has 
been shortened. (B) The Tev-Onu E1 (TO) substrate is colored according to the structural model. Shown is 
the top strand of the I-TevI td homing site substrate fused to the 5’ end of the Onu E1-binding site. The 
substrates are numbered from the first base of the td homing site sequence and differ by the deletion of td 
nucleotides at the junction of the td/Onu E1 sites. (C) Percent survival of Tev-LHEs in the bacterial two-
plasmid selection with various length target sites (TO1.12-1.30). All Tev-LHEs tested were in the I-OnuI 
E1 E22Q background. (D) Percent survival of TevR27A(N201G4)-OnuE1 and TevR27A(N201G4)-
OnuE1(E22Q) on TO1.30, TO1.30G5A, and TZ1.33. Data are plotted with standard deviation for n = 3. 
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An important consideration in the design of GIY-ZFEs or GIY-LHEs for genome-editing 
applications are the targeting requirements, notably the need for the CNNNG di-nucleotide 
cleavage motif (Fig. 2.5A). In a complex genome of ~ 3x 109 bp, the statistically predicted 
occurrence of the CNNNG motif is once every 15 bp assuming a 50% GC content. To determine 
if the frequency of the CNNNG motif would be limiting for targeting applications, we examined 
35 bp flanking 8,829 computationally predicted ZFN sites on zebrafish chromosome 1 for the 
occurrence of the CNNNG motif (38). As shown in Fig. 2.5B, the motif is highly represented at 
all positions within a 35-bp window relative to the ZFN sites. Of the 8,829 sites examined, 88% 
(7,845) of ZFN sites possessed at least one motif within 35 bp of the predicted binding site (Fig. 
2.5C). These requirements contrast sharply with those of the recently described PvuII-LHEs and 
PvuII-ZFNs that require the 6-bp 5’-CAGCTG-3’ PvuII site in addition to the LHE or ZF binding 
site (13, 14). Of the 8,829 ZFN sites, 97% lacked a PvuII site within the 35-bp window (Fig. S2.3). 
Thus, the requirement for a di-nucleotide cleavage motif in the context of a GIY-ZFE or GIY-LHE 
will not severely limit potential targeting sites. 
2.4 Discussion 
Here, we provide evidence that the GIY-YIG nuclease domain is a potential alternative to the 
currently used FokI nuclease domain for genome editing applications. We show that the I-TevI 
GIY-YIG nuclease domain is portable to two reprogrammable DNA-binding scaffolds, the 3-
member zinc fingers and LAGLIDADG homing endonucleases. The Tev-ZFE and Tev-LHE 
fusions are active in vitro and in vivo, with the activity of the Tev-ZFE in a yeast-based 
recombination assay on par with that of a characterized ZFN. We foresee the monomeric nature of 
the Tev-LHEs and Tev-ZFEs as a key advantage over existing ZFNs and TALENs, as a single 
fusion protein need be designed to target a given sequence, rather than two ZFNs or TALENs 
required to promote dimerization of the FokI nuclease domain (12). Moreover, the fact that the I-
TevI nuclease domain possesses a preferred cleavage motif adds another layer of specificity to 
targeting requirements, potentially limiting DSBs at off-target sites that do not posses the cleavage 
motif.  
One targeting consideration for chimeric GIY-YIG endonucleases is the DNA sequence 
requirement of the I-TevI linker. The I-TevI linker is a complex structure, consisting of defined 
structural elements with distinct roles in I-TevI function (28, 34, 36). The primary role of the linker  
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Figure 2.5: Cleavage requirements do not limit GIY-ZFE and GIY-LHE applicability  
(A) A diverse set of monomeric and sequence specific reagents can be generated by fusing distinct 
GIY-YIG domain linker lengths to engineered DNA-binding platforms, including zinc-finger 
arrays and inactive LAGLIDADGs. (B) Shown is the distribution of the CNNNG motif in a 35-bp 
window flanking 8,829 predicted ZFN sites on zebrafish chromosome 1. The number of 
occurences of the ‘C’ of the motif at each distance is indicated. (C) Unique ZFN sites were grouped 
according to the number of occurences of the CNNNG motif in the 35-bp window. The red line is 
the expected number of ZFN sites for each group based on a binomial distribution.  
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is to position the nuclease domain on substrate for cleavage at the CNNNG motif, which is found 
at a defined distance from the binding site on naturally occurring I-TevI substrates. However, the 
linker can direct the nuclease domain in vitro to search out displaced CNNNG motifs on both 
native and non-native substrates with insertions or deletions, albeit with reduced cleavage 
efficiency. Our Tev-LHE fusions recapitulate this distance versus sequence behaviour in vivo, as 
the fusions can cleave displaced CNNNG motifs with a periodicity that parallels the helical nature 
of DNA. We partially attribute this ability of the Tev-Onu fusions to the flexible N-terminus of I-
OnuI. The substrate flexibility of different length Tev-Onu fusions is an important consideration 
for targeting, as CNNNG motifs at various positions relative to the LHE binding site would be 
accessible by the choice of the appropriate Tev-LHE fusion. In contrast, the apparently inflexible 
N-terminus of the 3-member zinc fingers constrains cleavage to a distance of 33-36 bp from the 
ryA-binding site, mimicking the spacing of the CNNNG motif on native td substrate. Our longest 
Tev-ZFE and Tev-LHE fusions encompass all the known elements of the I-TevI linker that make 
multiple base-specific and non-specific contacts to DNA (28). However, biochemical studies 
revealed that I-TevI retains significant cleavage activity on substrates with multiple substitutions 
in the central region of its cognate DNA substrate that is contacted by the linker, equivalent to 
positions 6-33 of our longest chimeric substrates (39). The shortest Tev-LHE fusions do not 
contain any linker elements that are known to make base-specific DNA contacts, and cleave only 
at the preferred CNNNG motif. This observation implies that the I-TevI linker may contact 
substrate nucleotides adjacent to the CNNNG motif. Potential contacts may play a role in the 
positioning of the nuclease domain, rather than being necessary for cleavage, and any preference 
may be related to regulating the position of the nuclease domain on substrate or the maintenance 
of DNA-structure (36).    
Future work on Tev-ZFEs and Tev-LHEs will require a detailed dissection of binding affinity and 
specificity, and characterization of cellular toxicity that results from cleavage at off-target sites. In 
their current form, the targeting specificity of the Tev-ZFEs is a function of the 3-zinc finger 
domain, which could be further enhanced by addition of zinc fingers to generate a 4-, 5-, or 6-zinc 
finger fusion, as has been done with a variety of ZFNs (40). In contrast, the ~18-bp specificity of 
LHEs is sufficient to direct targeting and cleavage at endogenous loci in human cells. LHEs, 
however, are tolerant of nucleotide substitutions within their recognition sequence, and I-OnuI E1 
cleaves off-target sites that differ by one or two nucleotide substitutions (25). In the context of 
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Tev-LHEs, decoupling of DNA-cleavage and DNA-binding activity by using a catalytically dead 
LHE scaffold, combined with the requirement for a preferred I-TevI CNNNG cleavage motif, 
would significantly reduce cleavage at off-target sites (Fig. S2.4). Another advantage of the 
decoupled activities of Tev-LHEs is that they would not require re-optimization of catalytic 
activity that is often necessary in LHEs that have been reprogrammed to bind non-native target 
sites (25, 41). Similar to the exploration of alternative DNA-binding platforms (2), it is imperative 
to incorporate nuclease domains with distinct biochemical properties into the genome engineering 
pipeline to create highly precise tools. With further optimization, the I-TevI nuclease domain may 
become an alternative to the FokI-derived ZFNs and TALENs. 
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Chapter 3 
3 MegaTevs: Single chain dual-active site nucleases for efficient gene 
disruption 
The work presented in this chapter is reproduced (with permission, Appendix S1) from: 
Wolfs, J.M., Dasilva,M., Meister,S.E., Wang,X., Schild-Poulter,C. and Edgell,D.R. (2014) 
MegaTevs: Single-chain dual nucleases for efficient gene disruption. Nucleic Acids Res., 42, 
8816–8829. 
3.1 Introduction 
The rapid pace of development in the genome-editing field has led to a number of competing 
technologies, each with their benefits and limitations (1,2). The technologies can be broadly 
characterized based on the nuclease domain used to introduce a double-strand break (DSB) or nick 
at a target site. Two common reagents are zinc-finger nucleases (ZFNs) and TAL effectors 
nucleases (TALENs) that utilize the dimeric and non-specific FokI nuclease domain (3-6). Two 
head-to-head ZFN or TALENs pairs must be designed to target a single site, and positioned such 
that the FokI domains can dimerize to introduce a DSB (7-9), typically with 4-nt 5’ overhangs. 
The non-specific cleavage activity of the FokI nuclease domain facilitates targeting of a wide range 
of sequences, but can lead to off-target cleavage (10-12). The recently developed CRISPR/Cas9 
system has received significant attention due to the ease of programming targeting (13,14). In this 
system, a RNA guide molecule (the crRNA) targets the Cas9 nuclease to a DNA target through a 
RNA/DNA heteroduplex (15-18). A blunt-ended DSB results from two independent nicking 
reactions, one by a HNH nuclease domain, and the other by a RuvC-like domain. An alternative 
nuclease architecture utilizes the naturally occurring meganucleases, or LAGLIDADG family 
homing endonucleases, which are typically encoded within self-splicing group I introns and 
inteins, and are characterized by an extensive protein-DNA interface (19,20). The nuclease active 
site is formed at the interface of two parallel α-helices, with cleavage generating a DSB with 4-nt 
3’ overhangs. Recently, a number of recombinase (21,22) and sequence-specific nuclease domains 
have been developed as alternatives to the non-specific FokI nuclease domain (23-26). In 
particular, we and others showed that the monomeric and sequence tolerant GIY-YIG nuclease 
domain from the homing endonuclease I-TevI could be fused to zinc fingers, meganucleases, and 
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TAL effectors to create novel monomeric enzymes (27,28). The I-TevI-based reagents are active 
on substrates that contain a preferred CNNNG cleavage motif, generating 2-nt 3’ overhangs.    
Regardless of the technology, one common application of genome-editing nucleases is the 
generation of gene disruptions whereby mutagenic repair at the targeted DSB introduces frame-
shift mutations into a coding region. The mutagenic DNA repair events occur in the absence of an 
exogenously provided DNA repair template, and result mainly from the non-homologous end-
joining (NHEJ) pathway (29-31). However, many DSBs are repaired without mutation, as the 
compatible cohesive ends generated by the nucleases are re-ligated through the canonical NHEJ 
pathway, leading to a cycle of persistent cleavage and precise repair events that are non-productive 
for genome engineering. One strategy to bias repair events towards gene disruption is to co-express 
a DNA end-processing enzyme with the genome-editing nuclease (32,33). For instance, Trex2, a 
3’-5’ exonuclease, dramatically increases gene disruption when co-expressed with ZFNs, 
TALENs, and meganucleases by processing of DSBs before DNA repair. One potential limitation 
of this strategy is the requirement to transfect the Trex2 coding region with the ZFN, meganuclease 
or dimeric TALEN constructs, which may be problematic in size-constrained vectors. 
Overexpression of Trex2 could also enhance mutagenic repair at unwanted off-target sites, 
although no increases in cellular toxicity or off-target cleavages were observed with Trex2 over-
expressing cell lines (32,33). Gene disruption could be enhanced by targeting two reagents to the 
same locus, positioning two DSBs to effectively excise the intervening sequence and introduce a 
deletion. Such multiplexing of genome-editing regents is constrained by the dimeric architecture 
of the ZFNs and TALENs (34), and in the case of the CRISPR/Cas9 system, requires the use of 
nicking variants and dual-guide RNAs (35,36). 
Here, we propose an alternative strategy for gene disruption by coupling two different nuclease 
active sites into a single polypeptide. The MegaTev architecture is the fusion a meganuclease 
(Mega) with the nuclease domain derived from the GIY-YIG homing endonuclease I-TevI (Tev). 
The two active sites are positioned ~30-bp apart on DNA substrate, and generate two DSBs with 
non-compatible cohesive ends. The dual active MegaTev shows high gene disruption activity in 
HEK 293 cells without overexpression of DNA-end processing enzymes.  
3.2 Material and methods 
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3.2.1 Bacterial strains and plasmid construction 
Escherichia coli DH5α (New England Biolabs) was used for plasmid amplification, ER2566 (New 
England Biolabs) for protein expression and BW25141 (λDE3) for bacterial two-plasmid 
selections (Supplemental Table S1) (37). Tev-Onu and Tev-Ltr fusions were cloned into 
pACYCDuet-1 using 5’ NcoI and 3’ XhoI sites as previously described (27). For the yeast DNA 
repair assay (3,38), the Tev-Onu and Tev-Ltr genes were amplified using Phusion DNA 
polymerase (New England Biolabs) with a 3’ primer that introduced a C-terminal SV40 nuclear 
localization sequence (NLS) (primers are listed in Supplemental Table S2). PCR products were 
cloned into the NcoI/SalI sites of pGPD. The backbone target site plasmid for the yeast assay was 
created by amplifying a 300-bp fragment of the pTox plasmid and cloning it BglII/SpeI into 
pCP5.1 to create pCPTox. All target sites were subsequently cloned into pCPTox using in vivo 
homology directed repair. For mammalian assays, human codon optimized Tev-Onu fusions 
(synthesized by IDT-DNA) were PCR amplified and cloned PstI and RsrII into pExodus. Tev-Onu 
fusions were cloned in-frame with a mCherry gene linked by a T2A peptide sequence from Thosea 
asigna virus to separate the translated proteins. The TO15 target site was subcloned into the 
pMSCVpuro retroviral vector (Clontech) using BglII and XhoI sites to integrate into genomic 
DNA in HEK 293 cells. To generate target sites for episomal plasmid assays, substrates were 
cloned the SacI/XhoI sites of pcDNA3(+) vector. Constructs were confirmed by sequencing. 
3.2.2 In vitro randomized substrate selection 
A list of randomized target site oligonucleotides is found in Supplemental Table S2. The target 
site plasmid library for the randomized cleavage motif plus 3 bps of the spacer (N8) were 
constructed in the pSP72 backbone as described (39). The library complexity was estimated to be 
~ 6.4 x104 for the N8 library based on the number of independent transformants, and from analyses 
of next-generation sequencing data. 
Cleavage assays were performed with 23 nM of Tev169-Onu E22Q and 10 nM N8 plasmid in 
NEBuffer 3 (50 mM Tris-HCl pH 7.9, 100 mM NaCl, 10 mM MgCl2 and 1 mM DTT) at 37°C for 
5 mins. The Tev169-Onu fusions were purified as described (27) (Supplemental Fig. S1). Samples 
were prepared for Ion Torrent sequencing at the London Regional Genomics Centre by PCR 
amplification of the target site region from the input plasmid library, and from the plasmids isolated 
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after three rounds of selection using PWO (Roche) with barcoded primers. The sequencing data 
were parsed with custom Perl scripts that checked for anchor sequences either side of the 
randomized region, confirmed that the sequence between the anchors corresponding to the 
randomized region was 8 nts in length, and then extracted the randomized region for further 
analyses. For each round of selection, counts for each nucleotide j per position i were determined, 
and then converted to proportions using the centred log-ratio transformation 
Ci,j = log2(pi,j) − mean log2(pj) 
Nucleotide selection was then determined by taking the difference in proportions for each 
nucleotide per position between the final round of selection and the input library. A positive value 
indicates selection or enrichment for a particular nucleotide relative to the input library, and a 
negative value indicates selection against a particular nucleotide relative to the input. The 
enrichment values were plotted in heatmap format using R and ggplot2 (40,41), and enrichment 
values were considered significant if they were > 2 standard deviations from the mean enrichment 
value for each dataset. 
3.2.3 Cleavage assays on radiolabelled substrate 
In vitro cleavage assays were performed on internally radiolabelled substrates that were PCR 
amplified with [α-32P] dCTP. PCR products were loaded onto an 8% (w/v) polyacrylamide gel 
(29:1 acrylamide/bisacrylamide), run at 40 mA for ~1.5 hrs, gel purified, eluted overnight at 42°C 
in 5 mL of TE pH 8.0, and concentrated into 50- Cleavage reactions were performed 
in 20 μL reaction volumes with NEBuffer 3 (50 mM Tris-HCl pH 7.9, 100 mM NaCl, 10 mM 
MgCl2 and 1 mM DTT), 0.1 pmol of substrate and 2 pmols of Tev169-Onu fusion protein. 
Cleavage reactions were incubated at 37°C for 1, 5, 10 and 25 mins before stopping the reaction 
with 6 μL of 100 mM EDTA and 5 μL of loading dye containing 0.5% SDS. Mutant Tev169-Onu 
fusions were incubated for 1 hr at 37°C before stopping the reaction with 6 μL of 100 mM EDTA 
and 5 μL of loading dye containing 0.5% SDS. The entire reaction was loaded on a 15% (w/v) 
polyacrylamide gel (29:1 acrylamide/bisacrylamide) and electrophoresed at 40 mA for ~1.5 hrs. 
The gel was removed from the apparatus and soaked in 10% glycerol plus 8% acetic acid before 
drying on Whatman paper and visualized using a phosphorimager (GE Healthcare). 
3.2.4 Modified two-plasmid target site screen 
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The 64-triplet variants for the CNNNG cleavage motif were screened using a modified two-
plasmid selection (42). Transformants were gridded onto selective plates (LB plus 25 μg/mL 
chloramphenicol and 10 mM L-(+)-arabinose) and non-selective plates (LB plus 25 μg/mL 
chloramphenicol, 50 μL/mL kanamycin and 0.2% glucose) and incubated overnight at 37°C. 
Plasmids isolated from survivors and non-survivors were sequenced to identify the NNN variant 
of the CNNNG motif.  
3.2.5 Yeast β-galactosidase repair assay 
This assay was performed as described (27). Briefly, YPH499(a) containing target site constructs 
were mated in triplicate with YPH500(α) harbouring the MegaTev constructs. After an overnight 
selection for diploids, cells were assayed for β-galactosidase activity using orthonitrophenol 
(ONPG). Activity was normalized to either a validated homodimeric zinc-finger nuclease (Zif268) 
or the wild-type TP15 substrate depending on the assay. 
3.2.6 DdeI-resistance assays with plasmid substrates  
HEK 293T cells were cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 
10% fetal bovine serum (FBS). Approximately 2.5x106 million cells were seeded 24 hrs before 
transfection on 6 cm plates. Cells were co-transfected with 3 μg of pExodus Tev169-Onu E22Q 
and 3 μg of pcDNA3(+) TO15 using calcium phosphate and incubated at 37°C with 5% CO2 for 
16 hrs before changing media. After 48 hrs, plasmid was isolated from HEK 293T cells using the 
BioBasic miniprep kit. Target sites were PCR amplified, separated on a 1% agarose gel, and gel 
purified. After gel purification, 250 ng of PCR product was incubated with 2 U of DdeI (New 
England Biolabs) in NEBuffer2 for 1 hr at 37°C. Digests were electrophoresed on a 1.5% agarose 
gel, stained with ethidium bromide, and analyzed on an AlphaImagerTM3400 (Alpha Innotech). 
3.2.7 Surveyor assays with integrated targets 
Target site integration into HEK 293 cells was performed using the Phoenix Ampho retroviral 
packaging cell line. To accomplish this, 8 μg of pMSCV TO15 was transfected into Phoenix cells 
using calcium phosphate and incubated at 37°C with 5% CO2 for 48 hrs. Media was removed and 
filtered through a 0.45 μm filter into a falcon tube containing 6 μL of 4 mg/mL polybrene 
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(hexadimethrine bromide), and 6 mls of virus solution was used to infect HEK 293 cells to create 
the integrated cell line (HEK 293-TO15). Approximately 24 hrs before transfections, ~2.5x106 
HEK 293-TO15 cells were seeded on 6 cm plates, and subsequently transfected with 6 μg of 
pExodus Tev169-Onu or pExodus I-SceI. After 48 hrs, the HEK 293-TO15 cells were harvested 
and total genomic DNA isolated. Two rounds of nested PCR were performed, and gel purified 
PCR products were boiled at 95°C for 10min, then cooled slowly to 50°C before flash freezing at 
-20°C for 2 mins. To assay for indels, 200 ng of PCR product was incubated with 2 U of T7 
endonuclease I (New England Biolabs) in NEBuffer2 for 1 hr at 37°C, separated on a 1.5% agarose 
gel, and analyzed using an AlphaImagerTM3400 (Alpha Innotech). 
3.3 Results 
3.3.1 MegaTevs: Chimeric fusions of GIY-YIG and meganuclease components 
To determine if the I-TevI nuclease domain could function in the context of different 
meganucleases, we fused residues 1-169 of I-TevI (Tev169) to the native N-terminus of the 
catalytically inactive I-LtrI variant, I-LtrI E29Q, to create Tev169-Ltr E29Q (Tev-xLtr) (Fig. 
3.1A). Along with the previously constructed Tev169-Onu E22Q (Tev169-xOnu) (27), we assayed 
the activity of both MegaTevs using a yeast recombination assay where a target site is positioned 
between a partially duplicated lacZ gene. Cleavage of the target site induces the single-strand 
annealing pathway to reconstitute a functional lacZ gene resulting in β-galactosidase activity. We 
tested activity on hybrid target sites consisting of the native I-TevI CNNNG cleavage motif (5’-
CAACG-3’) and DNA spacer derived from the phage T4 thymidylate synthase (td) gene fused to 
either the I-OnuI or I-LtrI binding site (TO or TL, respectively) (Fig. 3.1A). The substrates differed 
in the length of the DNA spacer (from 11 to 21-bp) separating the I-TevI CNNNG cleavage motif 
from the I-OnuI or I-LtrI binding site. As shown in Figure 3.1B, Tev169-xOnu and Tev169-xLtr 
activity was highest with a DNA spacer length of 15 bp, agreeing with results from profiling DNA 
spacer length requirements of the Tev-xOnu construct in a bacterial two-plasmid survival assay 
(27). Furthermore, mutating the critical cleavage CNNNG motif to ANNNA abolished activity for 
both Tev169-xOnu and Tev169-xLtr on the 15-bp spacer substrate [TO15CS(-) and TL15CS(-)], 
demonstrating the I-TevI nuclease domain maintains cleavage specificity in the context of a 
meganuclease fusion. To demonstrate that the MegaTevs are directed to their target sites by the  
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Figure 3.1 MegaTev activity in yeast and HEK 293T cells 
(A) (top) Schematic for the modular MegaTev fusions, consisting of the I-TevI nuclease domain 
and various linker lengths fused to a meganuclease. Catalytically inactive R27A I-TevI and E22Q 
I-OnuI are denoted by xTev and xOnu, respectively. (bottom) The modular composition of the 
target site consisting of the 5’-CNNNG-3’ (CAACG) cleavage motif and variable length spacer 
region (11-21bp) from the native I-TevI thymidylate synthase (td) gene located upstream of the 
meganuclease binding site. The arrows highlight the top and bottom I-TevI cleavage sites. 
Highlighted in the box is the DdeI site adjacent to the I-TevI cleavage site used to identify 
mutagenic events in HEK 293T cells. (B) Boxplot of the activity for Tev169-xOnu (Top) and 
Tev169-xLtr (Bottom) on various DNA spacer lengths in the yeast recombination assay. TO15CS(-
), AAACA cleavage motif in the TO15 target site; TL15CS(-), AAACA cleavage motif in the 
TL15 target site; xLtr, a catalytically inactive E29Q I-LtrI. Activity was normalized to the 
homodimeric FokI-Zif268 fusion and data are plotted with SD for n=3. (C) DdeI digestion of PCR 
products to identify mutagenic events for an episomal target in HEK 293T cells. Shown is a 
representative agarose gel for DdeI digested PCR amplified target sites from plasmids isolated 48 
hrs post-transfection. Indicated by the asterisk is the DdeI cleavage-resistant product, with percent 
product indicated below each lane. (D) Cleavage-resistant products from HEK 293T cells 
transfected with Tev169-xOnu were cloned and analyzed by sequencing. The TO15 target site is 
highlighted in green and in the red box is the DdeI site used to identify cleavage resistant products. 
Deletions encompass the I-TevI cleavage site with the length of deletion illustrated by the dashed 
lines.  
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meganuclease and not the I-TevI nuclease domain and linker, we tested the Tev-xOnu against the 
TL15 target site, and tested Tev-xLtr against the TO15 target site. No activity was observed for 
either fusion on the reciprocal substrates (Fig. 3.1B), showing that the I-TevI nuclease domain 
does not direct targeting of the MegaTevs.  
To further demonstrate the genome-editing relevance of MegaTevs, we constructed a Tev169-
xOnu fusion codon-optimized for expression in human cells, and co-transfected it and the TO15 
target site cloned on a separate plasmid into HEK 293T cells. To monitor Tev-xOnu activity, we 
took advantage of a DdeI site that lies immediately downstream of the I-TevI CNNNG motif (Fig. 
3.1A). Plasmid substrates cleaved in vivo by the MegaTev would be subject to mutagenic non-
homologous end joining repair, destroying the DdeI site. Subsequent resistance of target sites to 
DdeI digestion after PCR amplification from genomic DNA reflects Tev-xOnu cleavage and 
mutagenic repair. Significantly, we observed 9% DdeI cleavage resistance for target sites 
amplified from unsorted HEK 293T cells co-transfected with Tev-xOnu and the TO15 target site 
(Fig 3.1C). In contrast, no DdeI resistant products were observed for cells transfected with the 
TO15 target site plasmid only. Cleavage resistant products were cloned and sequenced, revealing 
deletions that spanned the I-TevI cleavage site (Fig. 3.1D), demonstrating that MegaTevs function 
to induce mutagenic DNA repair in human cells. 
3.3.2 Dual active site MegaTevs for highly efficient targeted deletions 
A unique aspect of the MegaTevs is the fusion of two homing endonuclease active sites into a 
single polypeptide chain. Each active site is positioned such that the top-strand nicking sites are 
separated by ~30 bp on the TO15 DNA substrate. When both active sites are functional, this 
arrangement presents the opportunity to introduce two DSBs with different cohesive ends at a 
single site in a highly efficient and concerted process. As a proof of concept, we constructed and 
purified a Tev169-Onu dual nuclease where both the I-TevI and I-OnuI active sites are wild type 
(Tev169-Onu, Fig. 3.2A). Activity was tested in vitro utilizing an internally radiolabelled PCR 
product of 242-bp containing the TO15 target site. Cleavage by the dual nuclease would be evident 
by the release of 29-bp product corresponding to the internal sequence between the I-TevI and I-
OnuI cleavage sites (Fig. 3.2A). As shown in Figure 3.2B, the dual active MegaTev efficiently 
produced three products after 5 mins of digestion, with the accumulation of the internal product  
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Figure 3.2: Dual active site MegaTev activity in vitro  
(A) Schematic of substrate and cleavage products containing the TO15 target site indicated by a 
green-filled rectangle.  The black and red arrows indicate the top and bottom cleavage sites (CS) 
for I-TevI and I-OnuI, respectively. Black dashed lines indicate I-TevI cleavage products (TP1 and 
TP2), I-OnuI cleavage products (OP1 and OP2), and the red dashed line is the internal dual product 
(DP) from both I-TevI and I-OnuI cleavage. Sizes of the substrate and products are indicated in 
base pairs (bp). (B) Polyacrylamide gel of internally labeled TO15 PCR substrate (SUB) incubated 
with (+) or without (-) purified dual active Tev169-Onu and single-active site variants. The 
MegaTevs were incubated with substrate for the indicated times, and cleavage products are 
indicated on the right side of the gel based on their predicted sizes from panel (A). The sizing 
standard (in bp) was cropped from the gel image.  
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(IP) after 25 mins. Interestingly, cleavage by the I-TevI nuclease domain precedes cleavage by I-
OnuI, as I-TevI-specific products are detected at 1 min (TP1 and TP2), whereas I-OnuI products 
are detected after 5 mins (OP1 and OP2). Cleavage assays where I-TevI is active and I-OnuI is 
inactive (Tev169-xOnu) produced two products consistent with only I-TevI cleavage activity. 
Similarly, a catalytically inactive R27A I-TevI in the context an active I-OnuI fusion (xTev169-
Onu) produced two products consistent with I-OnuI cleavage. No cleavage was observed for the 
dual dead nuclease (inactive I-TevI R27A and I-OnuI E22Q, xTev-xOnu) after 1 hr of incubation. 
We also constructed and purified an analogous Tev169-Ltr dual nuclease, and tested for activity 
on an internally labeled PCR product containing the TL15 site (Supplemental Fig. S3.1). I-TevI-
specific cleavage products were observed before I-LtrI products, with the internal cleavage product 
visible after 5 mins of incubation. 
To extend these results to an in vivo context, we stably integrated the TO15 target site into the 
genome of HEK 293 cells, and assayed for activity after independent transfections with the 
Tev169-Onu dual nuclease and single nuclease variants. The expression constructs included the 
MegaTev open-reading frame (ORF), followed by an in-frame T2A peptide and mCherry ORF, 
allowing us to monitor MegaTev expression by mCherry levels (Fig. 3.3A). After 48 hours of 
incubation, the TO15 target site was PCR amplified and subject to digestion by T7 endonuclease 
I (T7EI) to evaluate the extent of MegaTev activity. T7EI was used rather than DdeI digestion to 
allow us to more accurately detect I-OnuI-specific events with the xTev-Onu construct. As shown 
in Figure 3B, the dual active Tev169-Onu showed 24 +/- 6% indels, whereas undetectable levels 
of cleavage were observed with both of the single active site Tev169-Onu fusions (xTev169-Onu 
and Tev169-xOnu), in spite of similar expression levels (Fig. 3.3A). It is important to note that we 
did not co-express DNA end processing enzymes, such as the 3’-5’ exonuclease Trex2, to enhance 
mutagenic repair at the TO15 cleavage site. Extremely low levels of cleavage by the xTev169-Onu 
variant, where I-OnuI E2 is active, is consistent with previous studies that required sorting for cells 
with high I-OnuI expression levels and multiple rounds of PCR enrichment to visualise I-OnuI E2 
cleavage (43).  
To confirm that cleavage by the dual MegaTev resulted in the deletion of the internal sequence 
between the I-TevI and I-OnuI cleavage sites, the PCR products that were resistant to cleavage by 
DdeI were cloned and sequenced. We recovered three sequences (M1, M2 and M3) that each  
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Figure 3.3: Dual active site MegaTev activity in HEK 293 cells 
 (A) Schematic of the expression construct, with the MegaTev ORF linked to mCherry through a 
T2A peptide. The CMV promoter was used to express the constructs. NLS, nuclear-localization 
signal. Representative contrast and fluorescence images for cells transfected with the indicated 
MegaTev fusions are shown below. (B) T7 endonuclease I (T7EI) digests of TO15 target site PCR 
products from HEK 293T cells transfected with the indicated MegaTevs. The extent of T7EI 
digestion is indicated below each lane. An asterisk indicates the T7EI cleavage products. (C) 
Summary of sequencing of PCR amplified TO15 target sites that were resistant to cleavage by 
DdeI. Three sequence types were found, indicated by M1, M2 and M3. The number of independent 
occurrences that each sequence type was identified from Tev169-Onu and Tev184-Onu 
transfections is indicated on the right.  
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occurred multiple times, and in each case the intervening sequence was deleted (Fig. 3.3C). We 
also transfected another dual active MegaTev construct containing the I-TevI 1-184 fragment fused 
to I-OnuI E2 (Tev184-Onu) into the HEK 293 cells, and observed a similar high level of activity 
(Fig. 3.3B). Sequencing of DdeI-resistant PCR fragments from the Tev184-Onu transfection 
revealed only the M1 sequence that was observed with the Tev184-Onu construct (Fig. 3.3C). One 
explanation for the recovered sequences is that the I-TevI 2-bp 3’-overhang is ligated directly to 
the I-OnuI 4-bp 3’-overhang with minimal processing and fill-in of the 2-bp gap.  
Collectively, our data show that the fusion of two homing endonuclease active sites into a single 
polypeptide chain creates a dual nuclease that can introduce two DSBs at a single target site. In 
both an in vitro and in vivo context, the two DSBs excise a short internal fragment, thus increasing 
the efficiency of targeted deletion without expression of DNA end-processing enzymes. 
3.3.3 Requirements of the I-TevI CNNNG cleavage motif in vivo 
Efficient cleavage by the I-TevI nuclease domain requires that the 5’-CNNNG-3’ cleavage motif 
be spaced 15 bp from the meganuclease binding site (Fig. 3.1B). The C and G of the motif are 
critical for cleavage, while the central three bases (the NNN triplet) exhibit a substantial degree of 
tolerance to substitution (44,45). To determine the tolerance of the central three bases to 
substitution in the context of the MegaTev fusion, we used a variation of a two-plasmid bacterial 
selection to rapidly assess survival of all 64 variants of the central triplet cloned into the toxic 
plasmid. In this assay (42), the 64 toxic plasmids were transformed into cells harbouring the 
Tev169-xOnu fusion, plated on non-selective plates, and then replica-gridded onto selective plates 
to induce expression of the ccdB gene on the toxic plasmid. Cells survive this challenge if Tev169-
xOnu can cleave and promote elimination of the toxic plasmid. The Tev169-xOnu fusion was used 
for this experiment to ensure that survival was due to I-TevI activity and not I-OnuI activity. Three 
different morphologies were observed on the selective plates; no growth (dead), colonies that grew 
to the same diameter on both the selective and non-selective plates (strong survivors), and colonies 
that grew on selective plates but were smaller in diameter than on non-selective plates and often 
formed a cauliflower morphology (weak survivors) (Supplemental Fig. S3.4). Weak survivors 
were determined to be target sites that promoted < 1% percent survival when assayed individually. 
Survival was plotted in a heatmap format (Fig. 3.4A) revealing that C/G rich triplets generally 
inhibited Tev169-xOnu survival.   
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Figure 3.4: MegaTev nucleotide preference within the CNNNG cleavage motif 
(A) The three nucleotides of the NNN triplet are labeled as 1, 2, and 3 from 5’ to 3’ within the 
CNNNG motif. Heat map of Tev169-xOnu activity on all 64 variants of the cleavage motif in the 
bacterial two-plasmid selection. The first nucleotide of the NNN triplet is plotted on the left axis, 
the second nucleotide of the NNN triplet on the bottom axis, and the third nucleotide on the right 
axis. (B) Heat map of the activity of Tev169-xOnu on all 64-nucleotide variants in the yeast -
galactosidase repair assay. The values are normalized to the wild-type sequence (AAC) and plotted 
on a log2 scale. The heatmap is labeled as in panel (A). (C) Boxplots depicting the log2 activity 
for NNN triplets that have 1, 2 or 3 nucleotide differences relative to the wild-type AAC sequence. 
For each boxplot, the upper and lower bounds of the boxes indicate the 25th and 75th percentile of 
the data, the solid horizontal bar indicates the median of the data, and the ends of the whiskers 
represent 1.5 times the interquartile range. Individual data points are shown as open circles, and 
data points that lie outside of the interquartile range (outliers) are shown as black points. (D) 
Boxplots of the influence of nucleotide identity at each of the three positions within the NNN motif 
on activity relative to the wild-type AAC sequence. The boxplots are labeled as in panel (C). 
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We also assayed all 64-triplet variants in the quantitative yeast-based lacZ repair assay, and plotted 
the activity for each triplet normalized to the activity of the wild-type AAC triplet on a log2 scale 
(Fig. 3.4B). In general, more substitutions within the triplet resulted in lower activity, however 
some triplets with 2 or 3 substitutions were as active as the wild-type AAC triplet (Fig. 3.4C). A/T 
rich target sites displayed activity on par with the wild type sequence. As with the bacterial two-
plasmid selection, triplets with a C and/or G in the first two positions supported lower β-
galactosidase activity, and triplets with a G in the third position were less active than other 
nucleotides at this position (Fig. 3.4D).  
3.3.4 MegaTevs selects for the appropriately spaced cleavage motif from a random 
substrate 
To determine the optimal sequence and spacing of the cleavage motif, we generated a plasmid 
library where the CAACG cleavage motif and three downstream base pairs were completely 
randomized (Fig. 3.5A, the N8 library). A round of in vitro selection with the N8 plasmid library 
consisted of in vitro digestion with purified Tev169-xOnu, isolation of linearized plasmid, re-
ligation and transformation into E.coli for amplification. After three rounds of selection, the input 
library and the final round of selection were sequenced using the Ion Torrent platform. After data 
processing, we first determined the proportion of all 16 possible dinucleotide combinations 
(ANNNA, ANNNC, ANNNG, etc) regardless of position within the N8 randomized region to 
ascertain if the MegaTev displayed a preference for the CNNNG motif. As shown in Figure 5A, 
the CNNNG motif was greatly enriched by round 1 relative to the other dinucleotide combinations, 
and predominated by round 3, indicating that CNNNG is the preferred motif. Although minor 
enrichment relative to the input library was observed for other dinucleotide combinations 
(ANNNA and ANNNT), these combinations do not support activity in cell-based assays, and are 
not considered relevant.  
We next analyzed the phasing of the CNNNG motif within the N8 randomized region for reads 
containing this motif. This analysis was undertaken as native I-TevI can cleave the wild-type 
CAACG motif that has been moved closer to the primary binding site (albeit with lower efficiency) 
(46). The statistical occurrence of the CNNNG motif is 1 in 15 bps, and would be expected to 
occur at the four possible positions within the input N8 library (C1:G5, C2:G6, C3:G7, and  
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Figure 3.5: MegaTev selects for an appropriately spaced cleavage motif 
(A) At top is a schematic of the TO15 substrate and N8 randomized library with the eight 
randomized positions colored in red. The randomized positions are labeled 1 to 8, with position 1 
corresponding to the C of the CNNNG cleavage motif. Shown below is a bar graph showing the 
fraction of reads with each of the 16 possible dinucleotide combinations. (B) Bar graph showing 
the fraction of reads with the CNNNG cleavage motif at positions C1:G5, C2:G6, C3:G7, and 
C4:G8 for the input library and selection rounds 1 and 3. (C) Heat map plotted on a log2 scale 
showing abundance of all 64 CNNNG motifs after three rounds of selection with the Tev169-xOnu 
fusion. The first, second and third nucleotide corresponds to the second, third and fourth nucleotide 
in the N8 library, respectively. (D) Correlation between the in vitro abundance from the selection 
experiments and in vivo activity in the yeast-based assay for each NNN triplet.  
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C4:G8). Indeed, we observed the CNNNG motif with approximately equal frequency at the four 
possible positions within the input N8 library (Fig. 3.5B, red bars). However, when the sequencing 
reads for selection rounds 1 and 3 were analyzed, we found an overwhelming preference for C and 
G at positions 1 and 5, respectively (Fig. 3.5B, blue and grey bars). This analysis confirms that the 
MegaTev is cleaving at correctly positioned CNNNG motifs within the N8 library, with the G of 
the motif positioned 15-bp from the LHE binding.  
Using sequencing reads that possessed the CNNNG motif at positions 1 and 5 of the randomized 
region, we determined the abundance of each NNN triplet within the motif and plotted the log2 
abundance in a heatmap format (Fig. 3.5C). As anticipated, A/T rich triplets were preferred over 
G/C rich triplets. This analysis also facilitated a comparison to the activity of each NNN triplet in 
the yeast DNA repair assay (Fig. 3.4B). Plotting the normalized abundance of each NNN triplet 
from the sequencing data versus the activity in the yeast-based assay showed that A/T rich NNN 
triplets supported higher activity relative to G/C rich sequences in both datasets (Fig. 3.5D). 
3.3.5 Nucleotide preference within the CNNNG motif and at flanking positions 
We next analyzed nucleotide preferences at each position in the N8 library after the third round of 
selection. Nucleotide preferences were determined by calculating the proportional abundance of 
each nucleotide at each position for both the input library and round 3 selection, and then plotting 
the difference (enrichment) between round 3 and input as a heatmap (Fig. 3.6A). One advantage 
of this analysis is that it corrects for nucleotide bias in the input library. As shown in Figure 6A, 
apart from the expected C and G preference at positions 1 and 5, the strongest preference was 
observed at position 7, where T or A were selected for while a C or G were selected against. 
Interestingly, in four of the positions (3, 6, 7, and 8), the wild-type nucleotide was not preferred, 
implying that the native td target site of I-TevI is not the optimal substrate.  
To provide an in vivo context for the nucleotide preferences observed in the flanking DNA 
sequence, we independently made point substitutions in the TO15 substrate at positions 6 and 7, 
and tested their activity in the yeast β-galactosidase assay (Fig. 3.6B). Substitutions to A or T at 
position 6 did not drastically reduce activity as compared to the TO15 substrate, while the C6G 
substitution showed a modest increase in activity. At position 7, the T7A substitution reduced  
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Figure 3.6: Nucleotide preference within the N8 randomized library  
(A) Heatmap for nucleotide enrichment after three rounds of selection with the Tev169-xOnu 
fusion. Dashed boxes represent enrichment values that are greater than two standard deviations 
away from the mean of enrichment values at all positions. The wild-type sequence is indicated at 
each position.  (B) Validation of nucleotide preferences within the N8 randomized region. Boxplot 
of Tev169-xOnu activity of on TO15 substrates with point mutants indicated by underlined, and 
italicized bold-type font. Activity is normalized to Tev169-xOnu on the TO15 substrate. Each 
mutant was assayed at least three times. Sequences are displayed on the left of the graph with the 
mutations bolded and underlined. 
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activity by half, while the T7G substitution reduced activity to background levels, supporting the 
enrichment preferences seen in the in vitro data.  
Collectively, these data show that the MegaTev strongly prefers to cleave CNNNG motifs spaced 
15-bp from the meganuclease-binding site, agreeing with previous studies on spacing of the 
cleavage motif (27). We also found that the I-TevI nuclease domain is tolerant of multiple 
substitutions within the CNNNG motif, with many variants cleaved better than the wild-type AAC 
triplet, but in general preferring A/T rich sequences. Defining a strict consensus sequence within 
the motif is complicated by the observation of different levels of activity for each of the 64-possible 
CNNNG variants. 
3.3.6 Testing for off-target cleavage 
Off-target cleavage is a significant concern for genome-editing endonucleases. To assess off-target 
cleavage of the MegaTev architecture, we took advantage of previously predicted off-targets for 
the I-OnuI E2 variant (the backbone meganuclease for our MegaTevs) (43). The I-OnuI E2 variant 
was optimized to cleave a site within the human MAO-B gene, and a CNNNG motif is positioned 
11-bp upstream of the I-OnuI E2 binding site. A number of the top-ranked off-target sites also 
possess CNNNG motifs within 30-bp of the I-OnuI E2 binding site (Fig. 3.7A), suggesting that 
they might be substrates for the I-TevI nuclease domain. These sites differ in the spacing of the 
CNNNG motif from the I-OnuI E2 binding site, and also in the NNN triplet of the cleavage motif. 
We tested for cleavage at these sites using T7EI digestion of PCR products amplified from HEK 
293 cells that were transfected with the dual active Tev169-Onu MegaTev. As shown in Figure 
3.7B, we did not observe any T7EI digestion products at these sites, whereas robust T7EI digestion 
was seen at the integrated TO15 site. We attribute undetectable (or extremely low) activity at these 
sites to the sub-optimal spacing of the CNNNG motif from the I-OnuI site, and to the presence of 
NNN triplets that are weakly active as judged by the yeast DNA repair assay. While the sites tested 
represent a small number of the potential off-target sites, our data suggest that very low levels of 
off-target cleavage will be observed with the MegaTev at off-target sites where the CNNNG motif 
is not optimally spaced, or where the NNN central triplet does not support robust activity. 
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Figure 3.7: Surveyor assay for off-target cleavage.   
(A) Schematic showing the TO15, MAO-B and three off-target sites. The I-OnuI E2 site is boxed, 
with the nucleotide differences in pink lower case font, while the upstream sequences are in lower 
case black font. Numbering is relative to the 5’ end of the I-OnuI binding site. Potential CNNNG 
cleavage motifs are highlighted in red boxes. (B) T7 endonuclease I (T7EI) digests of PCR-
products corresponding to the indicated target sites amplified from HEK 293 cells transfected the 
dual active site MegaTev. The extent of T7EI cleavage is indicated below each lane.  
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3.4 Discussion 
A number of characteristics of the I-TevI nuclease domain and meganucleases make them well 
suited for genome-editing applications. Of relevance to the current study is the fact that cleavage 
by each enzyme generates different length non-cohesive overhangs (2-nt 3’ overhangs for I-TevI, 
and 4-nt 3’ overhangs for meganucleases) (47-49). I-TevI remains bound to its cleavage products, 
and protects DNA ends from exonucleolytic resection, affecting the extent and directionality of 
DNA repair events (50). Kinetic studies have also shown that product release by meganucleases is 
rate limiting (51), and denaturation of meganuclease-DNA complexes is often required to resolve 
cleavage products in agarose gels (52). Thus, the efficiency of the dual active MegaTevs in HEK 
293 cells can in part be attributed to the non-compatible cohesive ends that are sequestered from 
the NHEJ repair machinery. Sequencing of cleaved targets sites largely supports this hypothesis, 
as the DSBs are repaired with minimal processing without evidence of deletions up- or down-
stream of the I-TevI and I-OnuI cleavage sites. End-sequestration by the single-chain MegaTev 
would also minimize DNA rearrangements such as translocations, inversions or duplications, as is 
observed with simultaneous expression of multiple genome-editing nucleases in multiplexing 
experiments. 
The MegaTevs used in this study were targeted to model DNA substrates. To be generally useful, 
the MegaTev platform must be able to target a range of sequences. Engineering meganuclease 
specificity has been greatly accelerated by a detailed understanding of protein-DNA contacts 
through crystallographic, computational, and biochemical studies, and by improvements in 
screening methodologies (43,53-56). Recent efforts suggest that 1 in 300 bp can be targeted by the 
current set of meganucleases for which detailed protein-DNA contacts maps are available. The 
targeting range of the MegaTev platform can also be increased by fusing the I-TevI domain to 
different meganucleases, as shown with the I-LtrI fusions. A series of tailored enzymes that can 
target sites with a variety of nucleotide compositions could also be achieved by fusing different 
GIY-YIG nuclease domains with distinct cleavage preferences to the same meganuclease 
backbone. Our preliminary studies in this regard have generated active enzymes by fusion of the 
GIY-YIG domain from the I-TuIa homing endonuclease to I-OnuI (J.M.W and D.R.E, unpublished 
results) (57).  
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Precise targeting and prediction of off-target sites will also require a detailed understanding of the 
nucleotide requirements of the GIY-YIG nuclease domain. In the case of I-TevI, past studies 
revealed that the nuclease domain required a 5’-CNNNG-3’ cleavage motif (45,46), and that the 
linker was tolerant of multiple substitutions within the DNA spacer that separates the cleavage 
motif from binding site (44). More recently, the I-TevI cleavage motif was defined as CDDHGS 
(D=A,G,T;H=A,C,T;S=G or C) in the context of a monomeric TALEN architecture (cTALENs) 
(28). This consensus sequence differs from our observed nucleotide preferences, and one reason 
may be that the cTALEN study examined cleavage preference within a CNNNG motif positioned 
7-bp from the TALE binding site. Our screen of DNA spacer length variation, in contrast, shows 
a clear spacing preference of 15-bp with MegaTevs derived from both I-OnuI and I-LtrI (Fig. 1B). 
Thus, the cTALEN study may in fact be describing nucleotide preference within the DNA spacer 
region that is contacted by the I-TevI linker. Our results also revealed a wide range of tolerance to 
substitution within the CNNNG motif, with some NNN triplets cleaved more efficiently than the 
wild-type AAC sequence. We anticipate that both the spacing and sequence requirement of the 
CNNNG motif will “de-toxify” off-target cleavage, for the simple reason that not all off-target 
sites will have a permissive motif positioned appropriately from the meganuclease binding site. 
Indeed, our data, while representing a small number of potential off-target sites, revealed no 
detectable cleavage by T7EI assays. 
In summary, the MegaTevs represent a novel fusion of two different active sites to generate a dual 
nuclease with a high efficiency of gene disruption without the need to overexpress DNA end-
processing enzymes. The compact size of the MegaTev, coupled with the high fidelity imparted 
by the specificity of the I-TevI and meganuclease domains, makes them suitable for genome-
engineering applications where minimizing off-target effects is paramount.    
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Chapter 4 
4 Biasing genome-editing events towards precise length deletions with 
RNA-guided TevCas9 dual nuclease (Part 1: I-TevI variants) 
The work presented in this chapter is reproduced (with permission, Appendix S1) from: 
Wolfs, J.M., Hamilton, T.A., Lant, J.T, Laforet, M., Zhang, J., Salemi, L., Gloor, G.B., 
Schild-Poulter,C. and Edgell,D.R. (2016) Biasing genome-editing events towards precise length 
deletions with RNA-guided TevCas9 dual nuclease. PNAS (pii: 201616343. [Epub ahead of 
print]) 
4.1 Introduction 
Genome editing with engineered nucleases has revolutionized the targeted manipulation of the 
genomes of organisms ranging from bacteria to mammals 1. Zinc finger nucleases (ZFNs) 2 
LADLIDADG homing endonucleases (also called LHEs or meganucleases) 3, transcription-like 
effector nucleases (TALENs) 4, and nucleases based on the clustered regularly interspersed short 
palindromic repeat (CRISPR) systems all represent programmable genome-editing nucleases that 
have successfully been used to introduce targeted changes in genomes 5. One of the most common 
applications of genome-editing nucleases is gene knockouts that are performed in the absence of 
an exogenously added repair template. The nuclease-introduced break is repaired by the mutagenic 
non-homologous end-joining pathway (mNHEJ) 6-8, resulting in small insertion or deletions 
(indels) that, if targeted to an exon, can change the reading frame to produce a non-functional 
protein. The efficiency of gene knockouts is dependent on multiple factors, including the 
chromatin context of the target site 9,10, the cell cycle stage 11, and the nature of the DNA overhangs 
generated by the nuclease 12. In the case of the commonly used Cas9 (CRISPR-associated protein 
9), robust activity coupled with blunt ends generated upon DNA cleavage often leads to a persistent 
cycle of re-ligation of the DNA ends and regeneration of the target site that will continue until 
sufficient modification of the target site by mNHEJ prevents cleavage, creating a heterogeneous 
population of modified sites 13. Although more commonly used for homology-directed repair 
applications 14, paired Cas9 nickase variants can also be used to create gene knockouts. 
We previously created a modular dual-active site nuclease that introduces two DSBs with non-
compatible DNA ends at a target site to bias repair events towards deletion of the intervening DNA 
segment between the two cleavage sites, escaping the cycles of persistent cleavage and re-ligation 
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cycle 15. We fused the monomeric nuclease and linker domains of the sequence-tolerant GIY-YIG 
homing endonuclease I-TevI to the N-terminus of the I-OnuI LAGLIDADG homing endonuclease 
(or meganuclease), which acts as both a targeting and nuclease domain, creating MegaTevs (Fig. 
4.1) 16-18. The I-TevI nuclease domain generates a 2-nt 3’ overhang 19, whereas the meganuclease 
generates a non-compatible 4-nt 3’ overhang 17. Using model DNA substrates derived from the 
native I-TevI thymidylate synthase (td) and meganuclease target sites, we showed that MegaTevs 
efficiently excises a 30-bp fragment from the target site in HEK 293 cells with minimal 
exonucleolytic processing 15. However, the utility of the MegaTev platform is limited by re-
engineering of meganuclease specificity on a case-by-base basis, and by uncharacterized 
interactions of the I-TevI linker domain with the DNA spacer region that are critical for positioning 
of the nuclease domain at the 5’-CNNNG-3’ cleavage site 20,21 (Fig. 4.1). 
Here, we address these limitations by profiling the sequence requirements of the I-TevI linker-
DNA spacer interactions, identifying nucleotide positions critical for activity and delineating a 
putative linker-DNA code. Directed evolution experiments isolated I-TevI linker variants with 
activity on DNA spacers not cleaved by the wild-type linker, generating a set of variants with 
defined DNA spacer preferences. We created MegaTev and Tev-mTALENs fusions with the new 
I-TevI linker variants to demonstrate that the variants maintain identified target specificity across 
different DNA-binding architectures. In addition, we used the I-TevI DNA code to develop a 
simple prediction module for novel cleavage site identification. 
4.2 Material and Methods 
4.2.1 Bacterial strains and plasmid construction 
Escherichia coli DH5α (New England Biolabs) was used for plasmid manipulations, and E. coli 
ER2566 (New England Biolabs) was used for protein expression. Unless stated, E. coli strains 
were grown in Luria-Bertani (LB) media. E. coli BW25141(DE3) was used for all two-plasmid 
selection assays (Supplementary Table S1) 50. MegaTev constructs that included residues 1-169 or 
1-184 of I-TevI were cloned into pACYCDuet-1 using the NcoI and XhoI sites as previously 
described 18. For the bacterial two-plasmid selection, MegaTev target sites were cloned into pTox 
using the XbaI and SphI cloning sites. The low mutational density MegaTev linker library  
77 
 
 
 
 
Figure 4.1: Schematic of modular genome-editing nucleases based on the I-TevI nuclease and 
linker domains.  
The corresponding interactions of each of the protein modules with DNA substrate is shown below. 
The cleavage motif and DNA spacer region are derived from bases –27 to –9 of the native I-TevI 
td substrate, but are renumbered here with +1 indicating the first base (C) of the top strand of the 
DNA spacer. Known interactions of I-TevI with the DNA spacer region based on genetic and 
biochemical data is summarized.  
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encompassing amino acids 104-164 of I-TevI were constructed using Mutazyme II Polymerase 
(Agilent Technologies) with an estimated complexity of 1.4 x 105 and a mutation frequency of 1-
3 base pairs per clone. A library with a higher mutational density was constructured with a 
mutation frequency of 3-10 base pairs per clone using mutagenic dNTPs (TriLink 
Biotechnologies) with an estimated library complexity of 5.7 x 104. Each linker library pool was 
cloned into pACYCDuet-1 harbouring a MegaTev open reading frame using the PciI and BamHI 
sites located in the I-TevI linker region. To create TevCas9 fusions, a human codon optimized 
version of I-TevI (amino acids 1-169) with a GGSGGS peptide at the C-terminal end was fused to 
the N-terminus of Cas9 using SOEing PCR, and cloned into the AgeI and BglII sites of pX458 
(Addgene). The TevCas9 gRNAs were cloned into the BbsI site of pX458, or into the XbaI and 
SphI sites of pTox. All constructs were confirmed by sequencing. 
4.2.2 In vitro enrichment assay  
Target site oligonucleotides containing a randomized 12 bp spacer in the context of a td target site 
were cloned into the pSP72 vector as previously described to create pSP72-N12 39. MegaTev 
purification was performed as previously described 18. Cleavage assays were performed with 360 
nM or 1100 nM purified MegaTev and 10 nM pSP72-N15 plasmid in cleavage buffer (50 mM 
Tris-HCl pH 7.9, 300 mM NaCl, 10 mM MgCl2 and 1 mM dithiothereitol (DTT)) at 37
oC for 5 
min. Subsequent rounds of enrichment was performed as previously described 39. Samples were 
prepared for Illumina sequencing at the London Regional Genomics Centre by PCR amplification 
of target site from both the input and round 3 enrichment samples using Phusion polymerase (New 
England Biolabs) with barcoded primers. Custom Perl scripts were used to separate the Illumina 
reads by barcode and to extract the randomized region. Enrichment was determined by using the 
center logarithmic transformation of the nucleotide counts 51, and by taking the difference between 
the enriched and input values per nucleotide per position. 
4.2.3 Bacterial two-plasmid selection 
The bacterial two-plasmid selection was performed with single MegaTev constructs or with 
MegaTev linker libraries as previously described 15,18. Briefly, 50 ng of MegaTev pEndo vector 
was transformed into E. coli BW25141 cells harbouring the pTox plasmid containing the target 
site of choice. Cells were recovered at 37 oC for 1.5 hrs and aliquots plated on selective (LB media 
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plus 25 μg/ml chloramphenicol and 10 mM L-(+)-arabinose) and non-selective plates (LB media 
plus 25 μg/ml chloramphenicol, 50 μg/ml kanamycin and 0.2% glucose). Survival was expressed 
as the ratio of the number of colonies on the selective plate versus the number of colonies on the 
non-selective plate. The MegaTev mutant linker libraries were screened either on solid media, or 
in liquid LB media under selective and non-selective conditions. Identified MegaTev linker 
variants were re-cloned into pEndo and the selection repeated on the appropriate target sites. 
4.3 Results 
4.3.1 Identifying and validating I-TevI nucleotide preference in the DNA spacer  
To determine nucleotide preference of the I-TevI linker for the DNA spacer region, we performed 
sequential in vitro enrichment with the Tev169-xOnu MegaTev nuclease (hereafter MegaTev) and 
a plasmid library containing a randomized 12-bp DNA spacer (Fig. 4.2A). In this construct, I-OnuI 
cleavage is inactivated by an E22Q mutation (represented by an xOnu), meaning that cleavage can 
only occur if the I-TevI linker interacts with the DNA spacer to correctly position the I-TevI 
nuclease domain on substrate. Supercoiled plasmid was incubated with purified MegaTev protein 
(consisting of I-TevI residues 1-169) under two different protein:DNA ratios. Substrates that were 
linearized by the MegaTev were isolated from an agarose gel, re-circularized by ligation and 
amplified in E. coli. After two rounds of enrichment, the DNA spacer region was PCR amplified 
and the nucleotide content at each position relative to the input DNA library was readout by 
Illumina sequencing. As shown in Fig. 4.2B, similar nucleotide enrichment was observed at each 
position under both protein:DNA conditions, differing only in the higher enrichment values for the 
more stringent protein:DNA conditions (~30:1 ratio MegaTev to substrate). We also tested a 
MegaTev construct with a longer I-TevI linker fragment encompassing residues 1-184, and found 
similar nucleotide enrichment in the DNA spacer (Supplementary Figure S4.1). In general, I-TevI 
tolerated a number of nucleotide substitutions at each position, with the exception of position 8 
where only G was enriched relative to the input pool.  
To extend these findings to an in vivo environment, we used a well-characterized two-plasmid 
selection system in E. coli where survival is promoted by the MegaTev endonuclease (expressed 
on pEndo) cleaving the target site cloned on a second plasmid that also encodes a DNA gyrase 
toxin (pTox) (Fig. 4.2C) 23. We made single substitutions in critical positions of the td wild-type  
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Figure 4.2: Determination of I-TevI nucleotide preference in the DNA spacer  
(A) Schematic of the MegaTev DNA substrate that contains the I-TevI cleavage motif, DNA 
spacer, and meganuclease (I-OnuI) binding site. The randomized bases of the DNA spacer region 
are represented by N. (B) Profiling of nucleotide preference in the DNA spacer using sequential 
enrichment of a randomized DNA spacer substrate. Two separate enrichment experiments were 
performed with different protein-DNA ratios. Nucleotide preference in the DNA spacer region is 
displayed as proportional log2 enrichment of each nucleotide at each position relative to the 
abundance in the input pool. Black dots indicate the wild-type nucleotide in the td DNA spacer at 
each position. (C) Schematic of the two-plasmid survival assay, and conditions that promote 
growth (circled green check mark) or no growth (circled red X). (D) Survival in the two-plasmid 
assay of the wild-type MegaTev against DNA substrates with single substitutions in the DNA 
spacer. Data is presented as mean of three independent experiments with error reported as standard 
deviation.   
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DNA spacer in the pTox plasmid, and individually tested these against the MegaTev (Fig. 4.2D). 
In this experiment, MegaTev activity is readout out as the ratio of colonies on non-selective versus 
selective plates, typically expressed as a percentage. The results of these experiments were in 
agreement with the in vitro enrichment data, as we observed survival on substrates with T2A, T6C 
or A9T substitutions. No survival was observed on any of the position 8 substitutions, agreeing 
with the singular preference for G at this position.  
4.3.2 Position G8 of the DNA spacer acts as an anchor for the linker  
The above data implicate G at position 8 of the DNA spacer as a critical determinant for linker 
interactions, possibly by acting as an anchor point for interactions with the DNA spacer such that 
the linker can correctly position the nuclease domain at the 5’-CNNNG-3’ cleavage motif, as is 
observed with the related enzyme I-BmoI. One prediction of the linker-anchor model is that the 
distance between the anchor G8 and the 5’-CNNNG-3’ cleavage motif should remain constant (8 
base pairs, measured from G8 to the G of the cleavage motif) independent of the position of the 
G8 anchor (Fig. 4.3). We tested this model by making substrates with a wild-type DNA spacer 
length of 15 bp, as well as two substrates that differed by +/- 1 base pairs, creating 14-bp and 16-
bp DNA spacers, respectively (Fig. 4.3). To determine if the position of the anchor G8 residue 
influenced selection of a CNNNG cleavage motif by the nuclease domain, the substrates were 
randomized in the predicted cleavage site region, allowing us to readout the distance (or phasing) 
between the G of observed CNNNG motifs and the anchor G8 residue by Illumina sequencing 
after in vitro enrichment. We found that regardless of the DNA substrate, the preferred spacing 
between the G8 anchor base and the cleavage motif was 8 base pairs (Fig. 4.3) as opposed to the 
random distribution of spacing seen in the input pools (Supplemental Fig. S4.2). Illumina 
sequencing also allowed us to determine nucleotide enrichment in the randomized region of each 
substrate, and we observed strikingly similar patterns between the substrates (Fig. 4.3). In 
particular, we noted a strong preference for A or T two base pairs downstream of the G of the 
CNNNG motif, corresponding to position 2 of the DNA spacer region (Fig. 4.3). This finding 
indicates that sequence preference at the critical position 2 of the DNA spacer is maintained 
regardless of the position of the cleavage motif.   
Collectively, these data show that I-TevI linker interactions with the DNA spacer include both 
sequence-preference and sequence-spacing requirements. Position G8 is critical for linker  
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Figure 4.3: Determination of I-TevI distance preference from G8 position in the DNA spacer  
(Top) Schematic of substrates used to determine the effect of positioning of the G8 anchor on 
cleavage motif spacing. (Bottom) For each substrate examined, the position of the G of the 
CNNNG cleavage motif relative to the G8 anchor nucleotide (highlighted by red rectangle) is 
plotted as the proportion of Illumina reads. Note that the maximum distance of the G of the 
cleavage motif from the G8 position is determined by the length of the randomized region. Below 
each substrate is a heat map and sequence logos plot showing nucleotide enrichment at each 
position in the randomized region relative to the starting input. Position 6 of the randomized region 
is equivalent to position 2 of the DNA spacer in Figure 4.2.   
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interactions, possibly by acting as an anchor for the linker such that the nuclease domain is 
positioned 8 base pairs upstream. Our data also agree with previous footprinting, modification 
interference assays, and low-resolution enrichment studies showing that positions 2-10 of the DNA 
spacer are important for I-TevI-DNA interactions 24-26 
4.3.3 Isolation of I-TevI linker variants that can cleave substrates with substitutions 
in critical positions 
The identification of nucleotide positions in the DNA spacer critical for I-TevI linker interactions 
prompted us to screen for I-TevI linker variants that could promote cleavage of substrates with 
substitutions in these positions (summarized in Fig. 4.4A). We used two strategies to isolate I-TevI 
linker variants. First, we created a mutagenic library encompassing amino acid residues 104 to 169 
of the I-TevI linker with on average 1-3 amino acids substitutions per clone. This library was 
screened using the two-plasmid genetic selection system on DNA substrates with single nucleotide 
substitutions in positions 2, 6, 8 and 9. This experiment resulted in the identification of the K135N 
linker variant on the T6G substrate, and the S134G variant on the A9G substrate. No viable clones 
were recovered on the other substrates. A library with a higher substitution rate (3-10 amino acid 
substitutions per clone), was also screened against the singly substituted substrates, resulting in 
the identification of the linker variants K135R/N140S, S134G/N140S, K135R/N140S/Q158R, 
K118R/K135R/N140S. All of these variants were recovered on the G8A substrate, but subsequent 
testing revealed survival on G8T substrates for some of the variants (Fig. 4.4B).  
Our second strategy used a hybrid non-native DNA spacer derived from the human monoamine 
oxidase B gene (MAO-B) 17. This substrate was used to determine if nucleotide identity at positions 
2, 6, 8 and 9 was sufficient for activity of the wild-type I-TevI linker, or if activity was influenced 
by context-dependent effects of the surrounding DNA spacer sequence. The MAO-B substrate 
possessed the wild-type I-TevI linker-DNA spacer nucleotides at positions 2 (A), 6 (C), and 9 (A), 
and an A8G substitution was made so that the substrate conformed to the I-TevI wild-type 
preferences (Fig. 4.4A). We found that the wild-type I-TevI linker did not promote cleavage of 
this substrate in the bacterial two-plasmid assay. Subsequent screening of the mutagenic libraries 
on this substrate identified the V117F/D127G linker variant. 
We de-convoluted the functional importance of the identified amino acid substitutions by   
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Figure 4.4: Identification and characterization of I-TevI linker variants with altered DNA 
preferences.  
(A) Summary of directed evolution experiments to isolate I-TevI linker variants with altered 
specificity against the indicated DNA spacers. For the three td substrates, nucleotide substitutions 
relative to the wild-type sequence are in red type font. Positions 2, 6, 8, and 9 of the DNA spacer 
that are important for I-TevI activity are highlighted by grey rectangles. (B) De-convolution of 
identified amino acid substitutions on MegaTev survival against singly substituted DNA spacer 
substrates in the bacterial two-plasmid survival assay. Mean values from three independent 
biological replicates are reported in the heat map, with white boxes representing linker variant-
substrate combinations that were not tested. MegaTev variants fall into three general classes; those 
with wild-type (WT) preference, those with preference on G8 substituted substrates (G8), and 
those with preference on T6 substituted substrates (T6). (C) Summary of I-TevI linker variant 
nucleotide preferences in the DNA spacer.   
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screening linker variants with individual substitutions, or with combinations of double or triple 
substitutions, against the singly substituted DNA spacer substrates (Fig. 4.4B). Based on these 
results, we classified the I-TevI linker variants into three types. The first type, including variants 
with the V117F substitution, increased activity on DNA spacers on which the wild-type linker was 
active (WT preference). The second type of variants were those active on DNA spacers with T6C 
or T6G substitutions (T6 preference). These variants possessed a K135N substitution, or a S134G 
substitution. The third type of variant was active on substrates with a G8A substitution, and weakly 
active on G8T substrates (G8 preference). These variants include K135R/N140S. Interestingly, 
both the second and third type of linker variants possessed substitutions in residue K135, and were 
not active on the WT DNA spacer substrate suggesting a changed specificity. We noted that the 
N140S substitution was only isolated in the context of a S134G or K135R substitution, suggestive 
of a cooperative effect on linker-DNA spacer interactions. When N140S was combined with the 
K135N substitution, the double mutant K135N/N140S lost activity on all DNA spacers tested, 
indicative of a negative epistatic interaction.  
4.3.4 I-TevI linker variants cleave target sites derived from human genes 
I-TevI linker variants with the strongest phenotypes were chosen for testing on non-native targets 
derived from human genes. We first tested the V117F linker variant that enhanced the wild-type 
preference in the MegaTev architecture. To identify potential DNA target sites, we searched 19-
21 bp windows of the human gene tuberous sclerosis 1 (TSC1) coding region for sites that 
contained a 5’-CNNNG-3’ cleavage motif followed by a DNA spacer of 14, 15, or 16 bps. Of the 
964 sites with DNA spacer lengths of 15 bp, we arbitrarily chose two sites, TSC1.2125 and 
TSC1.5054, for testing in the two-plasmid selection system in E. coli. (Fig 4.5). The MegaTev-
V117F variant showed robust survival (~100%) on both sites, whereas the MegaTev-WT protein 
had significantly lower levels of survival (2% and 5%). We also showed that the MegaTev-V117F 
variant promoted 100% survival on a target site from the human breast cancer 1 gene 
(BRCA1.2541), whereas the MegaTev-WT showed no survival (Fig 4.5). 
Encouraged by these results with the MegaTev-V117F variant, we next tested the I-TevI linker 
variants with altered DNA spacer preferences at position 6 (K135N) and positions 8 and 9 
(K135R/N140S). Potential target sites were chosen from human genes based on the presence and 
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Figure 4.5: I-TevI linker variants cleavage activity for various human gene sequences.  
 
(A) List of genes and target sequences for various human genes. Gene targets are color coded 
based on I-TevI variant used to cleave the site; V117F (V) in purple, V117F/K135N (VK) in red 
and V117F/K135R/N140S (VKN) in yellow (B) Survival percentage on various human target sites 
listed in (A). 
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predicted activity of the CNNNG cleavage motif, a DNA spacer of 15-bps, and nucleotide identity 
at positions 2, 6, 8 and 9 that correlated with preferences of the linker variants (Fig. 4.7). Because 
the potential DNA target sites had a T or A at position 2, and T or C at position 6, the V117F 
mutation (which enhances activity at these positions) was included in all MegaTev variants with 
the K135N and K135R/N140S substitutions. As shown in Figure 4.5B, we observed robust 
survival of the MegaTev variants on 5 of the 8 sites. No survival was seen with the MegaTev-WT 
protein.  
To further investigate new I-TevI variant specificity in alternative DNA-binding platforms we 
created Tev-mTALEN fusions and tested them using a yeast based recombination assay. TALEs 
were assembled using golden gate assembly into vectors containg various I-TevI variants (Fig. 
4.6A). Not surprisely, I-TevI linker variants enhanced activity compared to wild-type I-TevI 
consistent with MegaTev fusions (Fig. 4.6B). No cleavage was observed at other Tev-mTALEN 
sites with new I-TevI variants demonstrating that the TALE domain still guided targeting (Fig. 
4.7C). To further demonstrate the consistence between MegaTev and Tev-mTALENs, we created 
nucleotide substitutions in the Ku70 Tev-mTALEN target site. We made critical G8A substitution 
alone and full spacer sequence swap for XPC spacer sequence that is predicted to effect VK 
cleavage as well as a C12T that should not have detrimental effects (Fig 4.6D). We observed that 
a G8A substitution abolished activity and C12T had little effect (Fig 4.6E). To cleave the XPC 
spacer sequence swap, we used a VKN-Ku70 Tev-mTALEN and observed robust cleavage on the 
XPC spacer and not the Ku70 spacer sequence (Fig 4.6E). These results demonstrated that 
targeting rules identified in the MegaTev architecture was portable to the Tev-mTALEN 
architecture.  
4.4 Discussion 
Homing endonucleases are rare-cleaving enzymes with many properties that are suitable for 
genome-editing applications, including high fidelity, small size, and generation of 3’ DNA 
overhangs that enhance homology-directed repair 31. Of the six families of homing endonucleases, 
the most success in re-programming specificity has come with the LAGLIDADG family (LHEs 
or meganucleases), typically involving prior crystallographic knowledge to direct mutagenesis of 
the network of protein residues involved in DNA contacts by cycles of design and optimization  
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Figure 4.6: I-TevI linker variants function in the context of Tev-mTALENs.  
 
(A) Schematic of the target sites, TALE modules, and recommended I-TevI linker variants based 
on nucleotide identity at positions 6 and 8 of the DNA spacer. (B) Barplots of activity of the Tev-
mTALEN variants on the different target sites (bars are colored according to target site identity). 
The data represent activity values normalized to the activity of control Tev169-PthXO1 Tev-
mTALEN on the TP15 substrate. (C) Barplots showing that activity of Tev-mTALENs is a 
function of the TALE domain. (D) and (E) Testing the effects of single nucleotide substitutions in 
the DNA spacer region of the Ku70 target sites. The different substrates are indicated by the 
substitution in the DNA spacer, and are highlighted in yellow. For panels (B), (C), and (E),data 
are averages of at least three independent experiments with error bars representing standard 
deviation.  
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for each desired target site 32,33. Here, we have explored an alternative strategy to using homing 
endonucleases in genome-editing applications by taking advantage of the sequence-tolerant 
binding properties of the modular GIY-YIG family to design reagents that can be used without 
further engineering steps 24.  
I-TevI is the prototypical member of the GIY-YIG family of homing endonucleases that are 
characterized by a distinctive modularity, consisting of a N-terminal nuclease domain, a flexible 
linker domain, and a C-terminal DNA-binding domain 26,34,35. Known I-TevI-substrate 
interactions, as deduced from crystallographic and biochemical studies 24,26,36, are a mixture of 
discriminatory contacts to bases and sequence-tolerant interactions. In the native I-TevI protein, 
the linker domain acts as a communication device between the N-terminal nuclease and C-terminal 
DNA-binding domains to position the nuclease domain at the correct distance from the DNA-
binding domain such that it cleaves at the appropriate 5’-CNNNG-3’ cleavage motif 20. This 
stringent ruler-like behaviour likely evolved as a mechanism to prevent cleavage at a 5’-CCGTG-
3’ cleavage site that lies upstream of the I-TevI autoregulatory binding site in the phage T4 
genome37. Linker function is maintained in the chimeric I-TevI fusions, as substrates with 
suboptimal spacing of the cleavage site are poor substrates relative to those with optimal spacing 
of the cleavage site. Interestingly, for both the native and chimeric enzymes, cleavage activity 
correlates with a ~10-bp periodicity of the cleavage motif 15,18,27. One interpretation of this 
periodicity is that it reflects the molecular distance between where the linker contacts the DNA 
spacer and where the nuclease is domain positioned on DNA by the linker.  
A critical question thus becomes where does the linker contact the DNA spacer, and what 
residue(s) in the linker are involved in this contact? Our data strongly implicates position G8 of 
the DNA spacer as the anchor point for the linker, and linker residues 134-140 as mediating this 
contact, either directly or indirectly. The distance between G8 and the G of the CNNNG cleavage 
motif is 8-bps, closely matching the ~10-bp periodicity relationship seen between activity and 
motif spacing. The 8-bp distance is also maintained when the G8 nucleotide is moved, further 
emphasizing the ruler-like relationship between the linker and DNA spacer. Position G8 
corresponds to the first nucleotide of a universally conserved Asp codon (GAY) in thymidylate 
synthase genes 38,39. Homing endonucleases typically use conserved nucleotides such as this as 
cleavage determinants because these positions are mutationally constrained by the fact that they  
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Figure 4.7: Overview of TevCas9 targeting model  
(A) Schematic of chimeric I-TevI-based nucleases, with the individual components of the binding 
model highlighted for each domain. The heatmap of relative cleavage CNNNG activity is derived 
from reference (15). (B) Example of TevCas9 site predictions in the human TSC1 coding region 
ranked by Z-score.   
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encode functionally critical residues of the protein (the Asp residue is found near the thymidylate 
synthase active site40), and thus represent evolutionary stable recognition determinants. The related 
enzyme I-BmoI also uses a homologous G residue in its thyA target site as a critical cleavage 
determinant 41. Thus, at least for I-TevI and possibly for other GIY-YIG endonucleases, the linker-
DNA code can be partly deciphered by identifying nucleotides that correspond to conserved 
nucleotides of the target genes.  
Residues 123-148 of the I-TevI linker are predicted to form a β-strand 21, and it is possible that this 
region of the linker interacts with DNA substrate between the G of the cleavage motif and G8 in 
the DNA spacer. Our data implicate residue K135 as important for linker-DNA interactions at 
positions T6 and G8 of the DNA spacer. Interestingly, the phenotypes of the two substitutions we 
isolated at this position, K135N and K135R, have opposing effects and are modulated by 
substitutions at neighboring positions, notably S134 and N140, although we do not yet know how 
S134 or N140 modulate activity. More generally, our data imply that I-TevI linker libraries with a 
high mutational density focused on residues 128-148 may reveal variants that are tolerant of a 
broader range of nucleotide substitutions at positions T6 and G8, or in other positions of the DNA 
spacer we identified as important, notably position T2.    
In summary, we have shown that profiling the DNA sequence requirement of the sequence-tolerant 
I-TevI endonuclease facilitates genome-editing applications. That new I-TevI variants are portable 
to various DNA-binding domains and target sequences can be predicted to identify target sites 
within the genome (fig. 4.7).  
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Chapter 5 
5 Biasing genome-editing events towards precise length deletions with 
RNA-guided TevCas9 dual nuclease (Part 2: TevCas9 Fusions) 
The work presented in this chapter is reproduced (with permission, Appendix S1) from: 
Wolfs, J.M., Hamilton, T.A., Lant, J.T, Laforet, M., Zhang, J., Salemi, L., Gloor, G.B., 
Schild-Poulter,C. and Edgell,D.R. (2016) Biasing genome-editing events towards precise length 
deletions with RNA-guided TevCas9 dual nuclease. PNAS (pii: 201616343. [Epub ahead of 
print]) 
5.1 Introduction 
Genome editing with engineered nucleases has revolutionized the targeted manipulation of the 
genomes of organisms ranging from bacteria to mammals (1). Zinc finger nucleases (ZFNs) (2), 
transcription-like effector nucleases (TALENs) (3), MegaTALs (fusion of a LAGLIDADG 
homing endonuclease and TALE domain) (4-6), and nucleases based on the clustered regularly 
interspersed short palindromic repeat (CRISPR)-associated protein 9 (Cas9) all represent 
programmable genome-editing nucleases that have successfully been used to introduce targeted 
changes in genomes (7-11). One of the most common applications of genome-editing nucleases is 
gene knockouts that are performed in the absence of an exogenously added repair template (12). 
In the case of Cas9, the blunt DNA ends introduced at DNA cleavage are substrates for error-free 
repair by the classical NHEJ pathway (c-NHEJ) (13), regenerating the target site for re-cleavage 
by the nuclease. This cycle of cleavage, ligation and target site regeneration is perturbed when the 
DSB is sufficiently modified by exonucleolytic processing by c-NHEJ, or by the alternative NHEJ 
pathway (alt-NHEJ), to prevent cleavage by the nuclease (14-18). Imprecise repair by either of the 
NHEJ pathways generates the characteristic spectrum of heterogeneous length insertions or 
deletions (indels) centered around the break site (19, 20). The heterogeneous distribution of indels, 
and the fact that not all indels generate gene knockouts, means that downstream screening and 
confirmation of knockout genotypes is required. In addition, the chromatin context of the target 
site (21, 22), the cell cycle stage and cell type (23), and the nature of the DNA overhangs generated 
by genome-editing nucleases influence the types of indels and efficiency of gene knockouts (24). 
Coupling the expression of DNA end processing enzymes and genome-editing nucleases can bias 
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gene knockouts by enhancing exonucleolytic end-processing before ligation by NHEJ, with 
variable rates of success depending on the end-processing enzyme employed (24, 25). Although 
more commonly used for homology-directed repair applications (26), paired Cas9 nickase variants 
can be used to generate gene knockouts, but also generate heterogeneous length deletions. 
Here, we provide a simple and robust solution to bypass the persistent cycle of cleavage and re-
ligation and shift genome-editing events towards deletions of defined length. We created a dual 
nuclease that introduces two non-compatible DNA breaks at a target site such that the majority of 
the target site is deleted, preventing regeneration of the target site and continued cleavage.  We 
fused the monomeric nuclease and linker domains from the I-TevI homing endonuclease to Cas9 
(27, 28), creating an RNA-guided TevCas9 dual nuclease that functions robustly in HEK 293 cells 
at endogenous target sites. TevCas9 generates defined length deletions of 33-36 base pairs at high 
frequencies with minimal DNA end processing compared to Cas9. We envision that the non-
compatible and directional nature of the TevCas9 overhangs will enhance applications such as site-
directed mutagenesis by oligonucleotide ligation, deletion of binding sites, or epitope-tagging. 
5.2 Material and Methods 
5.2.1 Bacterial strains and plasmid construction 
See chapter 4, 4.2.1 Bacterial strains and plasmid construction for TevCas9 construction. 
5.2.2 Protein purification 
For bacterial expression and purification, TevCas9 or Cas9 variants were cloned in pACYC-Duet1 
expression plasmids under control of a T7-regulated promoter. The RARA gRNA was cloned in 
the BmsI sites of the pACYC plasmid. The expression plasmids were transformed into E. coli 
ER2566, and grown in 1L LB broth until an A600 reading of 0.5, induced with isopropyl-D-
thiogalactopyranoside (IPTG) at 1 mM final concentration, and grown overnight at 16C. Cells 
were harvested, resuspended in binding buffer (20 mM Tris-HCl pH 8, 500 mM NaCl, 10 mM 
imidazole, 1 mM dithiothreitol (DTT)), lysed and centrifuged to clarify cell debris. The lysate was 
loaded onto a 1 ml Ni-NTA affinity column (GE Healthcare), washed with 5 column volumes 
binding buffer and 5 column volumes of binding buffer with 25 mM imidazole, before step elution 
with binding buffer containing 100, 200, 300 or 400 mM imidazole. Fractions were dialyzed into 
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storage buffer (20 mM Tris-HCl pH 8, 500 mM NaCl, 1 mM DTT, 5% glycerol) and frozen at -
80C.   
5.2.3 gRNA visualization 
To confirm gRNA co-purification with TevCas9 or Cas9, purified protein (4.4 μg) was treated 
with 20 μg of proteinase K in NEB Buffer 3 at 37C for 30 mins. The sample was split, and half 
treated with RNase A for 30 mins at 37C. Samples were heated to 95C for 5 mins before loading 
on a 12% denaturing urea-polyacrylamide gel. RNA was visualized by staining with ethidium 
bromide.  
5.2.4 TevCas9 endonuclease assays 
The RARA target site was amplified from pTox-RARA by PCR using primers DE1544 and 
DE1191. Cleavage assays were performed with a 90:1 molar ratio of protein:DNA in a pooled 
reaction in cleavage buffer (20 nM DNA substrate, 50 mM Tris-HCl pH 8, 125 mM NaCl, 10 mM 
MgCl2, 1 mM DTT). Aliquots were taken at the appropriate time points, and stopped in stop buffer 
(200 mM ethylenediaminetetraacetic acid (EDTA), 30% glycerol, 1% sodium dodecyl sulphate, 
and xylene cyanol). Reactions were treated with proteinase K and RNase A before electrophoresis 
on an 8% polyacrylamide gel in Tris-borate EDTA buffer.  
5.2.5 HEK293 transfections and genomic extractions 
HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10 % 
fetal bovine serum and grown at 37 oC with 5 % CO2. One day before transfection, approximately 
1 x 105 cells were seeded into 24-well plates. Transfections were performed using JetPRIME® 
(Polyplus transfection) with 500 ng of pX458 plasmid as recommended in the JetPRIME® 
protocol. Transfection reagent was removed 4 hrs after transfection and replaced with fresh media 
and incubated for 48 hrs at 37 oC with 5 % CO2. Cells were harvested and resuspended in 100μl 
TE pH 8.0. Cells were lysed in 300μl of extraction buffer (100 mM NaCl, 10 mM Tris-HCl pH 
8.0, 25 mM Ethylenediaminetetraacetic acid (EDTA), 0.5 % sodium dodecyl sulfate (SDS) and 
0.1 mg/ml proteinase K) for 16 hrs at 50 oC. Cell lyses were treated with 1 mg/ml RNaseA for 1 
hr at 37 oC and genomic DNA was purified using phenol/chloroform extraction and ethanol 
precipitation. Genomic DNA was resuspended to a final volume of 70 μl in TE pH 8.0. 
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5.2.6 T7 endonuclease I mismatch repair assays and restriction endonuclease assays 
Genomic TevCas9 target sites were PCR amplified with Taq polymerase (Thermo Fisher) using 
nested PCR. For T7 endonuclease 1 (T7E1) mismatch assays 28,29, PCR products were boiled at 95 
oC for 5 min, slowly cooled to 50 oC before flash freezing at -20 oC for 2 min. Approximately 250 
ng of PCR product was incubated with 2 U of T7E1 (New England Biolabs) with NEBuffer 2 for 
15 mins at 37 oC. Cleavage products were separated on a 1.5% agarose gel stained with ethidium 
bromide and analyzed using AlphaImager™ (Alpha Innotech). For restriction endonuclease 
assays, 250ng of PCR product was digested with BamHI or PvuII for 1 hr at 37 oC. Digests were 
electrophoresed on a 1.5% agarose gel containing ethidium bromide and analyzed using 
AlphaImager™ (Alpha Innotech). 
5.2.7 Binding models for MegaTev and TevCas9 
The binding models for MegaTevs and Cas9 included two components essential for I-TevI activity: 
a 5’-CNNNG-3’ cleavage motif, and a DNA spacer. Putative MegaTev binding sites were found 
using custom Perl scripts that windowed across human coding regions for 5’-CNNNG-3 motifs 
followed by a DNA spacer of 14-16 bps. The raw score of the putative binding site was calculated 
by: (1) the log2 value of the activity of the 5’-CNNNG-3’ cleavage motif (relative to the 5’-
CAACG-3’ native motif); (2) the log2 score of the DNA spacer length, and given scores 18 bp = 
0.6; 17 bp = 1; 16 bp = 0.6; 15 bp = 0.4; 14 bp = 0 (3) the log2 score of the fit of the DNA spacer 
sequence to the position weight matrix (PWM) derived from the DNA spacer in vitro enrichment 
data. The predicted binding sites were subsequently ranked by their Z score. The gRNA portion of 
highly ranked TevCas9 sites were individually examined using the XXX server, and TevCas9 sites 
that included poor gRNAs were excluded.  
5.2.8 Next generation DNA sequencing  
Genomic DNA from HEK 293 cells corresponding to three independent transfections of TevCas9, 
Cas9, and one mock transfection, was used to PCR amplify the NQO2, RARA, TSC1-2125 or 
TSC1-5054 target sites with barcoded primers. The PCR products for each site were combined 
into pools, and a single-end 250-bp run performed on an Illumina Mi-Seq platform at the London 
Regional Genomics Centre. Reads were trimmed to 200 nts and then parsed for each barcode using 
custom Perl scripts. We first analyzed the reads for length differences (insertions and deletions) 
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relative to the unmodified site by extracting sequence between anchor sequences that flanked the 
TevCas9 and Cas9 target sites. The proportion of insertions or deletions for each length variant 
was the ratio of the number of reads with length N to the total number of extracted reads, excluding 
reads with less than 1000 counts. To map the positions of deletions within each target site, we used 
the UBLAST function of USEARCH 52, with the following parameters: -evalue 0.01, -mismatch -
5, -gapopen 20IQ/*LQ/*RQ, -gapext 0IQ, -strand plus, -maxhits 2. Searches were exported using 
the –userout option, with the following fields: query, target, id, alnlen, mism, opens, qlo, qhi, tlo, 
thi, thi, qrow. The output files were parsed for deletion start and deletion end point, and length, 
and each deletion plotted as a proportion relative to all mapped deletions using the graphing 
functions of the R project for statistical computing. 
5.3 Results 
5.3.1 Fusion of I-TevI to Cas9 creates an RNA-guided dual nuclease 
To create a TevCas9 RNA-guided dual nuclease, we fused the I-TevI nuclease domain (residues 
1-92) and a portion of the linker domain (residues 92-169) to the N-terminus of SpCas9 nuclease 
derived from the Streptococcus pyogenes Type II CRISPR system (27, 28) (Fig. 5.1A). A TevCas9 
target site includes the I-TevI 5’-CNNNG cleavage motif, a DNA spacer that interacts with the I-
TevI linker and that separates the cleavage motif from the binding site, the DNA-binding site 
complementary to the gRNA, and the downstream NGG protospacer-associated motif (PAM) 
sequence. Previous studies revealed that the length of the DNA spacer is crucial for I-TevI cleavage 
function, with lengths of 14-19 base pairs (bps) supporting activity in various chimeric contexts 
(27, 29, 30). We co-expressed TevCas9 with a C-terminal histidine tag and a gRNA targeting a 
site in the retinoic acid receptor alpha gene (RARA.233, numbered according to start of target site 
in the RARA cDNA) from the same plasmid in E. coli. The RARA.233 target site was predicted 
according to a binding model that utilized data from in vitro profiling of I-TevI linker-DNA spacer 
nucleotide preference (Fig. 4.1, 4.2 and 4.3), and the activity of the I-TevI nuclease domain on all 
possible 64 CNNNG variants (30). The TevCas9 variant used in this experiment (hereafter, TC-
V) contains an activity-enhancing V117F substitution in the I-TevI linker.  
We purified the TC-V by metal-affinity chromatography, and showed that TC-V was complexed 
with an RNA species of the size predicted for the transcribed gRNA (indicated by an asterisk, Fig. 
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Figure 5.1: Purification and characterization of a TevCas9 dual nuclease 
A) Schematic of the TevCas9 nuclease, and general organization of the DNA substrate. (B) 
Summary of in vitro profiling of I-TevI-linker DNA spacer nucleotide preferences, and directed 
evolution experiments that identified I-TevI linker variants with activity on DNA spacers with 
substitutions in positions T6 and G8. Linker variants used in the TevCas9 nuclease are indicated 
on the right, with DNA spacer preference indicated. (C) TevCas9 co purifies with an RNA species 
of the size predicted for the transcribed gRNA. Shown is an 12% urea-polyacrylamide gel of 
TevCas9 protein samples treated with proteinase K, and then with (+) or without (-) RNaseA. The 
marker is an RNA ladder with sizes in nucleotides indicated. (D) (top) Representative time course 
cleavage assay (in minutes) with TevCas9-V117F (TC-V) and a PCR substrate containing the 
RARA target site. The substrate and cleavage products are indicated on the right side of the gel. 
The gel image is inverted. (bottom) Reaction pathway as deduced from the appearance of products 
in the cleavage assay. Note that the 35-bp Tev-P2 is not shown on the gel image. (E) Plot of 
reaction progress in minutes versus percent DNA for the TevCas9 time course cleavage assay with 
the RARA substrate. Data points are mean values of four independent experiments, with vertical 
bars representing standard deviation.  
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1C). To determine if the TC-V/gRNA ribonucleoprotein complex (RNP) introduced two DSBs, 
we examined the cleavage profile on a PCR substrate that contained the RARA.233 target site. 
Cleavage was consistent with two sequential DSBs, first by the Cas9 nuclease, and second by the 
I-TevI nuclease (Fig. 5.1D and 5.1E). The predicted 33-bp product corresponding to the fragment 
excised between the I-TevI and Cas9 cleavage sites was difficult to reproducibly visualize, and not 
used to quantitate reaction progress. Interestingly, cleavage by Cas9 was ~30-fold faster than 
cleavage by I-TevI (Fig. 5.1E, as judged by time required for 50% product formation). 
5.3.2 TevCas9 functions robustly in HEK 293 cells 
TevCas9 is targeted by the Cas9-associated gRNA, a property that allowed us to directly compare 
TevCas9 and Cas9 activity at the same sites in HEK 293 cells. To do so, we used T7 endonuclease 
1 (T7E1) mismatch cleavage assays to measure on-target modification at the RARA.232 site and 
at two other sites, one in the tuberous sclerosis 1 gene (TSC1.2125) and one in the quinone 
reductase 2 gene (NQO2.54) (Fig. 5.2A) (31, 32). With TC-V transfections, we observed 
modification rates ranging from 16-23%, versus 12–29% modification rates at the same sites when 
cells were transfected with Cas9. We also targeted TevCas9 to a second site in the TSC1 gene 
(TSC1.5054). The TevCas9 variant (TC-VK) used in this experiment contained V117F and K135N 
substitutions in the I-TevI linker domain that enhance activity on DNA spacers with a T->C 
substitution in position 6 of the DNA spacer (Fig. 4.2). We observed very similar levels of 
modification with both TC-VK (mean = 15%) and Cas9 (mean = 13%) at the TSC1.5054 site. No 
activity at the NQO2.54, TSC1.2125 or TSC1.5054 sites was observed in cells transfected with 
TC-V programmed with the RARA.233 gRNA, showing that the I-TevI domains do not influence 
gRNA-mediated targeting of Cas9. We also predicted off-targets sites based on the NQO2.54 
gRNA (33), and examined cleavage at these sites by T7E1 mismatch assays (Fig. S4.4). No 
cleavage was observed at these sites, three of which had a correctly space CNNNG motif from the 
binding site for the gRNA. These experiments show that the I-TevI nuclease and variant linker 
domains can be directed by Cas9 to cleave target sites with diverse cleavage motifs and DNA 
spacers, suggesting that the I-TevI sequence requirements are not limiting for TevCas9 targeting.  
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Figure 5.2: Activity and specificity of TevCas9 in HEK 293 cells 
(A) T7E1 mismatch cleavage assays of PCR fragments amplified from the indicated target sites 
after transfection with Cas9 or TevCas9. TC-V, TevCas9-V117F; TC-VK, TevCas9-
V117F/K135N; TC-R27A, TevR27ACas9 (R27A inactivates ITevI cleavage activity). (B) 
Detailed schematic of the target site in exon 6 of the human NQO2 gene, positions of PCR primers 
used for amplification, and sizes of BamHI cleavage products. The I-TevI cleavage motif and DNA 
spacers are highlighted by red and blue rectangles, and the PAM motif by a green rectangle. 
Positions of I-TevI and Cas9 cleavage sites are represented by red and black arrows, respectively. 
(C) Representative agarose gel of BamHI cleavage assays on PCR products amplified from the 
NQO2 locus 48 hrs after transfection with Cas9 or with TC-V. Sizes of the substrate (1124 bp) 
and two BamHI cleavage products (673 bp and 487 bp) are indicated on the right. The percent of 
substrate resistant to cleavage by BamHI is indicated below each lane. (D) Activity of different 
TevCas9 variants at the NQO2 site measured by BamHI resistance. TevCas9 variants labelled as 
in panel (A) except for VKN – TevCas9-V117F/K135R/N140S. In panels (A) and (D), barplots 
are mean values of at least three independent experiments, with vertical bars representing standard 
deviation.  
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5.3.3 TevCas9 generates defined length deletions in HEK 293 cells  
T7E1 mismatch cleavage assays report on the overall nuclease modification rate at a particular 
site, but cannot distinguish the relative contributions of the I-TevI and Cas9 active sites. To do so, 
we used a BamHI restriction site in the NQO2.54 target site that overlaps the predicted I-TevI 
CAACG cleavage motif (Fig. 5.2B). After transfections, TevCas9 or Cas9 activity was estimated 
from the fraction of PCR products amplified from the NQO2 site that are BamHI resistant as a 
result of nuclease cleavage and mNHEJ repair (Fig. 5.2C and 5.2D). In transfections with the TC-
V and TC-WT (wild-type I-TevI) nucleases, we observed 14 – 16% BamHI cleavage resistance. 
This result implied that cleavage by the I-TevI nuclease domain at the CAACG motif knocked out 
the BamHI site. In contrast, transfections with Cas9 alone resulted in 5% BamHI cleavage 
resistance, implying that only a small fraction of Cas9-induced mNHEJ repair events destroy the 
BamHI site (Fig. 5.2D). A similar cleavage resistance assay was performed at the TSC1.5054 site, 
and showed that TC-VK cleavage generated a higher level of PvuII resistance than in transfections 
with Cas9 alone (18% versus 6%) (Fig. S4.3), consistent with deletion of the sequence between 
the I-TevI and Cas9 cleavage sites. We also took advantage of two adjacent NGG PAMs in the 
TSC1-5054 site to determine the effect of DNA spacer length on TevCas9 activity by simply 
changing the position of the gRNA (18_gRNA and 14_gRNA, Fig. 8A) (Fig. S4.3). We found that 
TC-VK programmed with the 18_gRNA produced ~4.5-fold more PvuII resistance than with TC-
VK programmed with the 14_gRNA (Fig. S4.3), suggesting that that the optimal DNA spacer 
length for the TevCas9 is between 15-18 bps. 
5.3.4 Deep sequencing reveals minimal processing of TevCas9 deletions 
 
To more accurately assess indels introduced by TevCas9 and Cas9 in HEK 293 cells, we used 
Illumina sequencing of PCR products amplified from the on-target sites to readout the type and 
length of indels. We first examined the reads for the length of deletions or insertions relative to the 
unmodified target site, and found that a high proportion of reads in the TevCas9 experiments were 
deletions that corresponded in length to the distance between the I-TevI and Cas9 cleavage sites 
(Fig. 5.3A, 5.3D, 5.3G, 5.3J) . For the Cas9 experiments, a range of insertion and deletion lengths 
were observed, including a high proportion of +1 insertions, particularly at the RARA.233 target 
site. The overall modification rates at each target site, estimated from indel-containing reads, was  
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Figure 5.3: TevCas9 generates deletions of precise lengths in HEK 293 cells 
Results from Illumina sequencing of PCR-amplified fragments for (A-C) NQO2, (D-F) TSC1- 
2125, (G-I) TSC1-5054, and (J-L) RARA target sites. (A,D,G,J) Proportion of reads with length 
differences relative to the unmodified target, with blue triangles representing TevCas9, red open 
circles representing Cas9, and grey dots representing mock transfection. (B,D,F,H) Proportion of 
TevCas9 reads with deletions mapped to the position in the target site. (C,F,I,L) Proportion of 
Cas9 reads with deletions mapped to the position in the target site. Dotted vertical lines indicate I-
TevI and Cas9 cleavage sites.  
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very similar for TevCas9 and Cas9, agreeing with the T7E1 mismatch cleavage assays (Fig. 
S4.4). Strikingly, when we mapped the position of the deletions, the predominant deletions in the 
TevCas9 experiments were precise excisions of the DNA segment between the two cut sites (Fig. 
5.3B, 5.3E, 5.3H, 5.3K). In contrast, we found that no single deletion product dominated the 
sequencing reads for the Cas9 experiment, that the deletion lengths were shorter and 
heterogeneous in length, and that the deletions were centered around the Cas9 cleavage site (Fig. 
5.3C, 5.3F, 5.3I, 5.3L). These results demonstrate that TevCas9 cleavage generates defined 
length deletions at a high frequency in HEK 293 cells, and that the two non-compatible DNA 
ends are repaired with minimal DNA processing (Fig. 5.4). 
5.3.5 Positioning of the I-TevI cleavage motif and gRNA biases in-frame to out-of-
frame deletions   
The relative position of the I-TevI and Cas9 cleavage sites at a given target site is determined by 
length of the DNA spacer that separates the I-TevI CNNNG cleavage motif from the gRNA 
binding site. At the NQO2.54 target, the distance between the I-TevI and Cas9 cleavage sites is 
33-bps (measured from the I-TevI top strand cleavage site), which would generate an in-frame 
deletion of 11 amino acids. We examined the proportion of events at the NQO2.54 site and found 
that 59% of deletions are in-frame versus 41% that are out-of-frame (Fig. 5.4). In contrast, 20% of 
events generated by Cas9 are in-frame, and 70% out-of-frame. Conversely, TevCas9 events can 
be biased towards out-of-frame events, as seen at the TSC1.2125 and RARA.233 sites that have 
an even number of bases between the I-TevI and Cas9 cut sites. In both cases, TevCas9 generates 
a higher percentage of out-of-frame deletions than does Cas9 (Fig. S4.5).  
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Figure 5.4: TevCas9 can bias the proportion of in-frame to out-of-frame indels 
Illumina read data for the NQO2 target site is plotted as the proportion of reads that are in-frame 
(green) and out-of-frame (red) for (A) TevCas9 (triangles) and (C) Cas9 (open circles). (C) 
Fraction of reads that are in-frame or out-of-frame for TevCas9 and Cas9.  
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5.4 Discussion 
Motivated by the observation that the majority of genome-editing nucleases generate a DSB with 
compatible cohesive ends, we hypothesized that a single-chain dual nuclease could bias genome-
editing outcomes towards defined length deletions by generating two non-compatible DNA breaks 
at a target site. Subsequent repair would effectively delete the majority of the target site such that 
it would not be a substrate for further nuclease activity. Our first attempt at creating a dual-active 
site nuclease involved fusing the I-TevI nuclease and linker domains to the N-terminus of the I-
OnuI LAGLIDADG homing endonuclease (or meganuclease), which acts as both a targeting and 
nuclease domain, creating MegaTevs (27, 34, 35). Using model DNA substrates, we showed that 
MegaTevs efficiently excises a 30-bp fragment from the target site in HEK 293 cells (30). 
However, the utility of the MegaTev platform is limited by re-engineering of meganuclease 
specificity to each desired target site, and by uncharacterized interactions of the I-TevI linker 
domain with the DNA spacer region that are critical for positioning of the nuclease domain at the 
5’-CNNNG-3’ cleavage site (36, 37).  
Here, we have overcome limitations of the MegaTev platform, in two ways. First, we profiled the 
sequence requirements of the I-TevI linker-DNA spacer interactions, identifying nucleotide 
positions critical for activity and delineating a putative linker-DNA code that enabled development 
of a targeting model. Directed evolution experiments isolated I-TevI linker variants with activity 
on DNA spacers not cleaved by the wild-type linker, generating a set of variants with defined DNA 
spacer preferences. Second, we created an easier-to-target dual nuclease by fusing the I-TevI 
nuclease and linker domains to the N-terminus of Cas9 (28), generating an RNA-guided TevCas9 
nuclease with two active sites. TevCas9 can be purified as an RNP that could be used for direct 
transfection of cell lines, as shown with Cas9 (38). 
The I-TevI nuclease and linker domains have successfully been fused to four different DNA-
binding architectures that are used in genome editing; zinc fingers (27), TALEs (29), 
meganucleases (30), and, as reported here, Cas9. An on-going debate in the genome-editing field 
centers on the ease of use (targeting range) versus specificity (off-target effects) of the various 
reagents, particularly for common laboratory manipulations of cell lines or model organisms. Of 
the I-TevI-based genome-editing nucleases, the TevCas9 fusions are likely to be the most user-
friendly given the ease of programming Cas9-substrate interactions. Similarly, the identification 
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Figure 5.5: Model of how TevCas9 biases DNA repair outcomes 
TevCas9 or Cas9 recognize and cleave a target site. The non-compatible DNA ends and 33-36 
base pair deletion generated by TevCas9 prevents regeneration of the target site. Compatible DNA 
ends generated by Cas9 are repaired by NHEJ, regenerating the target site and inducing a cycle of 
cleavage and ligation. At a lower rate (dashed line), some Cas9 events undergo repair by the 
alternative NHEJ pathway, getting heterogeneous length indels. 
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and characterization of I-TevI linker variants makes the TevCas9 reagent easy-to-use in that 
targeting of a desired site does not require extensive cycles of engineering and optimization of I-
TevI-DNA specificity. For TevCas9, we predicted a potential target site on average every 14 bps 
for the NQO2, TSC1 and RARA genes, with CG-rich regions having a higher number of potential 
sites due the nature of the NGG PAM and I-TevI 5’-CNNNG-3’ cleavage motif. The targeting 
requirements of TevCas9 (two cleavage sites separated by a defined length spacer) are similar to 
the parameters for paired Cas9 nickases and FokI-dCas9 nucleases that function as dimers (two 
independent gRNAs separated by a defined length) (9-11, 26, 33). While future refinements of the 
TevCas9 binding model will improve target site selection, especially for the I-TevI linker variants 
with preferences for substitutions in positions T6 or G8 of the DNA spacer, it is encouraging that 
the high density of predicted sites will not severely limit targeting of TevCas9. Moreover, our 
recent demonstration that I-TevI cleavage specificity can be modulated to include different 
cleavage motifs (notably 5’-NNNNG-3’) could also increase targeting potential by alleviating the 
requirement for a CNNNG motif (39). I-TevI fusions to Cas9 variants with altered PAM 
specificities (40, 41), or fusion to other Cas9 homologs (42), could similarly broaden targeting 
range. It remains to be seen if the I-TevI nuclease and linker domains mitigate Cas9 off-target 
effects, as observed with the chimeric ZF-Cas9 and FokI-dCas9 fusions (9, 11, 43).  The TevCas9 
fusions described here are further expand the repertoire of chimeric fusions that are possible with 
Cas9. Notably, the TevCas9 fusion is similar to the FokI-dCas9 fusion in that both I-TevI and FokI 
are nuclease domains.  
One striking result from our study was that TevCas9 generates defined length deletions of 33-36 
base pairs in HEK 293 with minimal DNA end processing. Sequences of the TevCas9 deletion 
products are consistent with repair by the c-NHEJ pathway whereby the protruding I-TevI 3’ 
overhang was directly ligated to the blunt end generated by Cas9, with subsequent fill-in of the 2-
nt gap on the opposite strand (Fig. 6). The nature of the repair products must mean that TevCas9 
sequesters the DNA ends from exonucleolytic processing associated with NHEJ pathways after 
cleavage, possibly because product release by I-TevI and Cas9 (at least in the context of the 
chimeric TevCas9) is slow (44, 45). In contrast, the heterogeneous length indels observed at Cas9 
events are typical of repair by the alternative NHEJ pathway. Although we did not examine the 
efficiency or types of indels generated by paired Cas9 nickases, published data demonstrates that 
Cas9 nickases introduce heterogeneous length indels (fig S4.5) (46, 47). Interestingly, our in vitro 
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data show that cleavage by I-TevI is ~30-fold slower than Cas9, which is also supported by the 
deep sequencing data showing that approximately half of all TevCas9 indel events are consistent 
with cleavage only by Cas9. This observed difference in cleavage rates could reflect a sub-optimal 
fusion point between I-TevI and Cas9 that hinders I-TevI activity, or inherently faster cleavage by 
Cas9. Improving the rate of I-TevI cleavage in the context of the chimeric TevCas9 nuclease by 
optimization of the fusion could conceivably bias events even more towards deletions of defined 
length than is observed now. 
Cas9 is commonly used to create gene knockouts for downstream phenotypic studies (33). 
However, in-frame deletions could generate different phenotypes than knockouts if the deletions 
encompass functionally important regions. The TevCas9 nuclease can generate in-frame deletions 
of 11 amino acids efficiently, because the length of the deletion is determined by the distance 
between the I-TevI and Cas9 cleavage sites. This property of TevCas9, coupled with the directional 
nature of the TevCas9 deletion (a 3’ 2-nt overhang by I-TevI and a blunt DNA end by Cas9), could 
enhance ligation of oligonucleotides, enabling applications such as site-directed mutagenesis, 
swapping of functional domains, or epitope-tagging (48). Conversely, TevCas9 could be used to 
tile across promoter regions to delineate functional elements (49), or protein-DNA interaction sites 
in introns or other non-coding regions.  
In summary, we have shown that the TevCas9 dual nuclease provides a strategy to bias genome-
editing events towards deletions of defined lengths, escaping the persistent cycle of cleavage and 
ligation of compatible DSBs that results in heterogeneous length deletions observed with other 
genome-editing nucleases.  
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 Chapter 6 
6     Discussion 
The desire to manipulate model organisms or correct human disease has led to a huge development 
in engineered nucleases. Genome engineering was named Method of the Year in 2011 by Nature 
Methods with “CRISPR” publications continuing to grow at an exponential rate (1). A number of 
genome-editing reagents have been created over the years from engineered LAGLIDADG homing 
endonucleases to ZFNs and TALENs, a set of FokI derived reagents, and finally the most recent 
CRISPR-Cas9 system. Each reagent has its own set of advantages and disadvantages that make up 
the genome-editing “toolbox”, with no single reagent being ideal for every situation. One similarity 
of all four reagents is the persistence of a cleavage and re-ligation cycling event (2). Here, we 
describe another potential genome-editing reagent using the GIY-HE I-TevI catalytic and linker 
domain fused to the LHE (MegaTev) or Cas9 (TevCas9) nuclease, creating a dual-active 
engineered reagent capable of making two DSBs at a single target site. We demonstrate that these 
dual-active endonucleases efficiently excise a short fragment from their target site and the 
remaining ends are ligated together in vivo. In addition, we demonstrate that I-TevI is a portable 
domain that can be fused to all four DNA-binding platforms: LAGLIDADG, ZFs, TALEs, and 
Cas9. Utilizing the MegaTev fusion, I investigated the nuclease and linker specificity and 
identified key DNA sequence preferences required to promote robust I-TevI cleavage. Using a 
bacterial selection system, I was able to isolate I-TevI mutants with alternative DNA specificity, 
expanding the number of sites available for I-TevI reagents. Adapting native I-TevI to new target 
sequences was a critical step in uncovering its potential in the genome-editing field. I demonstrate 
the new I-TevI variants are portable to three different DNA-binding platforms and maintain their 
identified specificity. Ultimately, we fused I-TevI to Cas9 to create TevCas9, an adaptable reagent 
and demonstrated for the first time that I-TevI can target novel genomic locus. Distinctly, TevCas9 
fusions are a programmable dual-endonuclease that can excise short fragments at a single target 
site which could provide alternative applications compared to conventional genome-editing 
reagents. 
6.1     Considering off-target cleavage of genome editing reagents 
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One of the most important aspects when optimizing genome editing reagents is minimizing off-
target cleavage events. Expressing a non-specific reagent can be detrimental to the cell, as off-
target DSBs can lead to chromosomal rearrangements, inversion, deletions and substitutions within 
the genome (3–5). A nuclease that has only a couple off-target cleavage events can still be 
detrimental to the cell as changes on the genomic level in the germline are passed to future 
generations. This presents a common conundrum, how do you create a reagent that is highly 
adaptable but also highly-specific. We proposed that the inherent specificity of the I-TevI catalytic 
domain and linker region would reduce off-target cleavage as seen with other genome-editing 
reagents (6). We demonstrate in every platform that I-TevI cleavage is directed by the DNA-
binding platform and not the I-TevI nuclease domain, which suggests minimal additional off-target 
cleavage events. This correlates well with previous studies of I-TevI, as the nuclease domain has 
low affinity for DNA substrates (7). We did explore some potential off-target sites for MegaTev 
and TevCas9 at predicted target sites and saw no evidence that I-TevI increased off-target 
cleavage. However a more exhaustive approach is required to better analyze the potential off-target 
effects of I-TevI-based reagents. Surveying for off-target events is a very technical and expensive 
challenge that should be performed with optimized reagents ready for agricultural or clinical 
applications.   
Many approaches have been used to study undesired modifications created by genome-editing 
reagents. Our initial screens for MegaTev and TevCas9 fusions involved only screening predicted 
sites with the fewest number of mismatches to the on-target. The challenge in developing a whole-
genome screening method is it requires high sensitivity techniques capable of detecting low 
frequency mutations. There are a number of thorough approaches that have been described to date, 
but like genome-editing reagents, each technique has its advantages and disadvantages. A large 
number of bioinformatics approaches to predict off-target cleavage were developed for a number 
of reagents but many fell short at predicting all potential off-target sites (8, 9). Researchers turned 
to an in vitro SELEX (system evolution of ligands exponential enrichment) that allowed them to 
cover a large number of sites (1012) but it failed to mimic a cellular environment (10).  A similar 
approach, known as digenome-seq, used cell free genomic DNA to analyze Cas9 off-target 
cleavage and resulted in an overestimation of the number of target sites similar to SELEX (11). 
ChIP-seq (Chromatin immunoprecipitation sequencing) was another technique that attempted to 
capture all  
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Figure 6.1: Schematic of off-target screening techniques using next-generation sequencing 
Various methods used to determine off-target cleavage frequencies of genome-editing reagents. 
SELEX (system evolution of ligands be exponential enrichment), ChIP-seq (Chromatin 
immunoprecipitation sequencing), HTGTS (high-throughput genome-wide translocation 
sequencing), IDLV capture (integrase-defective lentiviral vectors), dsODN (double-stranded 
oligonucleotide), NGS (next-generation sequencing), WGS (whole-genome sequencing)  
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the off-target sites for many nucleases, but the high background noise and capture of binding sites 
once again did not properly represent off-target cleavage events in a cell (12–14). Some studies 
report the number of off-target binding sites being greater than 1200, however not all bound sites 
are cleaved suggesting binding is more promiscuous than cleavage activity (1, 13). Two 
approaches, IDLV capture (integrase-defective lentiviral vectors) and guide-seq, used a DNA 
integration approach to capture off-target events of a linear IDLV genome or a small double-strand 
oligonucleotide, respectively (15, 16). The main limitations of these techniques is that they depend 
on DNA integration to capture the off-target events which may be less efficient then indel 
formation.  For IDLV, the major limitation is the sensitivity, as it can only detect mutation 
frequency of greater than 1% (15). Similarly, guide-seq failed to identify 7 well-defined off-target 
sites confirmed using chip-seq and cleavage by indel generation (13). The last method called 
HTGTS (high-throughput genome-wide translocation sequencing) detects DSBs based on 
translocation events to other DNA sequences (17). The most systematic comparison of these 
approaches was carried out using spCas9 at a VEGFA gene target with the same gRNA in all four 
studies ChiP-seq (5), Guide-seq (16), HTGTS (17) and digenome-seq (11) identifying 55, 21, 38 
and 87 off-target sites, respectively. Note the number of off-target sites varies greatly with each 
technique and no single method identified all the same off-targets sites. Since each technique 
identified novel off-target sites, it poses the question, how many off-target sites are there truly and 
how safe are engineered nucleases? The difficulty in detecting off-target cleavage should be a sign 
to proceed with caution using these reagents (18). In recent years, concerns have risen after the 
failed attempts to modify human embryos (18–20). 
Indeed, as technology advances our ability to survey for off-target cleavage will improve and 
engineering a precise reagent may become a reality. The limitation in current technology has not 
deterred researchers from attempting to develop precise reagents. A large number of studies have 
focused on improving genome-editing reagents using various techniques. Some of the first off-
target cleavage events observed by ZFNs was a result of ZFNs binding at “half-sites” that caused 
dimerization and cleavage from FokI at unintended target sites. This was improved by eliminating 
homo-dimerization of FokI to create an obligate hetero-dimerization to reduce complex formation 
at “half-sites” (21). The discovery of TALENs also helped to de-toxify FokI based fusions as 
longer recognition domain could be assembled.  Similarly, by fusing the TALE domain to LHEs, 
a reduction in off-target cleavage was observed and also resulted in an increase in on-target 
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efficiency (6). Off-target cleavage is no stranger to the new CRISPR-Cas9 system as the initial 
off-target analysis of spCas9 identified a large number of off-target sites (16, 5, 22). Initial studies 
demonstrated Cas9 could tolerate multiple mismatches in the target site with specificity varying 
based on Cas9 ortholog, gRNA architecture, target sequence, PAM, and relative concentration and 
duration of treatment (16, 23–26). Identified off-targets were poorly related to the on-target site 
making them difficult to predict bioinformatically (16, 22). However, as demonstrated with 
previous genome-editing reagents, modifications to the CRISPR-Cas9 architecture created more 
specific versions. One study truncated the gRNA to reduce the overall binding affinity of the 
DNA/RNA complex to reduce off-target cleavage (16, 27). Similarly, new spCas9 variants with 
mutations knocking-out the non-specific DNA interactions of spCas9 greatly reduced off-target 
cleavage (28, 29). Most recently, identification of new CRISPR-Cas Cpf1 nucleases have 
remarkable specificity only detecting off-target sites for 17 of 20 sites with AsCpf1 and 12 of 20 
with LbCpf1 (30, 31). Using the new high-fidelity Cas9 variants or Cpf1 Cas proteins would help 
reduce any potential off-targets observed for TevCas9 fusions. In addition, eliminating non-
specific contacts could be applied to I-TevI to further reduce the binding affinity to ensure only 
the on-target is cleaved.  
6.2     Implications of I-TevI biology for genome engineering 
I-TevI based genome engineering should proceed with caution as more thorough off-target 
profiling needs to be performed with these reagents. As discovered with FokI-based genome-
editing reagents, DNA-binding platforms that guide nucleases to various sites in the genome bind 
a number of promiscuous sites resulting in off-target cleavage.  FokI requirement of dimerization 
for cleavage was not sufficient in constructing a precise nuclease. However, this observation can 
also be attributed to its non-specific nature, resulting in cleavage at every dimerization complex. 
We approached this problem from the opposite direction, presenting an endonuclease, I-TevI 
which possesses inherent specificity and distance requirements for efficient DSB formation. At 
first glance, I-TevI seemed too restrictive to be a useful genome-editing reagent, but through 
further characterizing the nuclease and linker domain specificity, we were able to identify 
important base-pairs required for cleavage. This allowed us to take a directed evolution approach 
similar to engineering LAGLIDADG proteins, mutating specific modules that may be contacting 
these regions. Unfortunately, no crystal structures of the I-TevI nuclease domain and linker region 
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contacting DNA have been solved, so mutated regions were large to encompass potential DNA-
binding residues. We identified I-TevI linker variants with altered DNA specificity that could be 
utilized to increase the number of potential target sites available for I-TevI-derived reagents. Site-
specific nuclease fusions have been previously demonstrated to increase efficiency and specificity 
as described with the MegaTAL platform (6). In terms of available target sites in the genome, I-
TevI is more malleable then LHEs but more restrictive then the CRISPR-Cas9 system and on par 
with TALENs. Nevertheless, one must select the appropriate genome-editing reagent depending 
on your desired application. 
One important aspect of a good genome-editing reagent is its ability to be applied readily, without 
further protein engineering or understanding. The ultimate goal is to reach into a genetic “toolbox” 
and pick a reagent to manipulate a genome of interest, in the same fashion restriction 
endonucleases are used to manipulate plasmids. Therefore, a desirable reagent would check all 
three requirements of being highly efficient, specific and “ready-to-use”. CRISPR-Cas9 system is 
the closest reagent that checks all three of the boxes with exception of specificity that will require 
more studies. I-TevI-derived engineering reagents, specifically the TevCas9 fusion, is very close 
to checking all three requirements. With further characterization of the various I-TevI variants and 
profiling their specificity, a target site predictive software could be developed using a position-
specific scoring matrix (PSSM) to rank various sites in the genome. Similar to software developed 
for other reagents like CRISPR-Cas9, an online tool would be available to insert your gene of 
interest and would rank potential TevCas9 target sites for the user. Therefore, this would transition 
TevCas9 into a more “ready-to-use” reagent where you order the correct I-TevI variant and gRNA 
specified from the software predictions. 
Our ability to manipulate I-TevI to target various sites within the human genome was a large 
accomplishment in proving it could have a role in the genome-editing field. However, there are 
many hurdles that still must be overcome, as inherent sequence specificity is still restrictive and a 
thorough off-target profiling has yet to be performed. Understanding the basic biology of the I-
TevI nuclease and linker domain may aid in overcoming these future hurdles. Cross-linking studies 
would help to identify key residues within the protein that are making base-specific contacts and 
permit a more directed protein engineering approach. Identifying base-specific contacts could help  
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Figure 6.2: Considerations when targeting I-TevI derived nucleases  
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further engineer I-TevI variants with alternative specificity without reducing overall specificity of 
the nuclease domain. In addition, studying the mechanism could help reduce possible off-target 
sites by potentially making an I-TevI nickase variants. Whatever the implication, understanding 
the basic biology of I-TevI will aid in applying the nuclease domain in an effective manner. 
6.3     Potential for dual-active GIY-YIG endonucleases 
Current genome editing reagents only introduce a single DSB at their target site to induce 
mutagenic NHEJ repair to create gene knockouts. This may lead to persistent cleavage at their 
target sites with a cyclic cleavage and ligation reaction resulting in an unproductive gene 
modification. Although, a lot of reagents are efficient enough to overcome the classical NHEJ 
pathway and produce a mutagenic repair, the repair outcomes are unpredictable. This means only 
2/3 of outcomes will result in an out-of-frame mutation resulting in gene knockout. One potential 
application of the dual-active TevCas9 fusion is the ability to bias the outcome through excising a 
short fragment from its target site. With careful design, excising a fragment not divisible by 3 
(complete codons), would bias repair events to produce gene knockouts more frequently than 66%. 
As a result, dual-active TevCas9 would be more efficient genome-editing reagent in producing 
gene knockouts over Cas9 alone. However, expression of two active nuclease may result in 
increased off-target cleavage, but this has yet to be investigated. Alternatively, dual-active 
TevCas9 could be used to bias repair events toward in-frame deletions. This may be beneficial as 
the excised fragment is large enough to eliminate an alpha-helix from your protein of interest or a 
binding site from a promoter. Sequence deletions are not a new concept, multiplexing genome-
editing reagents such as Cas9 could be used to delete intervening sequences (32). However, these 
studies produce more variable repair products compared to TevCas9 likely attributed to TevCas9 
ability to sequester the excised fragment from cellular repair proteins more effectively than two 
independent nucleases. In addition, expressing two different gRNAs has been demonstrated to 
increase off-target events. 
Another aspect of genome-editing is the ability to bias cellular DNA-repair pathways from 
mutagenic NHEJ to a gene correction homologous recombination (HR) repair pathway. Gene 
correction events using HR (1-8%) still trouble the genome-editing field as the efficiency is orders 
of magnitude lower then mutagenic NHEJ (15-80%) (33–35, 23, 36). Since HR and NHEJ are in 
competition the challenge is inducing HR without any NHEJ background (5, 37). The efficiency 
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Figure 6.3: Potential genome engineering outcomes using TevCas9 dual-active nucleases 
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of both HR and NHEJ are highly dependent on chromosomal location, nuclease platform, cell 
cycle, cell type and topology of repair template (36, 38). Some efforts to increase HR and reduce 
NHEJ were to create nickases, this would still promote HR and yet not activate NHEJ by only 
cleaving one strand of DNA (39, 40). However, this did successfully reduce NHEJ but did not 
significantly increase the rate of HR. Other attempts to increase HR have been to use chemical 
inhibitors to inhibit NHEJ repair proteins and promote HR. One study utilized small molecules 
and only observed a 2-fold increase in knock-in efficiency ranging from 0.8% to 3.5% with only 
a 2-fold increase (41). Only moderate increases in HR were observed, but still not the efficiency 
required for widespread use. Recently, a study reported HR frequencies of ~60% through simple 
rules for designing a single stranded DNA donor template in conjunction with Cas9, but this has 
to be further studied at other genomic sites (42). Resection creating a free 3’ overhang is the first 
step in HR repair, which could be established using a TevCas9 mutant variant (Figure 6.3). It 
would be intriguing to determine if a TevCas9 fusion containing a Cas9 nickase mutant could be 
utilized to produce a long 3’ overhang to help stimulate HR repair. The long 3’ overhang may 
direct cellular repair away from NHEJ and towards HR increasing the efficiency. This is unique 
from past attempts of just reducing NHEJ repair instead of stimulating HR repair. 
The final potential application for the dual-active TevCas9 is to capitalize on its ability to excise a 
fragment from the genome and replace it with a novel sequence. Similar to off-target profiling 
approaches guide-seq and IDLV capture, a short double-stranded oligo or linear IDLV fragment 
are integrated into the genome. Similar to these two approaches, the excised TevCas9 fragment 
can be replaced with an alternative sequence of choice. This would circumvent the problem of low 
HR frequency as sequences could be readily swapped out of genomes using TevCas9, a protocol 
I termed “swap-seq”. This has the potential to be used to correct gene mutations, add alternative 
mutations, or insert protein tags on endogenous genes. However, the inherent specificity of I-TevI 
may restrict the available sites that can be modified using swap-seq. Overall, the unique dual-
active function and applicability of the I-TevI based genome-editing reagent TevCas9 presents 
some interesting new avenues for genome modifications.   
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Appendix S2: Supplemental information for Chapter 2 
S2 Supplemental material and methods 
Bacterial strains and plasmid construction. Escherichia coli strains DH5α and ER2566 (New England 
Biolabs) were used for plasmid manipulations and protein expression, respectively. E.coli strain 
BW25141(λDE3) was used for genetic selection assays [1]. A complete description of all plasmids used in 
this study are listed in Table S3, and oligonucloetides are listed in Table S4. The ryA and ryB zinc-finger 
genes were synthesized by Integrated DNA Technologies with 5’-BamHI and 3’-XhoI sites and a C-terminal 
6-histidine tag, and cloned into pACYCDuet-1 to generate pACYCryAZf+H and pACYCryBZF+H, respectively. 
A stop codon was introduced at the 3’ end of the ryAZf gene using Quikchange (Stratagene) to generate 
pACYCryAZf. To create GIY-ZFEs, the I-TevI and I-BmoI GIY-YIG domains were PCR amplified from 
bacteriophage T4 gDNA and pACYCIBmoI, respectively, and cloned into the NcoI/BamHI sites of 
pACYCryAZf+H,  pACYCryAZf, and pACYCryBZf+H. TevN201-ryA and TevN201R27A were subcloned into 
the XbaI and EcoRV sites of pTAL3 to generate the expression plasmids for the yeast reporter assay 
(pYTZN201 and pYTZN201R27A). To generate Tev-LHEs, the I-OnuI E1 gene was amplified with BamHI and 
SalI ends to clone into the BamHI and XhoI sites of pACYCDuet-1(PciI) to create pACYCOnuE1(+H). This 
vector was subsequently Quikchanged to introduce an E22Q mutation in I-OnuI E1 to create 
pACYCOnuE1E22Q (+H). I-TevI catalytic domains were amplified as above and cloned into PciI/BamHI of 
pACYCOnuE1E22Q (+H). The R27A mutants of Tev-ZFEs and Tev-LHEs were generated using Quikchange 
mutagenesis. Hybrid GIY-ZFE and Tev-LHE target sites (Fig. 1B and 4B, Table S1 and S2) were cloned into 
the toxic plasmid p11-lacY-wtx1 to generate reporter plasmids for the bacterial selection. Tev-ryA and 
Bmo-ryA target sites were cloned into pSP72 for in vitro cleavage assays. The Tev-ryA site hybrid homing 
site was also cloned into LITMUS28i using BamHI and XhoI to generate pTZHS1.35. The two-site Tev-ZF 
plasmids were created by sub-cloning the PvuII/HpaI fragment from pTZHS1.35 into the SwaI site of 
pTZHS1.35 to generate pTZHS2.35 and pTZHS3.35 (with the second TZHS in either orientation). The G5A 
or C1A/G5A mutations were introduced into pToxTZ and pTZHS plasmids by Quikchange mutagenesis. To 
generate the target plasmids for the yeast reporter assay, the TZ-ryA target sites from toxic plasmids 
containing TZ1.33, TZ1.33G5A, and TZ1.33C1A/G5A were amplified and cloned into the BglII and SpeI sites 
of pCS753. All constructs were verified by sequencing, and the amino acid sequences of all GIY-ZFEs and 
Tev-LHEs constructed are provided in Figure S5. 
Two-plasmid genetic selection. The two plasmid genetic selection was performed as described [1], with 
toxic (reporter) plasmids containing hybrid TZ-ryA, TZ-ryB, BZ-ryA, TO target sites (Table S1 and S2), 
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mutant target sites (with G5A or C1A/G5A substitutions), or plasmids lacking a target site (p11-lacY-wtx1).  
Survival percentage was calculated by dividing the number of colonies observed on selective by those 
observed on non-selective plates.  
Yeast reporter assay. Transformants of S.cerevisiae YPH500() with Tev-ZFE constructs and YPH499(a)  
with target constructs were grown overnight (~230 rpm) at 30°C in synthetic complete medium lacking 
histidine (Tev-ZFEs) or lacking tryptophan and uracil (targets). Tev-ZFEs and targets were mated by adding 
equal densities (~400 μl) of overnight culture to 1 ml YPD and left stationary for 5-6 hours at 30°C. Cells 
harvested by centrifugation were washed in 1 ml and resuspended in 4 ml of synthetic medium lacking 
histidine and tryptophan prior to shaking overnight at 30°C. Cells were harvested by centrifugation, 
washed in 1 ml Z buffer (60 mM Na2PO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, pH 7.0), and 
suspended in 250 μl Z buffer. The suspension was diluted 20-fold into 1 ml Z buffer containing 0.27% -
mercaptoethanol, and 75 μl CHCl3 and 45 μl 0.1% SDS were added prior to vortexing. Lysates were pre-
incubated at 30°C prior to the addition of 100 μl 4 mg/ml ONPG. Reactions proceeded until a yellow colour 
developed whereby progress was stopped by the addition of 300 μl 1M Na2CO3. Stopped reactions were 
pelleted and the absorbance of the supernatant was analyzed at 420 nm and 550 nm. 
Protein purification. Cultures overexpressing either TevN201-ZFE or BmoN221-ZFE were grown at 37°C 
to an OD600~0.5 and expression induced by 0.5 mM IPTG (Bio Basic Inc.) overnight at 15°C. Cells were 
harvested by centrifugation at 8983 x g for 12 minutes, re-suspended in binding buffer (20 mM Tris-HCl 
pH 8.0, 500 mM NaCl, 10 mM imidazole, 5% glycerol, and 1 mM DDT), and lysed by homogenization at 
15,000 psi.  The cell lysate was clarified by centrifugation at 20400 x g, followed by sonication for 30 
seconds, and centrifugation at 20400 x g for 15 minutes. The clarified lysate was loaded onto a 1 mL 
HisTrap-HP column (GE Healthcare), washed with 15 mL binding buffer and then 10 mL wash buffer (20 
mM Tris-HCl (pH 8.0), 500 mM NaCl, 50 mM imidazole, 5% glycerol, and 1 mM DDT). Bound proteins were 
eluted in 1.5 mL fractions in four 5 mL step elutions with increasing concentrations of imidazole. Fractions 
containing GIY-ZFEs were dialyzed twice against 1L dialysis buffer (20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 
5% glycerol, and 1 mM DDT) prior to storage at -80°C. 
Cleavage assays. Single time-point cleavage assays to determine the EC0.5max of TevN201-ryA were 
performed in buffer containing 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 10 mM MgCl2, 5% glycerol, 1 mM 
DTT and 10 nM pTZHS1.33. Reactions were incubated for 3 minutes at 37°C, stopped with 5 μl stop 
solution (100 mM EDTA, 40% glycerol, and bromophenol blue), and electrophoresed on a 1% agarose gel 
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prior to staining with ethiduium bromide and analysis on an AlphaImager™3400 (Alpha Innotech). The 
EC0.5max was determined by fitting the data to the equation 
 
where f([endo]) is the fraction of substrate cleaved at concentration of TevN201-ryA [endo], fmax is the 
maximal fraction cleavage, with 1 being the highest value, and H is the Hill constant that was set to 1. The 
initial reaction velocity was determined using supercoiled plasmid substrate with varying concentrations 
of TevN201-ryA (0.7 nM to 47 nM) and buffer as above. Aliquots were removed at various times, stopped 
and analyzed as above. The data for product appearance was fitted to the equation  
 
where P is product (in nM), A is the magnitude of the initial burst, k1 is the rate constant (s-1) of the initial 
burst phase and k2 is the steady state rate constant (s-1). The two-site plasmid cleavage assays were 
conducted as above, using 10 nM pTZHS2.33 or pTZHS3.33 as substrates, and ~90 nM purified TevN201-
ryA. The kobs rate constants were calculated from the decay of supercoiled substrate by fitting to the 
equation  
 
where [{Van Roey, 2001}] is the concentration (nM) of supercoiled plasmid at time t, [C0] is the initial 
concentration of supercoiled substrate (nM), and k1 is the first order rate constant (in s-1). At least 3 
independent trials were conducted for each data set.  
Cleavage mapping. Mapping of cleavage sites was performed as described [2]. Briefly, primers were 
individually end-labeled with  -32P ATP, and used in PCR reactions with pTox or pSP72 plasmids carrying 
TZ-ryA or BZ-ryA target sites to generate strand-specific substrates. The substrates were incubated with 
purified protein as above, and electrophoresed in 8% denaturing gels alongside sequencing ladders 
generated by cycle sequencing with the same end-labeled primers (US Biologicals). 
Bioinformatics. The distribution of the CNNNG cleavage motif was examined in a 35-bp window of ZFN 
sites predicted for Dania rerio chromosome 1 (Ensembl release 51) using a custom Perl script [6]. Briefly, 
40 bp flanking the downstream region of each predicted ZFN was extracted from the corresponding 
zebrafish chromosome 1 cDNA, and searched for position i = C and position i+4 = G, with the occurrences 
of each CNNNG reported at position i (the C of the motif). The number of CNNNG motifs for unique ZFN 

f ([ endo]) 
f max[endo]H
EC0.5max +[endo]H

P  A(1 ek1t ) k 2t

[C]  [C0]exp(k1t)
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sites was fit to a binomial distrubtion, and plotted in R.   
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S2 Supplemental figures 
 
 
Figure S5.1: Design and functionality of Bmo-ZFEs.  
(A) Schematic of Bmo-ZFE constructs, with I-BmoI protein and substrate shown in grey, and the 
ryA protein and binding site shown in red and yellow, respectively. Top panel, the fusion points 
for each of the Bmo-ZFEs are indicated as the last I-BmoI amino acid, with or without a 2xGlycine 
or 4xGlycine linker. Constructs were made with a 6xHis tag on the C-terminal end. Bottom panel, 
the substrate shown consists of 33-nts of the top strand I-BmoI thyA target site (BZ1.33), fused to 
the 5’ end of the ryA binding site. Substrates tested differ by the insertion of one or two T 
nucleotides at the junction of the thyA/ryA sites. (B) Purification of His-tagged BmoN221-ryA. 
Shown is a representative SDS-PAGE gel; M, marker with molecular weights in kDa indicated on 
the left; UN, uninduced culture; IND, induced culture; C, crude lysate; FT, flow-through from 
metal-affinity column; W, wash; E, elution. (C) BmoN221-ryA cleavage specificity. Shown are 
representative agarose gels of cleavage assays with 10 nM pBZ1.33 or pSP72 (no target site) 
substrates and the indicated concentrations of BmoN221-ryA under standard assay conditions for 
10 minutes. BmoN221-ryA cleaves the BZ-ryA target site plasmid (BZ1.33) but not the control 
plasmid (pSP72) lacking the target site. N, nicked; L, linear; SC, supercoiled. (D) Mapping of 
BmoN221-ryA cleavage sites on the BZ1.33 substrate, with top and bottom cleavage sites 
indicated by open and closed triangles, respectively. 
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Figure S2.2: TevN201-ryA purification for in vitro experiments.  
(A) Purification of TevN201-ryA. Shown is a representative SDS-PAGE gel; M, marker with 
molecular weights in kDa indicated on the left; UN, uninduced culture; IND, induced culture; C, 
crude lysate; FT, flow-through from metal-affinity column; W, wash; E, elution. (B) Graphical 
representation of cleavage assays with 90 nM TevN201-ZFE and 10 nM two-site pTZ1.33 plasmid 
with target sites in the same orientation. Data are plotted as averages of three independent 
replicates with standard deviations; SC, supercoiled; OC, open-circle (nicked); FLL, full-length 
linear; L1+L2, linear products. 
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Figure S2.3: PvuII site analysis.  
(A) Shown is the distribution of the 5’-CAGCTG-3’ motif in a 35-bp window flanking 8,829 
predicted ZFN sites on zebrafish chromosome 1. The number of occurences of the ‘C’ of the motif 
at each distance is indicated. (C) Unique ZFN sites were grouped according to the number of 
occurences of the 5’-CAGCTG-3‘ motif in the 35-bp window.  
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Figure S2.4: Occurrence of the 5’-CNNNG-3’ motif upstream of I-OnuI E1 off-target sites.  
Shown is 37-nt of upstream sequence adjacent to the 22-nt I-OnuI E1 MAO-B target site, along 
with 19 predicted off-target sites [3]. CNNNG motifs are highlighted in red, with only 3 of 19 
predicted I-OnuI E1 off target sites containing a CNNNG motif at a targetable distance by Tev-
LHE fusions. Nucleotide differences of the off-target sites to the I-OnuI E1 site are indicated in 
magenta lower case font. 
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S2 Supplemental tables 
Table S2.1: Tev-ZFE selection data. 
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Table S2.2: Tev-LHE selection data. 
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Supplemental Table 
S2.3: 
Strains 
Strains and plasmids used in this study. 
Description 
 
Source 
E.coli - DH5 F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, 
endA1, hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, 
relA1 
Invitrogen 
E.coli - ER2566 F- λ- fhuA2 [lon] ompT lacZ::T7 gene 1 gal sulA11 Δ(mcrC-
mrr)114::IS10 R(mcr-73::miniTn10-TetS)2 R(zgb-
210::Tn10)(TetS) endA1 [dcm] 
N.E.B. 
E.coli - 
BW25141(λDE3) 
F- lacIq rrnBT14 DlacZWJ16 DphoBR580 hsdR514 
DaraBADAH33 DrhaBADLD78 galU95 endABT333 
uidA(DMluI)::pir+ recA1,  λDE3 lysogen 
Ref [1],[4] 
S.cerevisiae - YPH499 MATa ura3-52 lys2-801_amber ade2-101_ochre trp1-Δ63 
his3-Δ200 leu2-Δ1 
Dr. Adam 
Bogdanove 
S.cerevisiae - YPH500 MATα ura3-52 lys2-801_amber ade2-101_ochre trp1-Δ63 
his3-Δ200 leu2-Δ1 
Dr. Adam 
Bogdanove 
   
Plasmids Description Source 
pACYCDuet-1 orip15A, cm Novagen 
pACYCDuet-1(PciI) orip15A, cm, pACYCDuet-1 with a PciI site substituted for 
the NcoI site 
Novagen 
p11-lacY-wtx1 oripBR322, amp Ref [4] 
pSP72 oripBR322, amp Promega 
LITMUS28i oripMB1, amp N.E.B. 
pACYCIBmoI pACYCDuet-1, containing the 798bp codon optimized I-
BmoI gene in the NdeI and XhoI sites 
Ref [1] 
pryAzf oripUC, kan I.D.T. 
pTAL3 oripBR322, amp Dr. Adam 
Bogdanove 
pCP5.1 pCP5 derivative, amp, with ColE1 origin from pBluescript 
IIKS(-), reporter plasmid for the yeast based recombination 
assay, see [5] 
Dr. Adam 
Bogdanove 
pOnuE1 oripBR322, amp Ref [3] 
pACYCryAZf+H pACYCDuet-1, containing the ryA zinc-finger gene with a c-
terminal 6-histidine tag cloned into the BamHI and XhoI 
sites 
This study 
pACYCryAZf pACYCDuet-1, containing the ryA zinc-finger gene cloned 
into the BamHI and XhoI sites 
This study 
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pACYCryBZf+H pACYCDuet-1, containing the ryB zinc-finger gene with a c-
terminal 6-histidine tag cloned into the BamHI and XhoI 
sites 
This study 
pTevN201-ZFE (or +H) pACYCryAZf (or +H), with residues 1-N201 of I-TevI 
(DE832/840) cloned into the NcoI and BamHI sites (+/- 
6xHis) 
This study 
pTevN201-ryB (or +H) pACYCryBZf (or +H), with residues 1-N201 of I-TevI 
(DE832/840) cloned into the NcoI and BamHI sites (+/- 
6xHis) 
This study 
pTevN201G2-ZFE (or 
+H) 
pACYCryAZf (or +H), with residues 1-N201 of I-TevI 
(DE833/840) + 2 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pTevN201G4-ZFE (or 
+H) 
pACYCryAZf (or +H), with residues 1-N201 of I-TevI 
(DE834/840) + 4 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pTevK203-ZFE (or 
+H) 
pACYCryAZf (or +H), with residues 1-K203 of I-TevI 
(DE835/840) cloned into the NcoI and BamHI sites (+/- 
6xHis) 
This study 
pTevK203G2-ZFE (or 
+H) 
pACYCryAZf (or +H), with residues 1-K203 of I-TevI 
(DE836/840) + 2 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pTevK203G4-ZFE (or 
+H) 
pACYCryAZf (or +H), with residues 1-K203 of I-TevI 
(DE837/840) + 4 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pTevS206-ZFE (or +H) pACYCryAZf (or +H), with residues 1-S206 of I-TevI 
(DE838/840) cloned into the NcoI and BamHI sites (+/- 
6xHis) 
This study 
pTevS206G2-ZFE (or 
+H) 
pACYCryAZf (or +H), with residues 1-S206 of I-TevI 
(DE839/840) + 2 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pBmoN221-ZFE (or 
+H)  
pACYCryAZf (or +H), with residues 1-N221 of I-BmoI 
(DE841/849) cloned into the NcoI and BamHI sites (+/- 
6xHis) 
This study 
pBmoN221G2-ZFE (or 
+H) 
pACYCryAZf (or +H), with residues 1-N221 of I-BmoI 
(DE842/849) + 2 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pBmoN221G4-ZFE (or 
+H)  
pACYCryAZf (or +H), with residues 1-N221 of I-BmoI 
(DE843/849) + 4 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pBmoR223-ZFE (or 
+H) 
pACYCryAZf (or +H), with residues 1-R223 of I-BmoI 
(DE844/849) cloned into the NcoI and BamHI sites (+/- 
6xHis) 
This study 
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pBmoR223G2-ZFE (or 
+H)   
pACYCryAZf (or +H), with residues 1-R223 of I-BmoI 
(DE845/849) + 2 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pBmoR223G4-ZFE (or 
+H)   
pACYCryAZf (or +H), with residues 1-R223 of I-BmoI 
(DE846/849) + 4 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pBmoI226-ZFE (or 
+H) 
pACYCryAZf (or +H), with residues 1-I226 of I-BmoI 
(DE847/849) cloned into the NcoI and BamHI sites (+/- 
6xHis) 
This study 
pBmoI226G2-ZFE (or 
+H)   
pACYCryAZf (or +H), with residues 1-I226 of I-BmoI 
(DE848/849) + 2 glycine residues cloned into the NcoI and 
BamHI sites (+/- 6xHis) 
This study 
pTevN201R27A Similar to pTevN201-ZFE, with an R27A mutation This study 
pTevN201G2R27A Similar to pTevN201G2-ZFE, with an R27A mutation This study 
pTevN201G4R27A Similar to pTevN201G4-ZFE, with an R27A mutation This study 
pTevK203R27A Similar to pTevK203-ZFE, with an R27A mutation This study 
pTevK203G2R27A Similar to pTevK203G2-ZFE, with an R27A mutation This study 
pTevK203G4R27A Similar to pTevK203G4-ZFE, with an R27A mutation This study 
pTevS206R27A Similar to pTevS206-ZFE, with an R27A mutation This study 
pTevS206G2R27A Similar to pTevS206G2-ZFE, with an R27A mutation This study 
pToxTZ1.35 p11-lacY-wtx1, that contains a 44-bp hybrid I-TevI/ryA 
zinc-finger homing site (td bases -27 to +8 fused to the 9-bp 
ryAZf site) cloned into the XbaI and SphI sites (DE824/825) 
This study 
pToxBZ1.35 p11-lacY-wtx1, that contains a 44-bp hybrid I-BmoI/ryA 
zinc-finger homing site (thyA bases -6 to +27 fused to the 9-
bp ryAZf site) cloned into the XbaI and SphI sites 
(DE826/827) 
This study 
pSP-TZHS1.35 pSP72, that contains a 44-bp hybrid I-TevI/ryA zinc-finger 
homing site (td bases -27 to +8 fused to the 9-bp ryAZf site) 
cloned into the XbaI and SphI sites (DE824/825) 
This study 
pTZHS1.35 LITMUS28i, with the 44-bp hybrid I-TevI/ryA zinc-finger 
homing site (td bases -27 to +8 fused to the 9-bp ryAZf site) 
sub-cloned from pSP-TZHS1.35 into the BamHI and XhoI 
sites 
This study 
pBZHS1.35 pSP72, that contains a 44-bp hybrid I-BmoI/ryA zinc-finger 
homing site (thyA bases +6 to -27 fused to the 9-bp ryAZf 
site) cloned into the XbaI and SphI sites (DE826/827) 
This study 
pTZHS2.35 Similar to pTZHS1.35, with a second Tev-ZFE1.35 target 
site sub-cloned from pSP-TZHS1.35 (using PvuII/HpaI) into 
the SwaI site 
This study 
pTZHS3.35 Similar to pTZHS2.35, with the second Tev-ZFE1.35 target 
site in the alternate orientation 
This study 
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pToxTZ1.35G5A Similar to pToxTZ1.35, with a G5A substitution 
(DE917/918) 
This study 
pToxTZ1.35C1A/G5A Similar to pToxTZ1.35, with C1A and G5A substitutions 
(DE919/920) 
This study 
pTZHS1.35G5A Similar to pTZHS1.35, with a G5A substitution This study 
pTZHS1.35C1A/G5A Similar to pTZHS1.35, with C1A and G5A substitutions This study 
pToxTZ1.34 p11-lacY-wtx1, that contains a 43-bp hybrid I-TevI/ryA 
zinc-finger homing site (td bases -27 to +7 fused to the 9-bp 
ryAZf site) cloned into the XbaI and SphI sites  
This study 
pToxTZ1.34G5A Similar to pToxTZ1.34, with G5A substitution This study 
pToxTZ1.34C1A/G5A Similar to pToxTZ1.34, with C1A and G5A substitutions This study 
pToxTZ1.33 p11-lacY-wtx1, that contains a 42-bp hybrid I-TevI/ryA 
zinc-finger homing site (td bases -27 to +6 fused to the 9-bp 
ryAZf site) cloned into the XbaI and SphI sites  
This study 
pToxTZ1.33G5A Similar to pToxTZ1.33, with G5A substitution This study 
pToxTZ1.33C1A/G5A Similar to pToxTZ1.33, with C1A and G5A substitutions This study 
pToxTZ1.33-ryB p11-lacY-wtx1, that contains a 42-bp hybrid I-TevI/ryB zinc-
finger homing site (td bases -27 to +6 fused to the 9-bp 
ryBZf site) cloned into the XbaI and SphI sites  
This study 
pToxBZ1.34 p11-lacY-wtx1, that contains a 43-bp hybrid I-BmoI/ryA 
zinc-finger homing site (thyA bases -6 to +26 fused to the 9-
bp ryAZf site) cloned into the XbaI and SphI sites 
(DE826/827) 
This study 
pToxBZ1.33 p11-lacY-wtx1, that contains a 42-bp hybrid I-BmoI/ryA 
zinc-finger homing site (thyA bases -6 to +25 fused to the 9-
bp ryAZf site) cloned into the XbaI and SphI sites 
(DE826/827) 
This study 
pTZHS1.34 Similar to pTZHS1.35, with a 43-bp hybrid I-TevI/ryA zinc-
finger homing site (td bases -27 to +7 fused to the 9-bp 
ryAZf site) 
This study 
pTZHS1.33 Similar to pTZHS1.35, with a 42-bp hybrid I-TevI/ryA zinc-
finger homing site (td bases -27 to +6 fused to the 9-bp 
ryAZf site) 
This study 
pBZHS1.34 Similar to pBZHS1.35, with a 43-bp hybrid I-BmoI/ryA 
zinc-finger homing site (thyA bases +6 to -26 fused to the 9-
bp ryAZf site) 
This study 
pBZHS1.33 Similar to pBZHS1.35, with a 42-bp hybrid I-BmoI/ryA 
zinc-finger homing site (thyA bases +6 to -25 fused to the 9-
bp ryAZf site) 
This study 
pTZHS2.34 Similar to pTZHS2.35, with both Tev-ZFE target sites as 43-
bp hybrid I-TevI/ryA zinc-finger homing site (td bases -27 to 
+7 fused to the 9-bp ryAZf site) 
This study 
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pTZHS3.34 Similar to pTZHS3.35, with both Tev-ZFE target sites as 43-
bp hybrid I-TevI/ryA zinc-finger homing site (td bases -27 to 
+7 fused to the 9-bp ryAZf site) 
This study 
pTZHS2.33 Similar to pTZHS2.35, with both Tev-ZFE target sites as 42-
bp hybrid I-TevI/ryA zinc-finger homing site (td bases -27 to 
+6 fused to the 9-bp ryAZf site) 
This study 
pTZHS3.33 Similar to pTZHS3.35, with both Tev-ZFE target sites as 42-
bp hybrid I-TevI/ryA zinc-finger homing site (td bases -27 to 
+6 fused to the 9-bp ryAZf site) 
This study 
pTZHS1.34G5A Similar to pTZHS1.34, with a G5A substitution This study 
pTZHS1.33G5A Similar to pTZHS1.33, with a G5A substitution This study 
pTZHS1.34C1A/G5A Similar to pTZHS1.34, with C1A and G5A substitutions This study 
pTZHS1.33C1A/G5A Similar to pTZHS1.33, with C1A and G5A substitutions This study 
pToxTZ1.30 p11-lacY-wtx1, that contains a 39-bp hybrid I-TevI/ryA 
zinc-finger homing site (td bases -27 to +3 fused to the 9-bp 
ryAZf site) cloned into the XbaI and SphI sites 
(DE1085/1086) 
This study 
pToxTZ1.32 p11-lacY-wtx1, that contains a 41-bp hybrid I-TevI/ryA 
zinc-finger homing site (td bases -27 to +5 fused to the 9-bp 
ryAZf site) cloned into the XbaI and SphI sites 
(DE1087/1088) 
This study 
pToxTZ1.36 p11-lacY-wtx1, that contains a 45-bp hybrid I-TevI/ryA 
zinc-finger homing site (td bases -27 to +9 fused to the 9-bp 
ryAZf site) cloned into the XbaI and SphI 
sites(DE1134/1135) 
This study 
pToxTZ1.38 p11-lacY-wtx1, that contains a 47-bp hybrid I-TevI/ryA 
zinc-finger homing site (td bases -27 to +11 fused to the 9-bp 
ryAZf site) cloned into the XbaI and SphI 
sites(DE1136/1137) 
This study 
pToxTZ1.33ryB p11-lacY-wtx1, that contains a 42-bp hybrid I-TevI/ryB zinc-
finger homing site (td bases -27 to +6 fused to the 9-bp 
ryBZf site) cloned into the XbaI and SphI sites  
This study 
pToxTO1.12 p11-lacY-wtx1, that contains a 34-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to -16  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE1072/1073) 
This study 
pToxTO1.14 p11-lacY-wtx1, that contains a 36-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to -14  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE1070/1071) 
This study 
pToxTO1.16 p11-lacY-wtx1, that contains a 38-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to -12  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE1068/1069) 
This study 
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pToxTO1.18 p11-lacY-wtx1, that contains a 40-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to -10  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE1066/1067) 
This study 
pToxTO1.20 p11-lacY-wtx1, that contains a 42-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to -8  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE1064/1065) 
This study 
pToxTO1.22 p11-lacY-wtx1, that contains a 44-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to -6  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE1062/1063) 
This study 
pToxTO1.24 p11-lacY-wtx1, that contains a 46-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to -4  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE1060/1061) 
This study 
pToxTO1.26 p11-lacY-wtx1, that contains a 48-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to -2  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE1058/1059) 
This study 
pToxTO1.28 p11-lacY-wtx1, that contains a 50-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to +1  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE1056/1057) 
This study 
pToxTO1.30 p11-lacY-wtx1, that contains a 52-bp hybrid I-TevI/I-OnuI 
E1 homing site (td bases -27 to +3  fused to the I-OnuI E1 
site) cloned into the XbaI and SphI sites(DE976/977) 
This study 
pToxTO1.18C1A/G5A Similar to pToxTO18, with C1A and G5A 
substitution(DE1154/1155) 
This study 
pToxTO1.20 C1A/G5A Similar to pToxTO20, with C1A and G5A 
substitution(DE1156/1157) 
This study 
pToxTO1.26 C1A/G5A Similar to pToxTO26, with C1A and G5A 
substitution(DE1158/1159) 
This study 
pToxTO1.30 G5A Similar to pToxTO30, with a G5A substitution This study 
pToxTO1.30 C1A/G5A Similar to pToxTO30, with C1A and G5A substitution This study 
pACYCOnuE1(+H) pACYCDuet-1(PciI), containing the I-OnuI E1 gene cloned 
into the BamHI and XhoI sites 
This study 
pACYCOnuE1(E22Q) 
(+H) 
pACYCDuet-1(PciI), containing the I-OnuI E1 gene with a 
E22Q mutation cloned into the BamHI and XhoI sites 
This study 
pTevK203-
OnuE1(E22Q)  
pACYCOnuE1(E22Q)(+H), with residues 1-K203 of I-TevI 
(DE) cloned into the PciI and BamHI sites 
This study 
pTevN201G4-
OnuE1(E22Q) (+H) 
pACYCOnuE1(E22Q)(+H), with residues 1-N201 of I-TevI 
+ 4 glycine residues (DE) cloned into the PciI and BamHI 
sites (+6xHis) 
This study 
pTevD184G2-
OnuE1(E22Q) (+H) 
pACYCOnuE1(E22Q)(+H), with residues 1-D184G2 of I-
TevI + 2 glycine residues (DE) cloned into the PciI and 
BamHI sites (+6xHis) 
This study 
pTevN169-
OnuE1(E22Q) (+H) 
pACYCOnuE1(E22Q)(+H), with residues 1-N169 of I-TevI 
(DE) cloned into the PciI and BamHI sites (+6xHis) 
This study 
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Table S2.4: Oligonucleotides used in this study 
Name Sequence (5'-3') Notes 
DE410 GGAAGAAGTGGCTGATCTCAGC Forward primer to generate all cycle-seq 
products for target sites cloned into 
pTox 
DE411 CAGACCGCTTCTGCGTTCTG Reverse primer to generate all cycle-seq 
products for target sites cloned into 
pTox 
DE613 GCTAAAGATTTTGAAAAGGCATGGA
AGAAGCATTTTAAAG 
Forward quikchange primer to create 
R27A Tev-ZFEs 
DE614 CTTTAAAATGCTTCTTCCATGCCTTTT
CAAAATCTTTAGC 
Reverse quikchange primer to create 
R27A Tev-ZFEs 
pTevN140-
OnuE1(E22Q) (+H) 
pACYCOnuE1(E22Q)(+H), with residues 1-N140 of I-TevI 
(DE) cloned into the PciI and BamHI sites (+6xHis) 
This study 
pTevD127-
OnuE1(E22Q) (+H) 
pACYCOnuE1(E22Q)(+H), with residues 1- D127 of I-TevI 
(DE) cloned into the PciI and BamHI sites (+6xHis) 
This study 
pTevS114-
OnuE1(E22Q) (+H) 
pACYCOnuE1(E22Q)(+H), with residues 1- S114 of I-TevI 
(DE) cloned into the PciI and BamHI sites (+6xHis) 
This study 
pTevN201G4R27A -
OnuE1(+H) 
pACYCOnuE1(+H), with residues 1-N201 of I-TevI + 4 
glycine residues (DE) with a R27A mutation in I-TevI 
(+6xHis) 
This study 
pTevN201G4R27A-
OnuE1(E22Q) (+H) 
pACYCOnuE1(E22Q)(+H), similar to  pTevN201G4-
OnuE1(E22Q) (+H) with an R27A mutation in I-TevI 
This study 
pZif268 pTAL3 expression vector containing homodimeric FokI-
Zif268 ZFN 
Dr. Adam 
Bogdanove 
pZif268target pCS753 reporter plasmid with a homodimeric FokI-Zif268 
target site interrupting a partially duplicated lacZ gene 
Dr. Adam 
Bogdanove 
pYTZN201 pTAL3, with TevN201-ryA cloned in XbaI/EcoRV using 
DE1121/1128 
This study 
pYTZN201R27A Similar to pYTZN201, with an R27A I-TevI mutation This study 
pTZYHS1.33 pCS753, with the 42-bp hybrid I-TevI/ryA zinc-finger 
homing site cloned into the BglII/SpeI sites using 
DE1117/1118 
This study 
pTZYHS1.33G5A Similar to PTZYHS1.33, with G5A substitution This study 
pTZYHS1.33C1A/G5A Similar to PTZYHS1.33, with C1A and G5A substitutions This study 
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DE824 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGTCTACCGTTTCCCACGCCGCA
TG 
Top-strand oligo to clone the hybrid 35-
bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
DE825 CGGCGTGGGAAACGGTAGACCCAAG
AAAACATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
35-bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
DE826 CTAGAGCCCGTAGTAATGACATGGCC
TTGGGAAATCCCTTTCCCACGCCGCA
TG 
Top-strand oligo to clone the hybrid 35-
bp I-BmoI/9-bp ryAZf using XbaI and 
SphI 
DE827 CGGCGTGGGAAAGGGATTTCCCAAG
GCCATGTCATTACTACGGGCT 
Bottom-strand oligo to clone the hybrid 
35-bp I-BmoI/9-bp ryAZf using XbaI 
and SphI 
DE832 CCGCGGATCCATTACTAGGCTTTTTA
CC 
Reverse primer for TevN201-ZFE 
cloning, BamHI site underlined 
DE833 CCGCGGATCCACCACCATTACTAGGC
TTTTTACC 
Reverse primer for TevN201G2-ZFE 
cloning, BamHI site underlined 
DE834 CCGCGGATCCACCACCACCACCATTA
CTAGGCTTTTTACC 
Reverse primer for TevN201G4-ZFE 
cloning, BamHI site underlined 
DE835 CCGCGGATCCTTTAATATTACTAGGC
TTTTTAC 
Reverse primer for TevK203-ZFE 
cloning, BamHI site underlined 
DE836 CCGCGGATCCACCACCTTTAATATTA
CTAGGCTTTTTAC 
Reverse primer for TevK203G2-ZFE 
cloning, BamHI site underlined 
DE837 CCGCGGATCCACCACCACCACCTTTA
ATATTACTAGGCTTTTTAC 
Reverse primer for TevK203G4-ZFE 
cloning, BamHI site underlined 
DE838 CCGCGGATCCTGAAATCTTTTTAATA
TTACTAGGC 
Reverse primer for TevS206-ZFE 
cloning, BamHI site underlined 
DE839 CCGCGGATCCACCACCTGAAATCTTT
TTAATATTACTAGGC 
Reverse primer for TevS206G2-ZFE 
cloning, BamHI site underlined 
DE840 GCCGCCATGGGTAAAAGCGGAATTT
ATCAGATT 
Forward primer for Tev-ZFE cloning, 
NcoI site underlined 
DE841 CCGCGGATCCGTTTTTCGGTTTACGA
CC 
Reverse primer for BmoN221-ZFE 
cloning, BamHI site underlined 
DE842 CCGCGGATCCACCACCGTTTTTCGGT
TTACGACC 
Reverse primer for BmoN221G2-ZFE 
cloning, BamHI site underlined 
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DE843 CCGCGGATCCACCACCACCACCGTTT
TTCGGTTTACGACC 
Reverse primer for BmoN221G4-ZFE 
cloning, BamHI site underlined 
DE844 CCGCGGATCCACGAGAGTTTTTCGGT
TTACG 
Reverse primer for BmoR223-ZFE 
cloning, BamHI site underlined 
DE845 CCGCGGATCCACCACCACGAGAGTTT
TTCGGTTTACG 
Reverse primer for BmoR223G2-ZFE 
cloning, BamHI site underlined 
DE846 CCGCGGATCCACCACCACCACCACG
AGAGTTTTTCGGTTTACG 
Reverse primer for BmoR223G4-ZFE 
cloning, BamHI site underlined 
DE847 CCGCGGATCCGATAACCGGACGAGA
GTTTTTCGG 
Reverse primer for BmoI226-ZFE 
cloning, BamHI site underlined 
DE848 CCGCGGATCCACCACCGATAACCGG
ACGAGAGTTTTTCGG 
Reverse primer for BmoI226G2-ZFE 
cloning, BamHI site underlined 
DE849 GCCGCCATGGGTAAATCTGGTGTTTA
CAAAATC 
Forward primer for Bmo-ZFE cloning, 
NcoI site underlined 
DE850 CTTGGGTCTACCGTTCCCACGCCGCA
TG 
Forward quikchange primer to make the 
1.34 I-TevI/ryA zinc-finger target site 
DE851 CATGCGGCGTGGGAACGGTAGACCC
AAG 
Reverse quikchange primer to make the 
1.34 I-TevI/ryA zinc-finger target site 
DE852 CTTGGGTCTACCGTCCCACGCCGCAT
G 
Forward quikchange primer to make the 
1.33 I-TevI/ryA zinc-finger target site 
DE853 CATGCGGCGTGGGACGGTAGACCCA
AG 
Reverse quikchange primer to make the 
1.33 I-TevI/ryA zinc-finger target site 
DE854 GCCTTGGGAAATCCCTTCCCACGCCG
CATG 
Forward quikchange primer to make the 
1.34 I-BmoI/ryA zinc-finger target site 
DE855 CATGCGGCGTGGGAAGGGATTTCCCA
AGGC 
Reverse quikchange primer to make the 
1.34 I-BmoI/ryA zinc-finger target site 
DE856 GCCTTGGGAAATCCCTCCCACGCCGC
ATG 
Forward quikchange primer to make the 
1.33 I-BmoI/ryA zinc-finger target site 
DE857 CATGCGGCGTGGGAGGGATTTCCCAA
GGC 
Reverse quikchange primer to make the 
1.33 I-BmoI/ryA zinc-finger target site 
DE858 CAGAAACAGCTGGTTTAATAACATCA
TCACCACTAACTCG 
Forward quikchange primer to add stops 
to the 3’-end of the ryA zinc-finger 
DE859 CGAGTTAGTGGTGATGATGTTATTAA
ACCAGCTGTTTCTG 
Reverse quikchange primer to add stops 
to the 3’-end of the ryA zinc-finger 
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DE917 CTAGACAACACTCAGTAGATGTTTTC
TTGGGTCTACCGTTTCCCACGCCGCA
TG 
Top strand oligo similar to DE824 with 
G-23A substitution  
DE918 CGGCGTGGGAAACGGTAGACCCAAG
AAAACATCTACTGAGTGTTGT 
Bottom strand oligo similar to DE825 
with C-23T substitution 
DE919 CTAGAAAACACTCAGTAGATGTTTTC
TTGGGTCTACCGTTTCCCACGCCGCA
TG 
Top strand oligo similar to DE824 with 
G-23A and C-27A substitutions 
DE920 CGGCGTGGGAAACGGTAGACCCAAG
AAAACATCTACTGAGTGTTTT 
Bottom strand oligo similar to DE825 
with C-23T and G-27T substitutions 
DE973 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGTCTACCGTTAGCTACTACGCAT
G 
Top-strand oligo to clone the hybrid 33-
bp I-TevI/9-bp ryBZf using XbaI and 
SphI 
DE974 CGTAGTAGCTAACGGTAGACCCAAGA
AAACATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
33-bp I-TevI/9-bp ryBZf using XbaI and 
SphI 
DE976 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGTCTAGGTCCACATATTTAACCTT
TTGCATG 
Top strand oligo to clone the hybrid 30-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE977 CAAAAGGTTAAATATGTGGACCTAGAC
CCAAGAAAACATCTACTGAGCGTTGT 
Bottom strand oligo to clone the hybrid 
30-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE978 CTAGACAACACTCAGTAGATGTTTTC
TTGGGTCTAGGTCCACATATTTAACCTT
TTGCATG 
Top strand oligo similar to DE976 with 
G5A substitution 
DE979 CAAAAGGTTAAATATGTGGACCTAG
ACCCAAGAAAACATCTACTGAGTGTT
GT 
Bottom strand oligo similar to DE977 
with G5A substitution 
DE980 CTAGAAAACACTCAGTAGATGTTTTC
TTGGGTCTAGGTCCACATATTTAACCTT
TTGCATG 
Top strand oligo similar to DE976 with 
C1A and G5A substitution 
DE981 CAAAAGGTTAAATATGTGGACCTAGAC
CCAAGAAAACATCTACTGAGTGTTTT 
Bottom strand oligo similar to DE977 
with C1A and G5A substitution 
DE982 CGGTTTCGCCGACGCGCAAGGCTCCT
TTTTGCTGCG 
Forward quikchange primer to create 
E22Q I-OnuI E1 mutant 
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DE983 CGCAGCAAAAAGGAGCCTTGCGCGT
CGGCGAAACCG 
Reverse quikchange primer to create 
E22Q I-OnuI E1 mutant 
DE991 CGCGTCGACTTAGAATACTCTGCCCT
TGTTC 
Reverse primer to amplify the I-OnuI E1 
gene with a 3’ SalI site 
DE1017 CGCGGATCCACCACCGTCTGAATGCT
TATGATTAAAG 
Reverse primer for TevD184G2 cloning, 
BamHI site underlined 
DE1040 CGCGGATCCAGAACGTTTCTTAATAA
TTTC 
Reverse primer for TevS114 cloning, 
BamHI site underlined 
DE1042 CGCGGATCCATCAGGTCCAAGTTTAA
GC 
Reverse primer for TevD127 cloning, 
BamHI site underlined 
DE1044 CGCGGATCCGTTTTTACTTCCGGGTT
TAC 
Reverse primer for TevN140 cloning, 
BamHI site underlined 
DE1045 CGCGGATCCATTTCTGCATTTACTAC
AAG 
Reverse primer for TevN169 cloning, 
BamHI site underlined 
DE1056 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGTCGGTCCACATATTTAACCTTTT
GCATG 
Top-strand oligo to clone the hybrid 28-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1057 CAAAAGGTTAAATATGTGGACCGACCC
AAGAAAACATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
28-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1058 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGGGTCCACATATTTAACCTTTTGC
ATG 
Top-strand oligo to clone the hybrid 26-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1059 CAAAAGGTTAAATATGTGGACCCCCAA
GAAAACATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
26-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1060 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGTCCACATATTTAACCTTTTGCAT
G 
Top-strand oligo to clone the hybrid 24-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1061 CAAAAGGTTAAATATGTGGACCCAAGA
AAACATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
24-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1062 CTAGACAACGCTCAGTAGATGTTTTC
TGGTCCACATATTTAACCTTTTGCATG 
Top-strand oligo to clone the hybrid 22-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
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DE1063 CAAAAGGTTAAATATGTGGACCAGAAA
ACATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
22-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1064 CTAGACAACGCTCAGTAGATGTTTTG
GTCCACATATTTAACCTTTTGCATG 
Top-strand oligo to clone the hybrid 20-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1065 CAAAAGGTTAAATATGTGGACCAAAAC
ATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
20-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1066 CTAGACAACGCTCAGTAGATGTTGGT
CCACATATTTAACCTTTTGCATG 
Top-strand oligo to clone the hybrid 18-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1067 CAAAAGGTTAAATATGTGGACCAACAT
CTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
18-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1068 CTAGACAACGCTCAGTAGATGGGTCC
ACATATTTAACCTTTTGCATG 
Top-strand oligo to clone the hybrid 16-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1069 CAAAAGGTTAAATATGTGGACCCATCT
ACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
16-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1070 CTAGACAACGCTCAGTAGAGGTCCAC
ATATTTAACCTTTTGCATG 
Top-strand oligo to clone the hybrid14-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1071 CAAAAGGTTAAATATGTGGACCTCTACT
GAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
14-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1072 CTAGACAACGCTCAGTAGGTCCACAT
ATTTAACCTTTTGCATG 
Top-strand oligo to clone the hybrid 12-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1073 CAAAAGGTTAAATATGTGGACCTACTG
AGCGTTGT 
Bottom-strand oligo to clone the hybrid 
12-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1074 CGCGTCGACTTAGTGGTGATGATGGT
GATGGAATACTCTGCCCTTGTTC 
Reverse primer to amplify the I-OnuI E1 
gene with a 3’ his-tag and SalI site 
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DE1082 GCGAGATCTGGTTCCGCCTATATGTC
CCG 
Forward primer to amplify the I-OnuI 
E1 gene with a 5’ BamHI site 
DE1085 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGTCTACCTCCCACGCCGCATG 
Top-strand oligo to clone the hybrid 32-
bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
DE1086 CGGCGTGGGAGGTAGACCCAAGAAA
ACATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
32-bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
DE1087 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGTCTATCCCACGCCGCATG 
Top-strand oligo to clone the hybrid 30-
bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
DE1088 CGGCGTGGGATAGACCCAAGAAAAC
ATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
30-bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
DE1117 GCAGATCTCTAGCATTACGCTAGGG Forward primer to amplify target site in 
pTox with 5’ BglII site to clone into 
pCS753 
DE1118 GCACTAGTCTTCTCTCATCCGCC Reverse primer to amplify target site in 
pTox with 3’ SpeI site to clone into 
pCS753 
DE1121 CGTCTAGAATGAAAAGCGGAATTTAT
CAGATT 
Forward primer to amplify I-TevI with 
5’ XbaI site to clone into pTAL3 
DE1128 CGGATATCTTATTAAACCAGCTGTTT
CTGACGCAGG 
Reverse primer to amplify ryAZF with 
3’ EcoRV site to clone into pTAL3 
DE1134 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGTCTACCGTTTTCCCACGCCGC
ATG 
Top-strand oligo to clone the hybrid 36-
bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
DE1135 CGGCGTGGGAAAACGGTAGACCCAA
GAAAACATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
36-bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
DE1136 CTAGACAACGCTCAGTAGATGTTTTC
TTGGGTCTACCGTTTCCCACGCCGCA
TG 
Top-strand oligo to clone the hybrid 38-
bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
DE1137 CGGCGTGGGAAACGGTAGACCCAAG
AAAACATCTACTGAGCGTTGT 
Bottom-strand oligo to clone the hybrid 
38-bp I-TevI/9-bp ryAZf using XbaI and 
SphI 
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DE1154 CTAGAAAACACTCAGTAGATGTTTTC
TTGGGGGTCCACATATTTAACCTTTTGC
ATG 
Top-strand oligo to clone the hybrid 26-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1155 CAAAAGGTTAAATATGTGGACCCCCAA
GAAAACATCTACTGAGTGTTTT 
Bottom-strand oligo to clone the hybrid 
26-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1156 CTAGAAAACACTCAGTAGATGTTTTG
GTCCACATATTTAACCTTTTGCATG 
Top-strand oligo to clone the hybrid 20-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1157 CAAAAGGTTAAATATGTGGACCAAAAC
ATCTACTGAGTGTTTT 
Bottom-strand oligo to clone the hybrid 
20-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
DE1158 CTAGAAAACACTCAGTAGATGTTGGT
CCACATATTTAACCTTTTGCATG 
Top-strand oligo to clone the hybrid 18-
bp I-TevI/22-bp I-OnuI E1 using XbaI 
and SphI 
DE1159 CAAAAGGTTAAATATGTGGACCAACAT
CTACTGAGTGTTTT 
Bottom-strand oligo to clone the hybrid 
18-bp I-TevI/22-bp I-OnuI E1 using 
XbaI and SphI 
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Appendix S3: Supplemental information for Chapter 3 
S3 Supplemental figures 
 
Figure S3.1: Dual active Tev169-Ltr activity in vitro  
(A) Schematic of substrate and cleavage products containing the TL15 target site indicated by a 
black-filled rectangle.  The black and red arrows indicate the top and bottom cleavage sites (CS) 
for I-TevI and I-LtrI, respectively. Black dashed lines indicate I-TevI cleavage products (TP1 and 
TP2), I-LtrI cleavage products (LP1 and LP2), and the red dashed line is the internal dual product 
(DP) from both I-TevI and I-LtrI cleavage. Sizes of the substrate and products are indicated in base 
pairs (bp). Mutant R27A I-TevI and E29Q I-LtrI are denoted by xTev and xLtr, respectively. (B) 
Polyacrylamide gel of internally labeled TL15 PCR product incubated with (+) or without (-) 
purified dual active Tev169-Ltr and single-active site variants. Tev169-Ltr was incubated with 
substrate for the indicated times, and cleavage products are indicated on the right side of the gel 
based on their predicted sizes from panel (A). The sizing standard (in bp) was cropped from the 
gel image.  
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Figure S3.2: Purified MegaTev constructs on a Ni2+ column 
SDS-Polyacrylamide gel of the purified MegaTev constructs used in vitro. Protein ladder was 
cropped from the image and sizes markers are indicated in kDa. 
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Figure S3.2: Representation of MegaTev cleavage 
(A) Agarose gel of a DdeI digest for MegaTev with inactive I-OnuI. (B) Sanger sequencing for 
individual DdeI resistant sites treated with Tev169-xOnu (inactive I-OnuI). (C)  Sanger sequencing 
for individual DdeI resistant sites treated with Tev169-Onu (MegaTev dual-active).  
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Figure S3.4: Examples of modified two-plasmid selection for CNNNG TO15 target sites 
(A) Schematic for the TO15 target site highlighting in red the NNN-triplet within the cleavage 
motif. All 64-variants in the CNNNG cleavage motif were screened on selective plates. (B) Sample 
selective plate for the two control target sites and two NNN-triplets substrates consisting of a 
strong and weak survivors. Eight colonies were gridded for each target site with the identity 
displayed on the right. 
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S3: Supplemental Tables 
Table S3.1: Strains used in this study 
 
Table S3.2: Oligonucleotides used in this study 
Name Sequence (5'-3') Notes 
DE-1058 CTAGACAACGCTCAGTAGATGTT
TTCTTGGGGGTCCACATATTTAAC
CTTTTGCATG 
Top strand for T021 target site, 
XbaI/SphI 
DE-1059 CAAAAGGTTAAATATGTGGACCC
CCAAGAAAACATCTACTGAGCGT
TGT 
Bottom strand for T021 target site, 
XbaI/SphI 
DE-1060 CTAGACAACGCTCAGTAGATGTT
TTCTTGGGTCCACATATTTAACCT
TTTGCATG 
Top strand for T019 target site, 
XbaI/SphI 
DE-1061 CAAAAGGTTAAATATGTGGACCC
AAGAAAACATCTACTGAGCGTTG
T 
Bottom strand for T019 target site, 
XbaI/SphI 
Construction Description Source 
Strains     
DH5 F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, 
endA1, hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, 
relA1 
Invitrogen 
ER2566 F- λ- fhuA2 [lon] ompT lacZ::T7 gene 1 gal sulA11 Δ(mcrC-
mrr)114::IS10 R(mcr-73::miniTn10-TetS)2 R(zgb-
210::Tn10)(TetS) endA1 [dcm] 
N.E.B. 
BW25141 
(λDE3) 
F- lacIq rrnBT14 DlacZWJ16 DphoBR580 hsdR514 
DaraBADAH33 DrhaBADLD78 galU95 endABT333 
uidA(DMluI)::pir+ recA1,  λDE3 lysogen 
 
S.cerevisiae - 
YPH499 
MATa ura3-52 lys2-801_amber ade2-101_ochre trp1-Δ63 
his3-Δ200 leu2-Δ1 
Dr. Adam 
Bogdanove 
S.cerevisiae - 
YPH500 
MATα ura3-52 lys2-801_amber ade2-101_ochre trp1-Δ63 
his3-Δ200 leu2-Δ1 
Dr. Adam 
Bogdanove 
HEK 293 and 
HEK293T 
Human Embryonic kidney  293 cells Dr. Schild-
Poulter 
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DE-1062 CTAGACAACGCTCAGTAGATGTT
TTCTGGTCCACATATTTAACCTTT
TGCATG 
Top strand for T017 target site, 
XbaI/SphI 
DE-1063 CAAAAGGTTAAATATGTGGACCA
GAAAACATCTACTGAGCGTTGT 
Bottom strand for T017 target site, 
XbaI/SphI 
DE-1064 CTAGACAACGCTCAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand for T015 target site, 
XbaI/SphI 
DE-1065 CAAAAGGTTAAATATGTGGACCA
AAACATCTACTGAGCGTTGT 
Bottom strand for T015 target site, 
XbaI/SphI 
DE-1066 CTAGACAACGCTCAGTAGATGTT
GGTCCACATATTTAACCTTTTGCA
TG 
Top strand for T013 target site, 
XbaI/SphI 
DE-1067 CAAAAGGTTAAATATGTGGACCA
ACATCTACTGAGCGTTGT 
Botttom strand for T013 target site, 
XbaI/SphI 
DE-1068 CTAGACAACGCTCAGTAGATGGG
TCCACATATTTAACCTTTTGCATG 
Top strand for T011 target site, 
XbaI/SphI 
DE-1069 CAAAAGGTTAAATATGTGGACCC
ATCTACTGAGCGTTGT 
Botttom strand for T011 target site, 
XbaI/SphI 
DE-1156 CTAGAAAACACTCAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand for TO15(CS-) target site, 
XbaI/SphI 
DE-1157 CAAAAGGTTAAATATGTGGACCA
AAACATCTACTGAGTGTTTT   
Bottom strand for TO15(CS-) target site, 
XbaI/SphI 
DE-1257 CCATCTCATCCCTGCGTGTCTCCG
ACTCAGtatcgCCggcagatctgatatcatcg 
Forward barcoded primer to amplify the 
N8 library for Ion Torrent sequencing 
DE1259 CCATCTCATCCCTGCGTGTCTCCG
ACTCAGtgcatCCggcagatctgatatcatcg 
Forward barcoded primer to amplify the 
N8 round 3 selected sites for Ion Torrent 
sequencing 
DE-1267 CCTCTCTATGGGCAGTCGGTGATg
aactcgagcagctgaagc 
Reverse primer to amplify the N8 target 
sites for Ion Torrent sequencing 
DE-1338 CTAGACAACGCTCAGTAGATGTT
TTAATGCTCCTATACGACGTTTAG
CATG 
Top strand for TL15 target site, 
XbaI/SphI 
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DE-1339 CTAAACGTCGTATAGGAGCATTA
AAACATCTACTGAGCGTTGT 
Bottom strand for TL15 target site, 
XbaI/SphI 
DE-1340 CTAGAAAACACTCAGTAGATGTT
TTAATGCTCCTATACGACGTTTAG
CATG 
Top strand for TL15(CS-) target site with 
an AAACA cleavage motif, XbaI/SphI 
DE-1341 CTAAACGTCGTATAGGAGCATTA
AAACATCTACTGAGTGTTTT 
Bottom strand for TL15(CS-) target site 
with an AAACA cleavage motif, 
XbaI/SphI 
DE-1379 CGGAATTCNNNNNNNNAGTAGAT
GTTTTGGTCCACATATTTAACCTT
TTGCATG 
Top strand oligo to create the N8 library 
with EcoRI site and SphI overhang 
DE-1380 CAAAAGGTTAAATATGTGG Bottom strand oligo to make the N8 
library double-stranded 
DE-1497 CTAGACAACGCGCAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG 
Top strand TO15 target site with a T7G 
mutation, XbaI/EcoRI 
DE-1498 AATTCAAAAGGTTAAATATGTGG
ACCAAAACATCTACTGCGCGTTG
T 
Bottom strand TO15 target site with a 
T7G mutation, XbaI/EcoRI 
DE-1499 CTAGACAACGCACAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG 
Top strand TO15 target site with a T7A 
mutation, XbaI/EcoRI 
DE-1500 AATTCAAAAGGTTAAATATGTGG
ACCAAAACATCTACTGTGCGTTGT 
Bottom strand TO15 target site with a 
T7A mutation, XbaI/EcoRI 
DE-1501 CTAGACAACGCTCAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG 
Top strand TO15 target site with a C6A 
mutation, XbaI/EcoRI 
DE-1502 AATTCAAAAGGTTAAATATGTGG
ACCAAAACATCTACTGAGCGTTG
T 
Bottom strand TO15 target site with a 
C6A mutation, XbaI/EcoRI 
DE-1503 CTAGACAACGGTCAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG 
Top strand TO15 target site with a C6G 
mutation, XbaI/EcoRI 
DE-1504 AATTCAAAAGGTTAAATATGTGG
ACCAAAACATCTACTGACCGTTG
T 
Bottom strand TO15 target site with a 
C6G mutation, XbaI/EcoRI 
DE-1505 CTAGACAACGTTCAGTAGATGTTT
TGGTCCACATATTTAACCTTTTG 
Top strand TO15 target site with a C6T 
mutation, XbaI/EcoRI 
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DE-1506 AATTCAAAAGGTTAAATATGTGG
ACCAAAACATCTACTGAACGTTG
T 
Bottom strand TO15 target site with a 
C6T mutation, XbaI/EcoRI 
DE-1544 GCAGATCTCCAGTGTGCCGGTCTC
CG 
Forward primer to clone target sites from 
pKox into pCSTox using homology-
directed repair 
DE-1545 GCACTAGTCTTCTGAGTTCGGCAT
GGG 
Reverse primer to clone target sites from 
pKox into pCSTox using homology-
directed repair 
DE-1645 GCTCTGCAGAATGGCCAACCTTT
AACG 
Forward internal primer to DE1680/1682 
to amplify the TO15 integrated target site  
DE-1646 CTACCCGCTTCCATTGCTCAGCGG
TGC 
Reverse internal primer to DE1680/1682 
to amplify the TO15 integrated target site 
DE-1662 CTAGACAACGCTCAGTAGATGTT
TTCTTGGGAATGCTCCTATACGAC
GTTTAGCATG 
Top strand for TL21 target site, 
XbaI/SphI 
DE-1663 CTAAACGTCGTATAGGAGCATTC
CCAAGAAAACATCTACTGAGCGT
TGT 
Bottom strand for TL21 target site, 
XbaI/SphI 
DE-1664 CTAGACAACGCTCAGTAGATGTT
TTCTTGAATGCTCCTATACGACGT
TTAGCATG 
Top strand for TL19 target site, 
XbaI/SphI 
DE-1665 CTAAACGTCGTATAGGAGCATTC
AAGAAAACATCTACTGAGCGTTG
T 
Bottom strand for TL19 target site, 
XbaI/SphI 
DE-1666 CTAGACAACGCTCAGTAGATGTT
TTCTAATGCTCCTATACGACGTTT
AGCATG 
Top strand for TL17 target site, 
XbaI/SphI 
DE-1667 CTAAACGTCGTATAGGAGCATTA
GAAAACATCTACTGAGCGTTGT 
Bottom strand for TL17 target site, 
XbaI/SphI 
DE-1668 CTAGACAACGCTCAGTAGATGTT
AATGCTCCTATACGACGTTTAGCA
TG 
Top strand for TL13 target site, 
XbaI/SphI 
DE-1669 CTAAACGTCGTATAGGAGCATTA
ACATCTACTGAGCGTTGT 
Bottom strand for TL13 target site, 
XbaI/SphI 
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DE-1670 CTAGACAACGCTCAGTAGATGAA
TGCTCCTATACGACGTTTAGCATG 
Top strand for TL11 target site, 
XbaI/SphI 
DE-1671 CTAAACGTCGTATAGGAGCATTC
ATCTACTGAGCGTTGT 
Bottom strand for TL11 target site, 
XbaI/SphI 
DE-1672 AATGTGCAGTCTAGGGCAGC Forward primer to PCR amplify I-OnuI 
E1 site in the MAO-B gene 
DE-1673 TGAGGGGCGAACTTTGAACA Reverse primer to PCR amplify I-OnuI 
E1 site in the MAO-B gene 
DE-1680 GCTAACTAGCTCTGTATCTGGCG Forward primer to amplify the TO15 
integrated target site  
DE-1682 CTGACGAGTTCTGAACACCC Reverse primer to amplify the TO15 
integrated target site 
DE-1853 TGAGGGGCGAACTTTGAACA Internal forward primer to DE1702/1703 
to PCR amplify I-OnuI E1 site in the 
MAO-B gene 
DE-1854 CAAATCACATAAGAAGTGATCG Internal reverse primer to DE1702/1703 
to PCR amplify I-OnuI E1 site in the 
MAO-B gene 
DE-1855 AGCAGAGAGGCATTCAACCC Forward primer to PCR amplify I-OnuI 
E1 off-target #3 
DE-1856 CTGGGGAGGAAGAGCTTTGG Reverse primer to PCR amplify I-OnuI 
E1 off-target #3 
DE-1857 CTGAGGGCAGTTAATGAGGC Internal forward primer to DE1855/1856 
to PCR amplify I-OnuI E1 off-target #3 
DE-1858 GGAGTCACAAAGCAGGGGC Internal reverse primer to DE1855/1856 
to PCR amplify I-OnuI E1 off-target #3 
DE-1859 AGAGTGAAGTCTGTGGTGG Forward primer to PCR amplify I-OnuI 
E1 off-target #4 
DE-1860 GGCTGATAAGGGAGACTGGC Reverse primer to PCR amplify I-OnuI 
E1 off-target #4 
DE-1861 CACACTGAACATCTAAACTCATG
G 
Internal forward primer to DE1859/1860 
to PCR amplify I-OnuI E1 off-target #4 
DE-1862 CAAAGAGTAGGATTGTGCTCC Internal reverse primer to DE1859/1860 
to PCR amplify I-OnuI E1 off-target #4 
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DE-1863 ATTGCCAAGAAGTCACCCG Forward primer to PCR amplify I-OnuI 
E1 off-target #15 
DE-1864 AAAGGTTTGCAAAGCAGCG Reverse primer to PCR amplify I-OnuI 
E1 off-target #15 
DE-1865 GAATACGCTACCACTCCTTACC Internal forward primer to DE1863/1864 
to PCR amplify I-OnuI E1 off-target #15 
DE-1866 CTGGAAGGAACGTCTCCAAGC Internal reverse primer to DE1863/1864 
to PCR amplify I-OnuI E1 off-target #15 
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Appendix S4: Supplemental information for Chapter 4 and 5 
S4 Supplemental Figures 
 
Figure S4.1: In vitro enrichment of N12 DNA spacer library with the MegaTev(1-169)or 
MegaTev(1-184) constructs under different reaction conditions.  
Nucleotide preference inthe DNA spacer region is displayed as proportional log2 enrichment of 
each nucleotide ateach position relative to the abundance in the input pool. Black dots indicate the 
wild-typenucleotide in the td DNA spacer at each position. 
  
167 
 
 
 
 
Figure S4.2: Frequency and phasing of all 16 NNNNN motifs in the three different DNA 
spacer substrates (panels A, B, and C).  
The frequency of each NNNNN is the proportion of reads with the indicated NNNNN sequence 
relative to total reads at each position (ie. pos1:pos5). The left barplot in each panel is derived from 
the selected data, and the right panel in each plot is from the input library. 
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Figure S4.3: Activity and specificity of TevCas9 in HEK 293 cells 
(A) Detailed schematic of the target site in exon 23 of the human TSC1 gene, positions of PCR 
primers used for amplification, and sizes of PvuII cleavage products. The I-TevI cleavage motif 
and DNA spacers are highlighted by red and blue rectangles, and the PAM motif by a green 
rectangle. Positions of I-TevI and Cas9 cleavage sites are represented by red and black arrows, 
respectively. (B) Representative agarose gel of PvuII cleavage assays on PCR products amplified 
from the TSC1 locus 48 hrs after transfection with Cas9 or with TC-VK. Sizes of the substrate 
(1124 bp) and two PvuII cleavage products are indicated on the right. The percent of substrate 
resistant to cleavage by PvuII is indicated below each lane. (C) Activity of TevCas9  TC-VK 
variant and Cas9 at the TSC1 site measured by PvuII resistance and T7E1. Barplots are mean 
values of at least three independent experiments, with vertical bars representing standard 
deviation. 
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Figure S4.4: Off-target profiling of TevCas9 and Cas9 programmed with the NQO2 gRNA.  
The 5 off-target sites were predicted using the CRISPR design tools (http://crispr.mit.edu/). (A) 
Representative agarose gel images of T7E1 mismatch cleavage assays of PCR fragments 
amplified from HEK 293 cells transfected with Cas9 or TevCas9. (B) For each site, the gRNA 
target is in captial letters with mismatches to the NQO2 gRNA in red font. The lower case letters 
are the 25-bp upstream of the gRNA that would include the DNA spacer contacted by the I-TevI 
linker, and a CNNNG cleavage motif (if present) highlighed by a yellow box. 
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Figure S4.5: TevCas9 can bias the proportion of in-frame to out-of-frame indels 
Illumina read data for the target site is plotted as the proportion of reads that are in-frame (green) 
and out-of-frame (red) for TevCas9 and Cas9. 
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Figure S4.6: Indels generated at the VEGFA gene by Cas9 paired nickases  
Illumina sequencing data was downloaded from the Sequencing Read Archive (SRP03315, 
experiments SRX380882 (control), SRX380880 (tru_gRNA), SRX380879 (gRNA)), and reads 
analyzed for length of insertion or deletion relative to the unmodified target. Data are plotted as 
length difference to unmodified site versus porportion of each indel relative to total reads.  
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S4 Supplemental Tables 
Table S4.1: Strains used in this study 
Table S4.2: Oligonucleotides used in this study 
 
Name Sequence (5'-3') Notes 
DE-1180 CGCATGCGGCGCNNCAAAAGGTT
AAATATGTGGACCNNNNNNNNNN
NNNNNCGTTGGCCGAATTCCG 
Bottom strand for MegaTev TO15 N15 
randomized spacer target site 
DE-1181 CGGAATTCGGCCAAC Forward primer to make DE1180 double-
stranded DNA for cloning 
DE-1064 CTAGACAACGCTCAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 (15-bp spacer) target site 
DE-1065 CAAAAGGTTAAATATGTGGACCA
AAACATCTACTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 (15-bp spacer) target site 
DE-1412 CTAGACAACGCTCAGTACATGTTT
TGGTCCACATATTTAACCTTTTGC
ATG 
Top strand oligonucleotide for TevOnu 
TO15 G8C target site 
DE-1413 CAAAAGGTTAAATATGTGGACCA
AAACATGTACTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 G8C target site 
Construction Description Source 
Strains     
DH5 F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, 
hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1 
Invitrogen 
ER2566 F- λ- fhuA2 [lon] ompT lacZ::T7 gene 1 gal sulA11 Δ(mcrC-
mrr)114::IS10 R(mcr-73::miniTn10-TetS)2 R(zgb-210::Tn10)(TetS) 
endA1 [dcm] 
N.E.B. 
BW25141 (λDE3) F- lacIq rrnBT14 DlacZWJ16 DphoBR580 hsdR514 DaraBADAH33 
DrhaBADLD78 galU95 endABT333 uidA(DMluI)::pir+ recA1,  λDE3 
lysogen 
 
S.cerevisiae - 
YPH499 
MATa ura3-52 lys2-801_amber ade2-101_ochre trp1-Δ63 his3-
Δ200 leu2-Δ1 
Dr. Adam 
Bogdanove 
S.cerevisiae - 
YPH500 
MATα ura3-52 lys2-801_amber ade2-101_ochre trp1-Δ63 his3-
Δ200 leu2-Δ1 
Dr. Adam 
Bogdanove 
HEK 293  Human Embryonic kidney 293 cells Dr. Schild-
Poulter 
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DE-1414 CTAGACAACGCTCAGTAAATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 G8A target site 
DE-1415 CAAAAGGTTAAATATGTGGACCA
AAACATTTACTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 G8A target site 
DE-1416 CTAGACAACGCTCAGTATATGTTT
TGGTCCACATATTTAACCTTTTGC
ATG 
Top strand oligonucleotide for TevOnu 
TO15 G8T target site 
DE-1417 CAAAAGGTTAAATATGTGGACCA
AAACATATACTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 G8T target site 
DE-1418 CTAGACAACGCTCAGTAGTTGTTT
TGGTCCACATATTTAACCTTTTGC
ATG 
Top strand oligonucleotide for TevOnu 
TO15 A9T target site 
DE-1419 CAAAAGGTTAAATATGTGGACCA
AAACAACTACTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 A9T target site 
DE-1420 CTAGACAACGCTCAGTAGGTGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 A9G target site 
DE-1421 CAAAAGGTTAAATATGTGGACCA
AAACACCTACTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 A9G target site 
DE-1422 CTAGACAACGCTCAGTAGCTGTTT
TGGTCCACATATTTAACCTTTTGC
ATG 
Top strand oligonucleotide for TevOnu 
TO15 A9C target site 
DE-1423 CAAAAGGTTAAATATGTGGACCA
AAACAGCTACTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 A9C target site 
DE-1209 CTAGACAACGCCCAGTAGACATA
GGGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 T2C (includes 10-15 bp spacer 
swapped for MAO-B sequence) target 
site 
DE-1210 CAAAAGGTTAAATATGTGGACCC
CTATGTCTACTGGGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 T2C (includes 10-15 bp 
spacer swapped for MAO-B sequence) 
target site 
DE-1497 CTAGACAACGCGCAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 T2G target site 
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DE-1498 CAAAAGGTTAAATATGTGGACCA
AAACATCTACTGCGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 T2G target site 
DE-1499 CTAGACAACGCACAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 T2A target site 
DE-1500 CAAAAGGTTAAATATGTGGACCA
AAACATCTACTGTGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 T2A target site 
DE-1501 CTAGACAACGATCAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 C1A target site 
DE-1502 CAAAAGGTTAAATATGTGGACCA
AAACATCTACTGATCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 C1A target site 
DE-1503 CTAGACAACGGTCAGTAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 C1G target site 
DE-1504 CAAAAGGTTAAATATGTGGACCA
AAACATCTACTGACCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 C1G target site 
DE-1505 CTAGACAACGTTCAGTAGATGTTT
TGGTCCACATATTTAACCTTTTGC
ATG 
Top strand oligonucleotide for TevOnu 
TO15 C1T target site 
DE-1506 CAAAAGGTTAAATATGTGGACCA
AAACATCTACTGAACGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 C1T target site 
DE-1958 CTAGACAACGCTCAGCAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 T6C target site 
DE-1959 CAAAAGGTTAAATATGTGGACCA
AAACATCTGCTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 T6C target site 
DE-1960 CTAGACAACGCTCAGGAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 T6G target site 
DE-1961 CAAAAGGTTAAATATGTGGACCA
AAACATCTCCTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 T6G target site 
DE-1962 CTAGACAACGCTCAGAAGATGTT
TTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15 T6A target site 
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DE-1963 CAAAAGGTTAAATATGTGGACCA
AAACATCTTCTGAGCGTTGT 
Bottom strand oligonucleotide for 
TevOnu TO15 T6A target site 
DE-2142 CTAGACAGAGGTGGGCAATGGCG
TGGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15-PKD1 2386 target site  
DE-2143 CAAAAGGTTAAATATGTGGACCC
ACGCCATTGCCCACCTCTGT 
Bottom strand oligonucleotide for 
TevOnu TO15-PKD1 2386 target site  
DE-2144 CTAGACTTTGGAAGGTAATTACA
GTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15-HPRT 5740 target site  
DE-2145 CCAAAAGGTTAAATATGTGGACC
ACTGTAATTACCTTCCAAAGT 
Bottom strand oligonucleotide for 
TevOnu TO15- HPRT 5740 target site  
DE-2146 CTAGACTGTGCTCAGGTGATCCTC
CGGTCCACATATTTAACCTTTTGC
ATG 
Top strand oligonucleotide for TevOnu 
TO15-Ku70 14915 target site  
DE-2147 CAAAAGGTTAAATATGTGGACCG
GAGGATCACCTGAGCACAGT 
Bottom strand oligonucleotide for 
TevOnu TO15- Ku70 14915 target site  
DE-2148 CTAGACTAAGGTGGTCCTTCCCA
GAGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15- XPC 1277 target site  
DE-2149 CAAAAGGTTAAATATGTGGACCT
CTGGGAAGGACCACCTTAGT 
Bottom strand oligonucleotide for 
TevOnu TO15-XPC 1277 target site  
DE-2206 CTAGACATTGCTGTGCTTTGGGGA
TGGTCCACATATTTAACCTTTTGC
ATG 
Top strand oligonucleotide for TevOnu 
TO15-VEGFA 2522 target site  
DE-2207 CAAAAGGTTAAATATGTGGACCC
TTGCAATAATTCTGCAATGT 
Bottom strand oligonucleotide for 
TevOnu TO15-VEGFA 2522 target site  
DE-2208 CTAGACAGAGGAAGATGGTGTGC
CCGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15-TSC1-2125 target site  
DE-2209 CAAAAGGTTAAATATGTGGACCG
GGCACACCATCTTCCTCTGT 
Bottom strand oligonucleotide for 
TevOnu TO15-TSC1-2125 target site  
DE-2210 CTAGACTGTGGTCTGGTGTTCCAG
CGGTCCACATATTTAACCTTTTGC
ATG 
Top strand oligonucleotide for TevOnu 
TO15-TSC1-5054 target site  
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DE-2211 CAAAAGGTTAAATATGTGGACCG
CTGGAACACCAGACCACAGT 
Bottom strand oligonucleotide for 
TevOnu TO15-TSC1-5054 target site  
DE-2212 CTAGACTGTGCAGCATGGAATTC
CTGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15-TSC1-6374 target site  
DE-2213 CAAAAGGTTAAATATGTGGACCA
GGAATTCCATGCTGCACAGT 
Bottom strand oligonucleotide for 
TevOnu TO15-TSC1-6374 target site  
DE-2216 CTAGACATTGCAGAATTATTGCA
AGGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15-APC 1440 target site  
DE-2217 CAAAAGGTTAAATATGTGGACCC
TTGCAATAATTCTGCAATGT 
Bottom strand oligonucleotide for 
TevOnu TO15-APC 1440 site  
DE-2218 CTAGACATTGGTACCTGGTACTG
ATGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15-BRAC1-2541 target site  
DE-2219 CAAAAGGTTAAATATGTGGACCA
TCAGTACCAGGTACCAATGT 
Bottom strand oligonucleotide for 
TevOnu TO15-BRAC1-2541 target site  
DE-2220 CTAGACAGAGGCGAATTTATTAT
CAGGTCCACATATTTAACCTTTTG
CATG 
Top strand oligonucleotide for TevOnu 
TO15-BRAC1-3999 target site  
DE-2221 CAAAAGGTTAAATATGTGGACCT
GATAATAAATTCGCCTCTGT 
Bottom strand oligonucleotide for 
TevOnu TO15-BRAC1-3999 target site  
DE-2645 CACCGTGGCTGTAGATGAACTGA
GC 
Top strand oligonucleotide for Cas9 
human NQO2 gRNA with BbsI 
overhangs 
DE-2646 AAACGCTCAGTTCATCTACAGCC
AC 
Bottom strand oligonucleotide for Cas9 
human NQO2 gRNA with BbsI 
overhangs 
DE-2701 CACCGTTAGCATCTTGGGGAACA
TG 
Top strand oligonucleotide for Cas9 
human RARA gRNA with BbsI 
overhangs 
DE-2702 AAACCATGTTCCCCAAGATGCTA
AC 
Bottom strand oligonucleotide for Cas9 
human RARA gRNA with BbsI 
overhangs 
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DE-2703 CACCGTACCTCCCCAATGGAAGT
GC 
Top strand oligonucleotide for Cas9 
human TSC1-1 gRNA with BbsI 
overhangs 
DE-2704 AAACGCACTTCCATTGGGGAGGT
AC 
Bottom strand oligonucleotide for Cas9 
human TSC1-1 gRNA with BbsI 
overhangs 
DE-2705 CACCGCTGAGGCAGGGGGATTTG
GT 
Top strand oligonucleotide for Cas9 
human TSC1-2 14bp gRNA with BbsI 
overhangs 
DE-2706 AAACACCAAATCCCCCTGCCTCA
GC 
Bottom strand oligonucleotide for Cas9 
human TSC1-2 14bp gRNA with BbsI 
overhangs 
DE-2707 CACCGGGCAGGGGGATTTGGTAG
GA 
Top strand oligonucleotide for Cas9 
human TSC1-2 gRNA 18bp with BbsI 
overhangs 
DE-2708 AAACTCCTACCAAATCCCCCTGCC
C 
Bottom strand oligonucleotide for Cas9 
human TSC1-2 18bp gRNA with BbsI 
overhangs 
DE-2510 GTTCAAACACACATGCTCTGC Forward primer for 1st round 
amplification of NQ02 54 site human site 
DE-2511 GCACTCCTGATGCTTCCTGTGGG Reverse primer for 1st round 
amplification of NQ02 54 site human site 
DE-2512 CAATCATCACAGGGTCCTGAGGC Forward primer for 2nd round 
amplification of NQ02 54 site human site 
DE-2513 GGAACCCCAGAAAATTGAGAAGC Reverse primer for 2nd round 
amplification of NQ02 54 human site 
DE-2359 TGAGAGCCGTTTTCAACCCT Forward primer for 1st round 
amplification of TSC1 2125 human site 
DE-2360 CCAGCCTTCTCTGTTCAGCA Reverse primer for 1st round 
amplification of TSC1 2125 human site 
DE-2361 GGGATGTCAGGCCATCTGAA Forward primer for 2nd round 
amplification of TSC1 2125 human site 
DE-2362 GGTGGAATACCGACTGCCAT Reverse primer for 2nd round 
amplification of TSC1 2125 human site 
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DE-2779 ACGTCCATGGAGCTTCTAGC Forward primer for 1st round 
amplification of TSC1 5054 human site 
DE2780 CCCGAGAAGCACTTGAGCAT Reverse primer for 1st round 
amplification of TSC1 5054 human site 
DE2713 TTCAGTACCAACTGCCAGCC Forward primer for 2nd round 
amplification of TSC1 5054 human site 
DE-2714 ACCCTTCTGTCTACTGGCCT Reverse primer for 2nd round 
amplification of TSC1 5054 human site 
DE-2777 ACGTCCATGGAGCTTCTAGC Forward primer for 1st round 
amplification of RARA 233 human site 
DE-2778 CCCGAGAAGCACTTGAGCAT Reverse primer for 1st round 
amplification of RARA 233 human site 
DE-2711 TTCAGTACCAACTGCCAGCC Forward primer for 2nd round 
amplification of RARA 233 human site 
DE-2712 ACCCTTCTGTCTACTGGCCT Reverse primer for 2nd round 
amplification of RARA 233 human site 
DE-2783 TTCTCTCCCACAGCTGTCCA Forward primer for 1st round 
amplification of NQ02 off-target #1 
DE-2784 CACTAGGTGCAGACTCAGGC Reverse primer for 1st round 
amplification of NQ02 off-target #1 
DE-2719 CAAGGCCCCTCTCTCTTTCG Forward primer for 2nd round 
amplification of NQ02 off-target #1 
DE-2720 ATGGGTAGAAGCAGATGCCG Reverse primer for 2nd round 
amplification of NQ02 off-target #1 
DE-2721 CCACTGCCAGATTTCTCCCC Forward primer for 1st round 
amplification of NQ02 off-target #2 
DE-2722 GGGCATTCATTTGTCTGCACTT Reverse primer for 1st round 
amplification of NQ02 off-target #2 
DE-2723 TCCTGCCAGGGAGTGATACA Forward primer for 1st round 
amplification of NQ02 off-target #3 
DE-2724 CCAGGGTCGCGAACTAATGA Reverse primer for 1st round 
amplification of NQ02 off-target #3 
DE-2785 TGCAACACCCTCTTTAATACTGA Forward primer for 1st round 
amplification of NQ02 off-target #4 
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DE-2786 AAAACGACCTCCGGTTTGTG Reverse primer for 1st round 
amplification of NQ02 off-target #4 
DE-2725 AGCTGAATCCAGATGCCAGT Forward primer for 2nd round 
amplification of NQ02 off-target #4 
DE-2726 GTGAAACTGGGTTTGCCCCT Reverse primer for 2nd round 
amplification of NQ02 off-target #4 
DE-2727 GCCCCATTTTCCTGATGGGA Forward primer for 1st round 
amplification of NQ02 off-target #5 
DE-2728 ATCCAGAGTGGTTCCATGCG Reverse primer for 1st round 
amplification of NQ02 off-target #5 
DE-2787 CTTGGTGCTGTTGCACTCAT Forward primer for 1st round 
amplification of NQ02 off-target #6 
DE-2788 GCCGCCTACTCCTCTTTTCTT Reverse primer for 1st round 
amplification of NQ02 off-target #6 
DE-2729 GTGCCTCCTCAATGGTGACT Forward primer for 2nd round 
amplification of NQ02 off-target #6 
DE-2730 GGTCAGGTGTGAGGGACTCT Reverse primer for 2nd round 
amplification of NQ02 off-target #6 
DE-2835 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNccaaggccTCTAT
GCACACCAGG 
Forward primer to amplify NQO2 54 for 
illumina sequencing 
DE-2836 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNcattaaggTCTATG
CACACCAGG 
Forward primer to amplify NQO2 54 for 
illumina sequencing 
DE-2837 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNataacgaaTCTATG
CACACCAGG 
Forward primer to amplify NQO2 54 for 
illumina sequencing 
DE-2843 CGGTCTCGGCATTCCTGCTGAACC
GCTCTTCCGATCTGGCTCAAGGTT
CATGGC  
Reverse primer to amplify NQO2 54 for 
illumina sequencing 
DE-2844 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNagttaaccGAGTGC
CCCAGTCCC  
Forward primer to amplify TSC1 2125 
for illumina sequencing 
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DE-2845 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNcaggcttaGAGTG
CCCCAGTCCC  
Forward primer to amplify TSC1 2125 
for illumina sequencing 
DE-2846 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNtggcggctGAGTG
CCCCAGTCCC  
Forward primer to amplify TSC1 2125 
for illumina sequencing 
DE-2847 CGGTCTCGGCATTCCTGCTGAACC
GCTCTTCCGATCTTGCCAAAGACA
GCCC  
Reverse primer to amplify TSC1 2125 for 
illumina sequencing 
DE-2848 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNcttcctggTTCGTA
CCGTGACAG  
Forward primer to amplify TSC1 5054 
for illumina sequencing 
DE-2849 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNgtactgcgTTCGTA
CCGTGACAG  
Forward primer to amplify TSC1 5054 
for illumina sequencing 
DE-2850 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNgctcattgTTCGTA
CCGTGACAG  
Forward primer to amplify TSC1 5054 
for illumina sequencing 
DE-2851 CGGTCTCGGCATTCCTGCTGAACC
GCTCTTCCGATCTTTGGCAGTGGC
AGAG  
Reverse primer to amplify TSC1 5054 for 
illumina sequencing 
DE-2852 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNgacactcgCGCTG
CTGGAGGCGC  
Forward primer to amplify RARA 233 
for illumina sequencing 
DE-2853 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNatccactaCGCTGC
TGGAGGCGC  
Forward primer to amplify RARA 233 
for illumina sequencing 
DE-2854 ACACTCTTTCCCTACACGACGCTC
TTCCGATCTNNNNttatacagCGCTGC
TGGAGGCGC  
Forward primer to amplify RARA 233 
for illumina sequencing 
DE-2855 CGGTCTCGGCATTCCTGCTGAACC
GCTCTTCCGATCTGGGCCAGGTGT
CGGG   
 
Reverse primer to amplify RARA 233 for 
illumina sequencing 
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Awards and Honors: 
Award Value (CDN) Level 
Location of 
Tenure Period Held 
 
FASEB 2nd place poster 
award 
 
500 
 
International 
 
University of 
Western Ontario 
 
2014 
NSERC PGS Doctoral 63,000 National University of 
Western Ontario 
2014/01-2016/12 
Ontario Graduate 
Scholarship 
10,000 Provincial University of 
Western Ontario 
2013/05-2013/12 
QEII Graduate Scholarship 
in Science and Technology 
(QEIIGSST)  
15,000 Institutional University of 
Western Ontario 
2012/05-2013/05 
Western Research Graduate 
Scholarship 
(tuition) Institutional University of 
Western Ontario 
2011/08-2013/08 
Schulich Graduate 
Scholarship 
- Institutional University of 
Western Ontario 
2011/08-2012/04 
183 
 
 
 
Biochemistry Undergraduate 
Summer Research Program 
6,000 Institutional University of 
Western Ontario 
2010 
Dean’s Honour List - Institutional University of 
Western Ontario 
2008/09-2011/05 
     
Experience: 
Committees 
 Area Safety Committee, Biochemistry department, 2012-14 
 Proctoring Committee, Biochemistry department, 2011-16 
Social Committee, Biochemistry department, 2011-14 
Society of Graduate Students, Biochemistry representative, 2012-13 
 
Laboratory 
Volunteer Research Program, University of Western Ontario, Department of Biochemistry 2009-
10 (Dr. Ball) 
Biochemistry Undergraduate Summer Research Program (BUSRP), University of Western 
Ontario, Department of Biochemistry 2010 (Dr. Ball)  
Summer research program, University of Western Ontario, Department of Biochemistry 2011 
(Dr. Edgell) 
Honours Research Thesis, University of Western Ontario, Department of Biochemistry 2010-11 
(Dr. Edgell) 
 
Teaching 
 2013 Biochemistry 2280A, University of Western Ontario 
2014 Biochemistry 2280A, University of Western Ontario 
2014 Biochemistry 3380G, University of Western Ontario 
2015 Biochemistry 2280A, University of Western Ontario 
2015 Biochemistry 3380G, University of Western Ontario 
 
 
 
 
